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Thrombosis is a serious medical complication because excessive thrombus for-
mation could lead to obstruction of blood vessels, resulting in tissue ischemia
or death. This study is aimed to understand the cell-biology and biophysics,
at the molecular level, of thrombosis in a blood vessel. We first review the bi-
ology underlying thrombosis and the previous mathematical models of throm-
bus formation (Chapter 1). In Chapter 2, mathematical modeling and sensitiv-
ity analysis were used to explore the mechanistic model of thrombus forma-
tion; the results support our working hypothesis that computationally derived
points of fragility of human relevant cascades could be used as a rational basis
for target selection despite model uncertainty. Chapter 3 focuses on the im-
pact of parametric sampling strategies of Monte-Carlo sensitivity analysis and
network structural uncertainty upon the assessment of the qualitative impor-
tance of molecular interactions in the coagulation network. While parametric
uncertainty can be partially overcome by sampling feasible parameter regions
using one of several strategies, structural uncertainty remains a critical deter-
minant of our ability to classify mechanisms as fragile or robust in networks
relevant to human health. The mathematical model was further extended to
describe platelet activation by other agonists besides thrombin and the intrinsic
pathway in Chapter 4. An ensemble of probable parameter sets were estimated
using nine experimental data sets from a cell-based model and then used to
predict the thrombin generation in experiments using patient-derived plasma
for coronary artery and hemophilia A patients. In Chapter 5, analysis of the
sensitivity results discloses that the intrinsic protease factor XI could be an ex-
cellent therapeutic target for thrombosis treatment with the advantage of not
affecting hemostasis. Chapter 6 describes the effect of flow on the initiation of
arterial clotting under conditions of exposed tissue factor (TF). Thresholds in
shear rates or TF patch sizes were observed for the initiation of clot formation;
the balance between the generation of active factors and the removal of those
factors by flow was possibly the reason for the threshold phenomena.
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CHAPTER 1
INTRODUCTION
Cardiovascular diseases are predicted as the leading cause of death for the fu-
ture two decades by the World Health Organization in 2008 [1]. Central to car-
diovascular diseases is Arteriosclerosis, the thickening or hardening of the arter-
ies. Arteriosclerosis is caused by aging, high blood pressure, cigarette smoke,
and high cholesterol levels. One particular kind of arteriosclerosis that con-
tributes to cardiovascular diseases is Atherosclerosis, which is characterized by
a buildup of plaque within the arteries. Plaque, which is formed from fatty sub-
stances, cholesterol, cellular waste, calcium, and fibrin, may partially or totally
block blood flow through arteries leading to chronic conditions, e.g., cardio-
vascular diseases. However, plaques are also linked with acute events such as
Myocardial Infarction (MI) or Ischemic Stroke (IS); plaques become fragile and
can rupture leading to clot or thrombus formation [2, 3, 4].
MI is a thrombotic event triggered by atherosclerosis plaque rupture. The
exposed procoagulant materials, e.g. collagen, tissue factor (TF), etc, following
plaque rupture lead to the activation of platelets and the formation of thrombin,
resulting in thrombosis or thrombus formation. Thrombosis is a serious medical
complication because excessive thrombus formation can lead to obstruction of
blood vessels, resulting in tissue ischemia or death. In addition to occluding the
blood vessel where it was formed, it is also possible for a thrombus to break free
(embolize) and lodge somewhere downstream in the microcirculation, the most
deleterious possibility being a brain infarction if it finds its way into a cerebral
artery or being a heart attack if it blocks a coronary artery. The specific aims of
this study are to understand the cell-biology and biophysics, at the molecular
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level, of thrombosis in a blood vessel. In particular, we will focus upon the
processes underlying thrombus formation in ruptured plaques: thrombin gen-
eration, platelet adhesion, activation and aggregation in the absence or presence
of an arterial flow field. We will employ tools from Systems Biology, Computa-
tional Fluid Dynamics (CFD) and High-Performance Computing (HPC) to con-
struct and validate a first-principles mathematical model of disease progression
which can be employed in a treatment planning context to improve the effective-
ness of current therapies in community practice, to better understand primary
and secondary prevention issues and to computationally screen novel therapeutic
strategies at a molecular level. It is hoped that this will one day lead to im-
proved computational design strategies for understanding the mechanisms and
the development of new drugs for thrombosis.
1.1 Thrombus formation
Although unraveling the many complex and intertwined chemical and biologi-
cal processes that lead to thrombus formation is a continuing challenge for mod-
ern medical research, the primary factors governing thrombosis were identified
nearly 150 years ago by the German pathologist Rudolf Virchow (1821-1902) [5].
Decades following his death, a consensus was reached proposing that thrombo-
sis is the result of “abnormalities of blood constituents”, “abnormalities of blood
vessel wall”, and “abnormalities of blood flow”, which are the three elements of
the well-know “Virchow’s triad” [6]. The contributions of each element of the
triad to the thrombotic process are described below.
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1.1.1 The constitution of the blood
The constituents of the blood are many and varied, but soluble coagulation fac-
tors, such as factor I (fI or fibrinogen) and factor II (fII or prothrombin), and
cells, such as platelets, are clearly important [6]. The blood elements primar-
ily responsible for coagulation are the coagulation factors, typically identified
by Roman numerals I – XIII. Most of the coagulation factors are synthesized
in the liver. In addition, factor VIII (fVIII) is synthesized in a large number of
other tissue. Other important factors in the coagulation process include pro-
thrombin, factor VII (fVII), factor IX (fIX), factor X (fX) and factor XI (fXI); these
proteins are synthesized in precursor form, which are biochemically termed as
zymogens. These zymogens are precursor enzymes that are converted to active
enzymes by the cleavage of one or in some instances two peptide bonds dur-
ing blood coagulation. There are two protein cofactors, factor V (fV) and fVIII,
that also play an important role in blood coagulation by binding to activated
platelets surface and forming a focal point for the organization of certain pro-
tein complexes. The corresponding active forms of these proteins are denoted
as FVa, FVIIa, FVIIIa, FIXa, FXa and FXIa, respectively.
Blood coagulation cascades
Clotting can be achieved via either of two coagulation cascades, or via platelet
aggregation and deposition. However, all three feed into and depend upon one
another, meaning none usually occurs independent of the others. What follows
is a brief overview of these complex processes. More detail can be obtained from
any basic physiology text, e.g. Guyton & Hall [7], and the references therein.
Upon plaque ruptures, the exposed collagen is one of the most thrombogenic
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materials because it supports platelet adhesion and it is a strong platelet ago-
nist. The collagen-activated platelet membranes expose receptors which bind
circulating fibrinogen to their surfaces. An aggregation of platelets and fibrino-
gen build up to form a soft plug. This is often called primary hemostasis, which
is normally short lived. If flow is allowed to increase, the soft plug could be
sheared from the injured surface, possibly creating emboli. Secondary hemosta-
sis or blood coagulation is responsible for stabilizing the soft clot and maintain-
ing vasoconstriction. The soft plug is solidified through complex interactions
that bring about the generation of thrombin and the formation of fibrin from
fibrinogen. Thrombin cleaves fibrinogen into fibrin monomers and these fib-
rin monomers polymerized to form fibrin mesh on and between the soft plug,
resulting in the formation of the stable fibrin clot [8, 9].
The intrinsic and the extrinsic pathways of coagulation are involved in the
generation of thrombin; each is activated by a different trigger, although they
share many steps in the course of thrombin generation. It is generally believed
that the extrinsic pathway is the main mechanism in vivo. The extrinsic blood co-
agulation cascade is thought to be triggered when tissue factor (TF) is exposed
as a consequence of vascular damage or plaque rupture. TF activates fVII to
activated FVIIa, and with which it forms an enzymatic complex TF-FVIIa. TF-
FVIIa complex activates fX and fIX. FIXa in complex with its cofactor, FVIIIa,
activates fX at an ≈50-fold higher rate than the factor TF-FVIIa complex [10].
FXa and FVa in turn form a complex on the surface of activated platelets which
converts prothrombin (fII) to thrombin (FIIa). The terminal protease thrombin
plays a key role in the activation of upstream factors and platelets [8, 9, 11].
The intrinsic or contact pathway of coagulation consists of a group of plasma
proteins which are activated by interaction with exogenous negatively charged
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surfaces such as glass or kaolin. This pathway has been described as a series
of enzymatic reactions which starts with the formation of activated factor XIIa
(FXIIa). FXIIa activates fXI to FXIa, which could cleave fIX to FIXa. The intrin-
sic pathway of coagulation joins with the extrinsic at this point. The reactions
of this pathway have been well characterized in vitro; however, the physiologic
activator of fXII has not been identified. Furthermore, individuals with fXII defi-
ciencies have developed no significant bleeding diathesis; however, individuals
have been identified with fXI deficiencies do have significant episodes of bleed-
ing complications associated with surgical challenges [12]. Some investigators
have reported that FXIa could also be activated by thrombin as complement to
the extrinsic pathway when the extrinsic pathway is shut down by inhibitors
[13, 14, 15, 16, 17, 18, 19].
To maintain normal hemostasis, it is necessary to have the appropriate bal-
ance between pro- and anti-coagulant constituents in the blood. There are three
major anti-coagulants in the blood that sever as control points in the cascade
to inhibit thrombin formation. Tissue Factor Pathway Inhibitor (TFPI) down-
regulates FXa formation catalyzed by TF-FVIIa by sequestering free FXa and
the TF-FVIIa-FXa complex. Antithrombin III (ATIII) neutralizes all serine pro-
teases generated during the coagulation response, making it perhaps the most
powerful control element in the cascade. Thrombin itself plays an inadvertent
role in its own inhibition by binding to thrombomodulin which is constitutively
expressed on normal vasculature. The binding of thrombin with thrombomod-
ulin in turn activates Protein C (PC) to activated PC (APC) which attenuates the
coagulation response by the proteolytic cleavage of fV/FVa and fVIII/FVIIIa
[20, 21, 22, 23].
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Hemophiliacs
Defects in the balance of blood constituents can result in either thrombotic of
bleeding tendencies. Some genetic deficiencies in the sex-linked, X chromo-
somes may lower blood plasma clotting factor levels of coagulation factors
needed for a normal clotting process and result in bleeding disorders [24].
Hemophilia is a group of hereditary genetic disorders that impair the body’s
ability to control blood clotting or coagulation. In its most common forms,
hemophilia A and B are congenital bleeding disorders caused by deficiencies
of the coagulation factors fVIII and fIX, respectively [24]. Hemophilia A occurs
in about 1 in 5,000-10,000 male births, while hemophilia B occurs at about 1 in
about 35,000-50,000 male births [25]. Hemophilia C, caused by deficiency in fXI,
is a mild form of hemophilia affecting both sexes. In the USA it is thought
to affect 1 in 100,000 of the adult population, making it 10% as common as
hemophilia A [26]. The concept of mild bleeding disorders has evolved in con-
trast to severe hemophilia A and B to indicate less severe disorders [27]. A
hemophilia patient do not bleed more intensely than a normal person, but for a
much longer amount of time. In severe hemophiliacs even a minor injury could
result in blood loss lasting days, weeks, or not ever healing completely. The crit-
ical risk here is with normally small injuries which, due to missing coagulation
factors, take long times to heal. In areas such as the brain or inside joints this
can be fatal or permanently debilitating. The bleeding with external injury is
normal, but incidence of late re-bleeding and internal bleeding is increased, es-
pecially into muscles, joints, or bleeding into closed spaces. Major complications
include hemarthrosis, hemorrhage, gastrointestinal bleeding, and menorrhagia.
Though there is no cure for hemophilia, it can be controlled with regu-
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lar infusions of the deficient clotting factor, i.e. fVIII in hemophilia A or fIX
in hemophilia B. Replacement therapy markedly improves the management
of bleeding of most patients with hemophilia. However, fVIII and fIX in-
hibitors have developed in 18-32% and 2-3% of hemophiliacs A and B in re-
sponse to fVIII and fIX, respectively [28] and those inhibitors make the sub-
sequent management of patient, using coagulation factor concentrates, diffi-
cult. In the 1980s, activated prothrombin complex concentrates (APCCs) from
pooled plasma were developed for hemophiliacs with inhibitors, assuring ‘fVIII
bypassing activity’ [29, 30]. However, APCCs induce disseminated intravascu-
lar coagulation syndromes or acute MI [31]. Recently, recombinant factor VIIa
(rFVIIa) was developed as a new bypassing agent, and its clinical efficacy and
safety have been established [32, 33]. However, because of its short half-life,
therapy with rFVIIa requires frequent administration (at intervals of 2-3 h) to
achieve hemostasis [28]. Therefore, the search for a novel therapeutic agent for
hemophilia with inhibitors is still ongoing.
Fibrinolysis
Fibrinolysis is the process wherein a fibrin clot, the product of coagulation, is
broken down. The set of enzymatic reactions that constitute fibrinolysis is ini-
tiated when thrombin and fibrin, formed during coagulation, activate endothe-
lial cells resulting in enhanced production of tissue plasminogen activator (tPA)
or urokinase-like plasminogen activator (uPA) [9]. tPA and uPA catalyze the
transformation of plasminogen into the active form plasmin, which cuts the fib-
rin mesh at various places, leading to the production of circulating fragments
that are cleared by other proteases or by the kidney and liver. Plasminogen con-
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tains secondary structure motifs known as kringles, which bind specifically to
lysine and arginine residues on fibrin(ogen). When converted from plasmino-
gen into plasmin, it functions as a serine protease, cutting C-terminal to these
lysine and arginine residues. tPA and uPA are themselves inhibited by plas-
minogen activator inhibitor-1 and plasminogen activator inhibitor-2 (PAI-1and
PAI-2) [34]. Plasmin activity is also reduced by thrombin-activatable fibrinoly-
sis inhibitor (TAFI), which modifies fibrin to make a less potent cofactor for the
tPA-mediated plasminogen [35].
1.1.2 Quality of the vessel wall
Blood vessels are lined with endothelial cells which, in their normal state, ex-
press anticoagulant activity and do not support platelet adhesion [36]. Exposure
of the subendothelial surface by injury, however, initiates coagulation. This is
due both to exposure of tissue factor, which activates the extrinsic cascade, and
to the presence of collagen, which not only activates platelets, but also avidly
supports their adhesion [9]. In addition, biomaterial-induced blood coagulation
remains a major impediment to the successful use of implantable and periph-
eral medical devices [37]. When the blood-contacting surface is a foreign mate-
rial, the interactions are mediated by blood proteins. Within seconds of blood
contact, proteins begin to adsorb to the foreign surface. Once adsorbed, the pro-
teins can change their conformations to interact more strongly (or in some cases,
weakly) with cells and platelets than their bulk counterparts do [38]. In terms of
thrombosis, adsorption of high-molecular-weight kininogen (HMWK) can lead
to activation of fXII and initiation of the intrinsic coagulation cascade, while
adsorption of fibrinogen or von Willebrand factor (vWF) will support platelet
8
adhesion via the GpIIbIIIa and GpIb receptors, respectively, with aggregation
and thrombus formation following thereafter [39, 40].
1.1.3 Nature of the blood flow
The last leg of the triad is the one that ties everything together. Clearly, in order
for platelets and coagulation factors to reach an artificial surface or the site of an
injury, they must be transported there. Hemostasis, atherogenesis and throm-
bosis are processes which occur in flowing blood. Hence, the flow behaviour
of blood may partly explain the localisation and morphology of arterial, intrac-
ardiac and venous thrombi within the human circulation [41]. Furthermore, it
may partly explain why increases in hematocrit, fibrinogen and other macro-
molecules and rigid blood cells may increase the risk of ischaemic events [42].
The rheological behavior of normal whole blood is dominated by red blood
cells (RBCs), which typically account for about 40% of the total blood volume
and 99% of the volume of particulate matter [43]. Largely due to their deforma-
bility, an excess of RBCs develops in the central core of a steady tube flow, while
an RBC-depleted layer develops near the wall; this is the well-known “Fahraeus
effect” [44]. Due to the crowding of RBCs in the center of the vessel, platelets
are expelled to the near-wall region, where an excess which has been observed
to be as high as nine times the bulk concentration can develop [45]. RBC col-
lisions and rotational motions also enhance mixing and transport of platelets
near the vessel wall, where they are strategically placed for adhesion and acti-
vation. In streamline (laminar) flow, shear stresses are maximal at the vessel
wall, and affect endothelial cell morphology and function. Endothelial cells
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elongate and align in the direction of flow. Furthermore, high shear forces at
the vessel wall may activate platelets and increase their vWF-induced adhe-
sion to exposed subendothelium. However, high wall shear forces also increase
removal of platelet aggregates, thrombin and fibrin monomer; hence stasis (in-
duced by internal or external pressure) is required to allow fibrin formation and
secondary hemostasis.
Atherogenesis occurs preferentially at arterial bifurcations and bends, at
which sites flow separation results in areas of low-flow, low-shear recirculation
of blood cells and proteins, in contact with the vessel wall [41, 42]. Such flow
conditions may favour adhesion of platelets and monocytes, as well as infiltra-
tion of plasma components such as low density lipoprotein (LDL) cholesterol
and fibrinogen. Rheological variables such as wall shear stress, and blood vis-
cosity and its determinants (hematocrit, fibrinogen, LDL) have been correlated
with the extent of ultrasonic carotid artery intima-media thickening (IMT) [46].
This may partly account for the predictive value of blood viscosity for stroke in
the same study [46]. Blood viscosity has also been associated with the extent of
coronary and peripheral atherosclerosis.
Arterial thrombosis usually follows rupture of atherosclerotic plaques, and
is the commonest pathophysiological process in acute coronary syndromes, MI
or IS. High intra-stenotic shear stresses may be one factor promoting arterial
plaque rupture, and through high-shear activation of blood platelets they may
also promote the initial platelet-rich “white head” of arterial thrombi. Distal to
the atherothrombotic stenosis, low-shear stresses may promote the subsequent,
fibrin-and red-cell-rich “red tail” [3]. Low post-stenotic perfusion pressure may
also promote the ability of blood viscosity (which increases under low shear
10
conditions, due to red cell aggregation), platelet microemboli, and activated
leucocytes to reduce microcirculatory blood flow, promoting infarction. These
rheological mechanisms may explain the associations of blood and plasma vis-
cosity, hematocrit, erythrocyte sedimentation rate (ESR; which reflects red cell
aggregation), white cell count, fibrinogen and von Willebrand factor with the
risk and the outcome of myocardial, cerebral and limb infarction [47].
1.2 Previous mathematical models
Complexity of blood coagulation and flow has been an obstacle and a simulat-
ing challenging factor for theoretical research in hemostasis and thrombosis for
decades. Recent decades witnessed an explosion of mathematical modeling and
computer-simulation-based research in all areas of biochemistry and biology,
including coagulation. Two possible reasons could be suggested to explain the
popularity of theoretical methods. First, efficient theoretical analysis is possible
only when a sufficient amount of empirical information is collected. Second,
the complexity of biochemical objects makes analysis of mathematical models
extremely complicated without computer simulation. Thus the role of mathe-
matical and computer modeling gradually becomes more and more important
in the selection of the most effective experimental approaches, and blood coag-
ulation is not an exception in this sense.
The function of the complex reaction network of coagulation is to provide
thrombin where and when it is needed to form the fibrin. Understanding the
roles of the system components (feedback loops, inhibitors, platelets functions,
etc) in this regulation is important for a therapeutic control of thrombotic and
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bleeding disorders. Initial theoretical studies of the system structure were stim-
ulated by the hypothesis that reactions of coagulation form a cascade [48]. The
study of Levine [49] analyzed the kinetics of a simple enzymatic cascade consist-
ing of second-order reactions, with each enzyme being inhibited in a first-order
reaction. The system response (kinetics of the bottom enzyme of the cascade)
was a pulse with an amplitude proportional to the degree of stimulation, and
the steepness of the initial kinetics increased with the increase of the number of
stages in the cascade. Thus, the amplification role of the cascade was demon-
strated. Later, rapidly increasing volume of experimental knowledge about the
coagulation system induced modifications of this model. Models of greater
complexity, which brought together the kinetics of various sets of reactions and
included feedback loops and inhibitors under different reaction conditions (like
flow, extent of stimulus, etc.), emerged towards the late 1980s [50, 51]. Jones and
Mann [52] presented an early large scale model for thrombin generation via the
extrinsic pathway, and extended it to include the role of inhibitors [53]. Leipold
and coworkers [54] developed a linear system of ordinary differential equations
(ODEs) to simulate the generation of thrombin and compared with published
experimental results without the adjustment of any parameter value.
Within the context of this historical trend, individual research groups have
focused on certain important questions related to the coagulation response. Bel-
trami and Jesty [55] focused on the threshold response of simple representa-
tive systems of the enzyme cascade, and found that the activation threshold of
these systems was affected by flow rate, the size of the patch/injury, initial con-
centrations of active enzymes, etc. Basmadjian and coworkers investigated the
possible steady states of their models, and also studied the regulation of the
activation threshold by flow rate, surface area (of injury), and the type of sur-
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face [56, 57, 58]. Khanin and coworkers presented one of the earliest models
of thrombin generation in plasma that integrated five zymogen conversion re-
actions, and investigated the regulation of the activation threshold by levels of
stimulation of VII and XII [50], and the sensitivity of clotting time to concen-
trations of zymogens [59]. These models primarily described spatially homoge-
nous systems, i.e., ODEs were used. Kuharsky and Fogelson [60] also reported
a threshold manner to changes in the availability of binding sites for surface
bound enzyme complexes. They included the role of bulk flow in controlling
the mass transfer of reactants to and from a thin shell where they were well
mixed and also with different levels of binding site densities; such study elim-
inated the role that convection and diffusion may in all probability play in clot
formation and, especially, clot dissolution but remain significant in view of the
insight into the coagulation pathway that they offer.
In addition, numerous empirical studies have shown [61, 62], platelet aggre-
gation [63] and clot formation can be highly spatially variable, especially when
flow disturbances or highly reactive surfaces are present. Predicting such varia-
tions may be important if one is to accurately determine where clinically signif-
icant thrombi will form [64]. Studies on the growth of clots upon the activation
of a series of enzymatic reactions, chosen to represent various features of the
coagulation pathway, have emerged since late 1980s. Basmadjian used classical
fluid dynamical correlations to estimate critical ranges of thrombus height and
fluid shear rate which predisposed to embolization [65]. He also predicted that
thrombus porosity and fluid inertial effects have relatively less effect on throm-
bus stability than drag forces. Ataullakhanov and coworkers studied the growth
and termination of clot formation in spatially inhomogenous unstirred systems
primarily due to contact activation (intrinsic pathway) by means of a mathemat-
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ical model [66, 67]. Post-activation, the growth of the fibrin clot into the blood
zone was studied in one spatial dimension. In a similar study, Ataullakhanov et
al. [68] described and corroborated a slightly improved version of this model,
and again investigated the spatial growth of a clot on a segment. Sorensen et
al. [69, 70] proposed a set of coupled convection-reaction-diffusion equations
to govern 6 components that the authors believed were crucial to the processes
governing platelet activation and deposition in flowing human blood. They,
however, incorporated these reactions as taking place in a Newtonian (Navier-
Stokes) fluid, and solved the equations governing the platelets and platelet ago-
nists while ignoring the effect of the growing thrombus on the flow field. Similar
models which specifically attempt to predict spatially varying platelet deposi-
tion in the presence of two-dimensional disturbed flow have been published
by David et al. [71], who consider stagnation-point flow, and Wootton et al.
[72], who simulated axisymmetric stenoses. Both models used steady-state two-
dimensional convection-diffusion equations to model platelet transport, with
adhesion simulated by a non-saturating surface-flux boundary condition whose
rate constant was the only adjustable parameter in the model. And surprisingly,
both models showed the poorest agreement between predicted and experimen-
tal results in the downstream, fully-developed-flow regions of their geometries,
rather than in the disturbed flow regions.
While in almost all the mathematical models that have been published thus
far decoupled the complex reactions in the coagulation cascade from the rheo-
logical aspects of the local environment. In these studies, the coagulation net-
work was either simplified or only activities of platelets were considered in the
flowing blood. In addition, scant attention has been paid to the role of the fib-
rinolytic mechanisms or shear stresses in clot formation, growth and dissolu-
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tion [9]. Thus in this study, we developed, to the best of our knowledge, the
most detailed model of thrombus formation in both normal and pathological
conditions; we further studied the effect of flow and wall shear stresses on the
formation and dissolution of thrombi.
1.3 Computational systems biology and sensitivity analysis
Computational systems biology, a term coined by Kitano in 2002 [73], is a field
that aims at a system-level understanding by analyzing biological data using
computational techniques [74]. As the need for a complete quantitative part list
in biology is recognized, the understanding develops that living systems, e.g.,
cells, tissues, and organisms, cannot be understood by studying just individual
parts. Under the guiding vision of systems biology, sophisticated computational
methods, e.g. mathematical modeling and sensitivity analysis, are currently be-
ing developed to analyze the data generated by this new technology in a sys-
tematic fashion.
1.3.1 Computational systems biology
These days it is well recognized that the many mechanisms involved in the pro-
liferation of complex diseases such as cancer cannot be understood solely on
the basis of knowing all of their molecular components. However, a lack of
system-level understanding of cellular dynamics has prevented any substantial
increase in the number of new drugs available to the public and any increase
in drug efficacy or eradication of any specific diseases. In contrast, pharma-
15
ceutical companies are currently lacking criteria for selecting the most valuable
targets, research-and-development expenses skyrocket, and new drugs rarely
hit the market and often fail in clinical trial, while physicians face an increasing
wealth of information that needs to be interpreted intelligently and holistically
[75]. Analysis of this dilemma reveals primary difficulties due to the enormous
biomolecular complexity, structural and functional unknowns in a large portion
of gene products, and a lack of understanding of how the concert of molecular
activities transfers into physiological alterations and disease.
We are at a very important turning point in biology, in that the ever-
increasing quality and quantity of molecular data now provides the basis for
building mathematical models of biological processes with increasing complex-
ity. The general focus of biomedical research needs to change from a primarily
steady-state analysis at the molecular level to a systems biology level capturing
the characteristic dynamic behavior. Such concepts will likely transform cur-
rent diagnostic and therapeutic approaches to medicine [75]. Assmus et al. and
others maintained that analysis of the dynamics of human relevant networks
using predictive computer models and high-throughput data generation would
play an increasingly important role in medical research and the elucidation of
disease mechanisms [76, 77].
The multitude of computational tools needed for systems biology research
can roughly be classified into two categories [78]: system identification and be-
havior analysis. Once the system has been identified and a model constructed,
the system behavior can be studied, for instance, by numerical integration or
sensitivity analysis against external perturbations. In molecular biology, sys-
tem identification amounts to identifying the regulatory relationships between
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genes, proteins, and small molecules, as well as their inherent dynamics hidden
in the specific kinetic and binding parameters. System identification is arguably
one of the most complicated problems in science. Whereas behavior analysis is
solely performed on a model, model construction is a process tightly connected
to reality.
1.3.2 Sensitivity analysis
Sensitivity analysis is an essential part of analyses for complex systems [79].
Specifically, sensitivity analysis refers to the determination of the contributions
of individual uncertain analysis inputs to the uncertainty in analysis results. A
number of approaches to sensitivity analysis have been developed, including
differential analysis [79], Monte Carlo analysis [80], and variance decomposi-
tion procedures [81]. Overviews of these approaches are available in several re-
views [82, 83]. The focus of this study is on Monte Carlo (i.e., sampling-based)
approach to sensitivity analysis, which is both effective and widely used [82, 80].
Analyses of this type involve the generation and exploration of a mapping from
uncertain analysis inputs to uncertain analysis results. The underlying idea is
that analysis results y(x) are functions of uncertain analysis inputs x. This leads
to the question: How important are the individual elements of x with respect to
the uncertainty in y(x)? The goal of sensitivity analysis is to answer the ques-
tion.
Sensitivity analysis has also been used to explore the robustness and fragility
of metabolic and signaling networks. Robustness, the ability to maintain system
performance in the face of perturbation and uncertainty, is a desirable feature
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in both biological as well as man-made networks, machines and systems [84].
Conversely, fragility, i.e., extreme sensitivity to small perturbations, is a very un-
desirable trait that could lead to catastrophic system failure following seemingly
innocuous perturbations, e.g., a Boeing 777 crashing because of minor software
failures or microscopic alterations in a few integrated chips [85]. Stelling et al. re-
viewed several examples of robustness in biological networks [84], while Leibler
first computationally predicted and later experimentally verified robust features
of chemotaxis control networks [86, 87]. Bullinger and coworkers explored the
robustness of models of programmed cell death or apoptosis [88], while Stelling
et al. computationally identified points of robustness and fragility, using Monte
Carlo sensitivity analysis and overall state sensitivity coefficients, in models of
circadian rhythm [89]. In this study, the sensitivity analysis was used to extract
qualitative information about the critical elements, i.e., sensitive mechanisms,
in the process of blood clotting, and these mechanisms could serve as a rational
basis for therapeutic target selection.
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CHAPTER 2
COMPUTATIONALLY DERIVED POINTS OF FRAGILITY OF A HUMAN
CASCADE ARE CONSISTENT WITH CURRENT THERAPEUTIC
STRATEGIES 1
2.1 Abstract
The role that mechanistic mathematical modeling and systems biology will play
in molecular medicine and clinical development remains uncertain. In this
study, mathematical modeling and sensitivity analysis were used to explore the
working hypothesis that mechanistic models of human cascades, despite model
uncertainty, can be computationally screened for points of fragility, and that
these sensitive mechanisms could serve as therapeutic targets. We tested our
working hypothesis by screening a model of the well-studied coagulation cas-
cade, developed and validated from literature. The predicted sensitive mech-
anisms were then compared with treatment literature. The model, composed
of 92 proteins and 148 protein-protein interactions, was validated using 21 pub-
lished datasets generated from two different quiescent in-vitro coagulation mod-
els. Simulated platelet activation and thrombin generation profiles in the pres-
ence and absence of natural anticoagulants were consistent with measured val-
ues, with a mean correlation of 0.87 across all trials. Overall state sensitivity
coefficients, which measure the robustness or fragility of a given mechanism,
were calculated using a Monte Carlo strategy. In the absence of anticoagu-
lants, fluid and surface phase factor X/activated factor X (fX/FXa) activity and
thrombin-mediated platelet activation were found to be fragile, while fIX/FIXa
1Deyan Luan, Michael Zai and Jeffrey D. Varner, PLOS Computational Biology, 2007 3(7),
1347-1359. Open Access: No permission is required from the authors or the publishers.
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and fVIII/FVIIIa activation and activity were robust. Both anti-fX/FXa and di-
rect thrombin inhibitors are important classes of anticoagulants; for example,
anti-fX/FXa inhibitors have FDA approval for the prevention of venous throm-
boembolism following surgical intervention and as an initial treatment for deep
venous thrombosis and pulmonary embolism. Both in-vitro and in-vivo experi-
mental evidence is reviewed supporting the prediction that fIX/FIXa activity is
robust. When taken together, these results support our working hypothesis that
computationally derived points of fragility of human relevant cascades could
be used as a rational basis for target selection despite model uncertainty.
2.2 Introduction
The role that mechanistic mathematical modeling and systems biology will play
in molecular medicine and clinical development remains uncertain. Kitano sug-
gested that understanding of critical questions in biology required the integra-
tion of experimental and computational research [73]. Assmus et al. and others
maintained that analysis of the dynamics of human relevant networks using
predictive computer models and high-throughput data generation would play
an increasingly important role in medical research and the elucidation of disease
mechanisms [76, 77]. However, parametric and structural uncertainty remains
an open challenge to mechanistic modeling in medicine.
Strategies that integrate experimental and computational techniques have
had success at elucidating network structures. Arm and Arkin reviewed ex-
perimental and computational techniques to uncover molecular interaction net-
works [90]. The central experimental advancements in the area of protein-
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protein network identification have been the yeast two-hybrid system [91, 92]
and quantitative mass spectrometry proteomic techniques to determine protein
complexes [93, 94]. Young and coworkers explored proteinDNA interactions
using the chromatin immunoprecipitation technique [95] where likely transcrip-
tion factor binding sites were determined using a combination of chromatin im-
munoprecipitation chips and DNA microarrays. Time-lagged correlation matri-
ces [96, 97], genetic programming techniques [98], and network decomposition
strategies have also been used with time-series concentration measurements to
estimate reaction network structures [99].
Sensitivity analysis has been used to integrate model identification and dis-
crimination with optimal experimental design and knowledge discovery. Cho
et al. used sensitivity analysis to study TNF-αmediated NF-κB signalling where
parametric uncertainty was addressed using Monte Carlo sensitivity analysis;
using the best-guess parameter set, a family of random parameter sets was gen-
erated where sensitivity coefficients were calculated for each member of the ran-
dom family [80]. Cho et al. went on to develop a unifying framework, building
upon the earlier work of Kholodenko et al. and Sontag et al. to unravel the func-
tional interactions in biomolecular networks using a stimulus-response strategy
and metabolic control analysis [100, 101, 102]. Kremling et al. investigated the
benchmark problem of growth of a microorganism in a continuous bioreactor
subject to feed shifts using sensitivity-based model identification and discrim-
ination strategies; they determined optimal experimental design and perturba-
tion strategies to identify and discriminate between rival model formulations
[103]. Gadkar et al. identified signal transduction models from time-course mea-
surements using a nonlinear scheme to estimate missing protein measurements
from measured values [104]. They went further and proposed strategies to cal-
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culate D-optimal experimental designs that maximized the experimental infor-
mation used to identify signal transduction models as well as an iterative strat-
egy to explore model structure [104, 105]. Sensitivity analysis has also been used
to explore the robustness and fragility of metabolic and signaling networks. Ro-
bustness, the ability to maintain system performance in the face of perturba-
tion and uncertainty, is a desirable feature in both biological as well as man-
made networks, machines and systems [84]. Conversely, fragility, i.e., extreme
sensitivity to small perturbations, is a very undesirable trait that could lead to
catastrophic system failure following seemingly innocuous perturbations, e.g.,
a Boeing 777 crashing because of minor software failures or microscopic alter-
ations in a few integrated chips [85]. Stelling et al. reviewed several examples of
robustness in biological networks [84], while Leibler first computationally pre-
dicted and later experimentally verified robust features of chemotaxis control
networks [86, 87]. Bullinger and coworkers explored the robustness of models
of programmed cell death or apoptosis [88], while Stelling et al. computation-
ally identified points of robustness and fragility, using Monte Carlo sensitivity
analysis and overall state sensitivity coefficients, in models of circadian rhythm
[89].
In this study, we use tools from systems biology, namely mathematical mod-
eling and sensitivity analysis, to explore the working hypothesis that mecha-
nistic models of human relevant cascades, despite model uncertainty, can be
computationally screened for points of fragility, i.e., sensitive mechanisms, and
that these mechanisms could serve as a rational basis for therapeutic target se-
lection. We test our working hypothesis by computationally screening a mech-
anistic model of the well-studied coagulation cascade developed and validated
from literature sources. After model validation, using 21 published datasets
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generated from two different quiescent in vitro coagulation models, we use
Monte Carlo sensitivity analysis to computationally screen the model for sen-
sitive mechanisms in the presence and absence of natural anticoagulants. We
then contrast the predicted fragile mechanisms with literature to determine if
they are consistent with experimental investigation, thereby proving or disprov-
ing our working hypothesis. While the current development is restricted to co-
agulation, the broader strategy is general and could be applied to an arbitrary
network.
2.2.1 A review of the coagulation cascade
Coagulation, mediated by a family of serine proteases (factors) and a key group
of blood cells (platelets), both of which are normally inactive in the circulation,
is directly relevant to human health and has been suggested by Somogyi and
Greller to be an ideal candidate for in silico drug discovery [106]. Insufficient
coagulation is manifested in disorders such as hemophilia A (1 in 5,000 live
births), hemophilia B (1 in 30,000 live births), or von Willebrand disease (1 in
1,000 live births) [107, 24]. Conversely, unwanted clotting can be a serious com-
plication following surgical intervention and is directly involved in coronary
artery diseases, which collectively account for 38% of all deaths in North Amer-
ica [4].
The salient features of the coagulation cascade included in our model, shown
schematically in Figure 2.2.1 and presented in detail in Appendix A Table A.3,
are reviewed here. Several extensive reviews of the underlying biochemistry
and cell biology of coagulation can be found elsewhere [108, 109, 110, 111].
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Figure 2.1: Schematic of the coagulation cascade. (A) Upstream coagula-
tion factors are activated by substances exposed because of ves-
sel injury; chief among these factors is TF. Activated upstream
coagulation factors initiate a cascade of events that culminate
in the activation of platelets and the key protease thrombin
(FIIa). Thrombin forms an amplification loop by activating it-
self and other coagulation factors as well as platelets. (B) Ac-
tivated platelets then aggregate to form platelet plugs, which
serve as scaffolds for fibrin clots.
There are two pathways that lead to activation of the master protease throm-
bin and eventually to a clotthe intrinsic and extrinsic cascades. It is generally
believed that the extrinsic cascade is the main mechanism of thrombinogenesis
in the blood [110, 111, 22]. Upstream coagulation factors are activated by ma-
terials exposed because of vessel injury chief among these tissue factors (TFs)
[112]; TF and activated factor VIIa (FVIIa) present in the blood form a complex
that activates factor X (fX) and fIX. FXa activates downstream factors, including
fV, fVIII, and fIX. FXa can also, along with FVa, form a complex on the surface of
activated platelets that converts prothrombin (fII) to thrombin (FIIa). TF-FVIIa
is not the only mechanism to activate fX; FIXa and FVIIIa can complex on the
24
surface of activated platelets and catalyze the formation of FXa. Platelet localiza-
tion at the wound site occurs through specific interactions between the platelet
and the subendothelium, primarily through recognition of exposed materials
such as collagen, fibronectin, and von Willebrand factor. Localized platelets
are activated by external signals such as adenosine diphosphate and thrombin.
Thrombin irreversibly activates platelets through a family of transmembrane
receptors on the platelet surface called protease-activated receptors [113, 114].
Thrombin, in addition to playing a key role in platelet activation, catalyzes the
conversion of fibrinogen (secreted by activated platelets from internal stores)
to fibrin. Fibrin, with the help of FVIIIa, forms a cross-linked mesh inside the
platelet plug that stops blood flow. Thrombin also activates upstream coag-
ulation factors, thereby forming a strong positive feedback that ensures rapid
activation. Three control points that inhibit thrombin formation are considered
in the model. TF pathway inhibitor (TFPI) downregulates FXa formation and
activity by sequestering free FXa and TF-FVIIa in an FXa-dependent manner.
Antithrombin III (ATIII) neutralizes all serine proteases generated during the
coagulation response, making it perhaps the most powerful control element in
the cascade. Thrombin itself plays an inadvertent role in its own inhibition by
binding the surface protein thrombomodulin (TM), expressed on normal vascu-
lature [23]. The FIIaTM complex catalyzes the conversion of protein C (PC) to
activated PC (APC); APC attenuates the coagulation response by the proteolytic
cleavage of fV/FVa and fVIII/FVIIIa [23].
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2.3 Results
Simulations of TF-FVIIa initiated coagulation in the presence and absence of
anticoagulants were compared with 21 published datasets from two different in
vitro coagulation models [108, 115, 116]. The model parameters used in the val-
idation simulations (unless otherwise noted) were compiled from literature and
are shown in Appendix A Table A.3. Initial conditions for the validation sim-
ulations are given in the Appendix A Table A.2. To gauge the robustness and
fragility of each interaction in the cascade, overall state sensitivity coefficients
(OSSCs) were calculated for each of the 148 model parameters over a family
of random parameter sets (see Methods and Materials). Simulation results are
shown in Figure reffig-sim-results, and error quantification is reported in Ta-
ble 2.1. With the exception of PC and one TFPI case, the model explained the
time-resolved thrombin generation profile following TF-FVIIa addition to qui-
escent synthetic plasma. Platelet activation was assumed to be instantaneous
for the synthetic plasma simulations. To test the ability of the model to simul-
taneously describe platelet activation and thrombin formation, simulations of
TF-FVIIa initiated coagulation were compared with the in vitro cell-based assay
of Roberts and coworkers [115] (Figure 2.2F); both platelet activation and throm-
bin generation profiles were consistent with the cell-based assay after adjusting
three parameters used in the synthetic plasma simulations. Analysis of the sen-
sitivity results for the control (no inhibitors) revealed that thrombin formation
is controlled by both initiation and amplification mechanisms; the 25 most frag-
ile mechanisms for the control are reported in Table 2.2, and the rank-ordered
fragility results for 100 random parameter sets for the control, TFPI, and ATIII
cases are shown in Figure 2.3.2AC. Mechanisms involving fluid and surface
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phase fX/FXa and thrombin were found to be the most sensitive, while mech-
anisms involving fIX/FIXa and fVIII/FVIIIa were found to be robust. Binding
interactions were found to be the most sensitive group of interactions. Analysis
of the significant shifts in the overall state sensitivity coefficients (see Methods
and Materials) revealed both additive and synergistic effects when compared to
the control (Figure 2.3.2).
2.3.1 Thrombin activation in synthetic plasma in the presence
and absence of natural anticoagulants.
The predicted thrombin concentration profiles following the addition of TF-
FVIIa to synthetic plasma were quantitatively consistent with in vitro observa-
tions (Figure 2.2E). The fraction of variation explained by the model (Table 2.1)
was found to be inversely proportional to TF-FVIIa input strength. In the ab-
sence of inhibitor, thrombin generation was characterized by two regimes; at
first, FXa generated thrombin in the bulk fluid, and then subsequently, the
thrombin signal was amplified by activity of FVa-FXa surface complex (pro-
thrombinase). Decreasing the TF-FVIIa input prolonged the initiation phase as
it slowed the rate of generation of FXa and thrombin in the bulk. However, TF-
FVIIa input strength did not influence the maximal rate of thrombin formation
because this is surface dominated; this was observed by comparing the slope or
total net rate of thrombin generation across the TF-FVIIa cases.
TFPI and ATIII influenced both the initiation and amplification of the FIIa
signal (Figure 2.2A and 2.2B). Increased TFPI concentration lead to a longer
initiation delay and a decreased rate of FIIa amplification (Figure 2.2A). TFPI
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Figure 2.2: Model validation using published in-vitro datasets. (A) Throm-
bin concentration versus time as a function of TFPI concentra-
tion following the addition of 1.25pM TF-FVIIa to synthetic
plasma. (B) Thrombin concentration versus time for differ-
ent combinations of TFPI and ATIII following the addition of
1.25pM TF-FVIIa to synthetic plasma. (C) APC concentration
versus time as a function of TM concentration following the
addition of 1.25pM TF-FVIIa to synthetic plasma. (D) Throm-
bin concentration as a function of time as a function of TM
concentration following the addition of 1.25pM TF-FVIIa to
synthetic plasma. (E) Thrombin concentration versus time as
a function of TF-FVIIa initation strenght in synthetic plasma.
(F) Fraction of activated platelets and thrombin concentration
as a function of time in the cell-based assay. The synthetic
plasma assay cases were reproduced from Mann and cowork-
ers [108, 116, 117], while the platelet activation data (panel F)
was reproduced from Roberts et al. [115]. The GraphClick soft-
ware (Arizona Software, www.arizona-software.ch) was used
for data extraction where a coefficient of variation (CV) of ±10
was added to the data to account for extraction and experimen-
tal error. The initial conditions are shown in the Appendix A
Table A.2.
28
delayed initiation through interaction with free FXa and TF-FVIIa in an FXa-
dependent manner; sequestering FXa reduced flux through the initial FXa-
dependent route of FIIa generation. Thrombin amplification was negatively im-
pacted by TFPI by reducing free FXa available for the formation of the FVaFXa
surface complex. On average, the model explained 95% of the TFPI dynamics;
one exception was the 2.5 nM TFPI case (Figure 2.2B), where the correlation be-
tween model and experiment was 0.90. In contrast, ATIII reversibly binds FIXa,
FXa, and TF-FVIIa, and irreversibly inactivates FIIa. ATIII produced a differ-
ent thrombin generation profile when compared with TFPI (Figure 2.2B). ATIII
influenced FIIa initiation by sequestering FXa (a mechanism similar to TFPI)
and inactivated FIXa, thereby decreasing the rate of formation of the FVIIIaFIXa
surface complex. However, unlike TFPI, ATIII directly inactivated FIIa, leading
to the decreasing FIIa concentration observed experimentally. While the model
captured the qualitative features of ATIII (3.4 µM) activity, the correlation be-
tween the model and experiment was 0.68, indicating that slightly more than
half of the FIIa dynamics were correctly described. The combination of TFPI (2.5
nM) and ATIII (3.4 µM), consistent with the experiment, completely quenched
FIIa formation following TF-FVIIa addition.
Simulations of APC generation and inhibition of thrombin formation in the
presence and absence of TM were qualitatively consistent with in vitro data
(Figure 2.2C and 2.2D). APC was generated from PC via TM-dependent and -
independent routes; the TM-dependent route catalyzes the conversion of PC to
APC at a rate 400-fold greater than the thrombin route alone [116]. Three dif-
ferent TM concentrations were simulated, and the time course of APC and FIIa
were compared with published data [116]. The correlation between model and
experimental data for APC was approximately 96% for TM values 1 nM. How-
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Table 2.1: Quantification of model error.
Simulation Normalized Standard Error Correlation r2
FVIIa-TF Simulations
5 nM 0.12 0.80
500 pM 0.08 0.93
50 pM 0.08 0.96
10 pM 0.07 0.97
5 pM 0.06 0.98
TFPI Simulations
0 nM 0.07 0.96
1.0 nM 0.06 0.98
2.5 nM 0.13 0.90
5.0 nM 0.06 0.96
ATIII and TFPI Simulations
No TFPI + No ATIII 0.03 0.99
2.5 nM TFPI + No ATIII 0.03 0.99
3.4 µM ATIII 0.21 0.68
2.5 nM TFPI + 3.4 µM ATIII ND ND
APC+TM Simulations
0 nM TM (APC) 0.07 0.95
1 nM TM (APC) 0.06 0.97
10 nM TM (APC) 0.29 0.49
0 nM TM (FIIa) 0.45 0.51
1 nM TM (FIIa) 0.19 0.82
10 nM TM (FIIa) 0.69 0.57
Platelet Activation and Thrombin Simulations
Platelet Activation 0.12 0.94
Thrombin 0.15 0.89
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ever, the average correlation between the predicted and measured FIIa profile
for TM 1 nM was 67%. Simulations of the TM 10 nM case failed to quantita-
tively capture both APC and FIIa formation; the correlation between model and
experiment for APC in the presence of 10 nM TM was 49%, while 57% of the
FIIa dynamics were correctly described.
In-vivo, amplification of the thrombin signal requires the surface of acti-
vated platelets. Preliminary simulations of simultaneous platelet activation and
thrombin formation (Figure 2.2F) were found to be consistent with the results
of the cell-based coagulation assay of Roberts and coworkers [115]. The corre-
lations between the measured and the simulated fraction of activated platelets
and thrombin were 0.94 and 0.89, respectively. In contrast with coagulation in
synthetic plasma, lag periods were observed for platelet activation and throm-
bin generation. Following the initial lag, the activated platelet concentration
increases rapidly to a plateau of ≈100% activation. The thrombin concentration
reaches a maximum of 55 nM at 30 min and then decreases to 0 nM at 70 min be-
cause of ATIII activity. Three parameter values were changed in the cell-based
assay simulations compared with synthetic plasma; the rate constant controlling
the activation of subendothelial bound platelets by thrombin was changed from
9.0 × 10−3 s−1 to 4.5 s−1, the activation of prothrombin by prothrombinase was
changed from 30 s−1 to 6 s−1, and the binding of ATIII to thrombin was changed
from 1.5 × 10−5 nM−1s−1 to 4.8 × 10−5 nM−1s−1.
31
2.3.2 The fragility and robustness of the coagulation architec-
ture.
Overall state sensitivity coefficients were calculated for treatment cases AD
shown in Table 2.3. The top 25 fragile mechanisms for the control (case A) are
shown in Table 2.2; four of the top five fragile mechanisms involve the binding
or activation of fX/FXa, with the fifth being platelet activation by FIIa. Other
sensitive mechanisms include the formation of the FVaFXa surface complex, the
activation of thrombin by the FVaFXa complex, and the activation of surface
or fluid phase fIX and fV. Fragility is spread across initiation and amplification
mechanisms; 14 of 25 fragile mechanisms were upstream of the FVaFXa or FVI-
IIaFIXa surface complexes, while the remaining 11 involved platelet activation,
FVaFXa activity, and FIIa inactivation. Binding interactions were found to be the
majority of fragile mechanisms; 21of 25 of the top fragile points were binding
interactions. Six paired binding interactions were found to be sensitive, indicat-
ing affinity was controlling in these cases; the exception was the TF-FVIIaX and
VaP5sXaP10s complexes, where on rate, catalytic turnover, and off rate were all
found to be sensitive. Of the predicted robust mechanisms, the most nonintu-
itive were the formation and activity of the FVIIIaFIXa surface complex respon-
sible for FXa amplification.
Statistically significant changes in overall sensitivity coefficients relative to
the control were used to gauge the importance of mechanisms in each treatment
case. For example, if the sensitivity of a binding interaction increased relative to
2A family of random parameter sets (N = 100) was generated by perturbing the nominal
parameter by up ±50%. OSSCs were calculated for each random family member where the
resulting OSSC values for each parameter were scaled by the maximum OSSC. Statitics of the
population of scaled OSSC values were computed and the mean OSSC value (µ) ± one standard
deviation (σ) is reported.
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Table 2.2: The twenty most fragile coagulation mechanisms in the absence
of inhibitors.2
µ ± σ Reaction Description
0.85±0.12 TF-FVIIa-Xa→ TF-FVIIa+Xa X activation by TF-FVIIa (catalytic)
0.85±0.21 X+P10s
 X-P10s X binding with platelet active sites (on)
0.85±0.21 X-P10s
 X+P10s X binding with platelet active sites (off)
0.83±0.22 Xa+P10s
 Xa-P10s Xa binding with platelet active sites (on)
0.77±0.17 PL-IIa→ AP+IIa Platelet activation by thrombin (catalytic)
0.62±0.18 X+TF-FVIIa
 X-TF-FVIIa X binding with TF-FVIIa (on)
0.57±0.28 II-P2s-Va-P5s-Xa-P10s→ IIa-P2s+Va-P5s-Xa-P10s IIa activation by prothrombinase (catalytic)
0.53±0.20 Xa+IX
 Xa-IX Binding of IX by Xa (on)
0.52±0.25 II-P2s+Va-P5s-Xa-P10s
 II-P2s-Va-P5s-Xa-P10s IIa interaction with prothrombinase (on)
0.50±0.18 Xa-IX
 Xa+IX Binding of IX by Xa (off)
0.48±0.19 X+TF-FVIIa
 X-TF-FVIIa X binding with TF-FVIIa (off)
0.38±0.17 IX+TF-FVIIa
 IX-TF-FVIIa Binding of IX by TF-FVIIa (on)
0.38±0.17 Va-P5s + Xa-P10s
 Va-P5s-Xa-P10s Formation of prothrombinase (on)
0.35±0.17 Va-P5s+Xa-P10s
 Va-P5s-Xa-P10s Formation of prothrombinase (off)
0.31±0.18 IIa+P2s
 IIa-P2s IIa binding with platelet active sites (off)
0.31±0.17 IX+TF-FVIIa
 IX-TF-FVIIa Binding of IX by TF-FVIIa (off)
0.23±0.19 V-P5s + IIa-P2s
 V-P5s-IIa-P2s Activation of V by IIa (on)
0.23±0.10 PL + IIa
 PL-IIa Activation of platelets by IIa (on)
0.22±0.10 TF-FVIIa
 TF + FVIIa Interaction of FVIIa with TF (off)
0.20±0.08 IX+P9s
 IX-P9s IX binding with platelet active sites (on)
0.20±0.08 IX+P9s
 IX-P9s IX binding with platelet active sites (off)
0.19±0.08 X+II
 X-II X binding with II (on)
0.19±0.13 II+P2s
 II-P2s II binding with platelet active sites (on)
0.18±0.10 IIa→ IIa IIa inactivation (catalytic)
0.18±0.15 IX-P9s+Xa-P10s
 IX-P9s-Xa-P10s IX binding with Xa on platelet surface (on)
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Table 2.3: Treatement cases considered in the sensitivity analysis.
Case FVIIa-TF (pM) TFPI (nM) ATIII (µM) PC (nM) TM (nM)
A 1.25 – – – –
B 1.25 2.5 – – –
C 1.25 – 3.4 – –
D 1.25 2.5 3.4 – –
the control (became more fragile), then that interaction assumed increased im-
portance in the treatment case. Conversely, a decrease in sensitivity relative to
the control (mechanism became more robust) indicated a decrease of the overall
impact of the mechanism. The anticoagulants TFPI and ATIII modulate throm-
bin formation by different mechanisms and have distinct regions of molecular
influence. Although ATIII and TFPI share a common target (FXa), only two of
15 significant OSSC shifts were shared between the treatment cases (cases B and
C) relative to the control (case A). TFPI was found to influence thrombin forma-
tion primarily through the FXa-specific interaction with TF-FVIIa; there were 13
mechanisms whose OSSC values changed significantly in response to TFPI (case
A versus case B), nine of which become more robust, while two become more
fragile (Figure 2.3.2B). TFPI reduced the fragility of the affinity of fIX and fX for
TF-FVIIa, the sensitivity of TF-FVIIamediated formation of FXa, the affinity of
FXa for fluid phase fIX, the stability of the TF-FVIIa complex, and the binding
of fX and FXa with free-platelet binding sites. Conversely, TFPI increased the
fragility of the off rate governing the disassociation of FXa from platelet binding
sites and the interaction of itself with FXa. While ATIII had a more pronounced
effect on FIIa generation than TFPI alone (Figure 2.2B), only four mechanisms
were significantly affected by ATIII (case A versus case C). ATIII influenced
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Figure 2.3: Sensitivity analysis of the coagulation cascade. OSSCs were
calculated using randomly generated parameter sets con-
structed by perturbing the nominal parameter set by up to ±
50% for each parameter (N=100). (A-C): The x-axis denotes the
trial index (index of the random parameter set), while the y-
axis denotes the fragility index. The fragility index is calculated
by determining the parameter index of the rank-ordered the
OSSC values (The parameter index corresponding to the most
fragile parameter has fragility index of 1; the next fragile is 2,
while the most robust parameter has a fragility index of 148).
The fragility index shows the robustness of a parameter; the
smaller the fragility index, the more fragile the parameter. The
parameter types are color-coded (shown in the color bar) and
organized by biological function: 1-16, subendothelium inter-
actions; 17-40, plasma interactions; 41-62, platelet surface bind-
ing; 63-77, platelet activation; 78-107, reactions on platelet sur-
face; and 108-148, inhibitory reactions. (D-F) The OSSC values
from TFPI, ATIII, and TFPI+ATIII cases versus the control.
thrombin formation through direct interaction with FXa and FIIa; ATIII reduced
the sensitivity of the affinity of FXa for fIX in the fluid phase, while the on rate
governing the binding of FXa and FIIa with ATIII was found to be of increased
importance.
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The predicted mechanism of action of anticoagulant combinations is not
equivalent to the union of the individual treatment cases. The combination
of TFPI + ATIII (case D) resulted in 14 statistically significant shifts relative
to the control. Initiation mechanisms, e.g., the affinity of TF-FVIIa for fX and
the affinity of FXa for fIX in the bulk fluid, were predicted to be less impor-
tant. Conversely, the sensitivity of the off rate governing FXa interaction with
the platelet surface was found to increase. Some amplification mechanisms
became more robust, while others became fragile. The activation of platelets
by FIIa via the protease-activated receptor family of surface receptors became
less important, but the retention of FXa and the affinity of the surface FVaFXa
complex increased in importance. Last, trivial interactions resulting from the
addition of TFPI and ATIII (the direct interactions of TFPI and TF-FVIIa in an
FXa-dependent manner and ATIII with FXa) were predicted to become fragile
relative to the control. Shifts in sensitivity coefficients were not additive across
treatment cases; e.g., the compilation of significant shifts resulting from TFPI
and ATIII addition was found not to be equivalent to the combination treat-
ment. Of the 14 significant shifts observed in the TFPI + ATIII case (relative to
the control), four mechanisms found to be sensitive in the individual cases were
missing in the combination, while three novel shifts were observed. Interac-
tion of fX/FXa with surface binding sites and the disassociation of the TFFVIIa
complex were found not to be significantly different than the control. The novel
shifts in the TFPI + ATIII combination were all amplification mechanisms; the
catalytic rate of IIa formation by FVa-FXa and the rate of platelet activation by
IIa were found to be less important in the ATIII + TFPI combination, while in-
teraction of surface-bound fV and FXa was found to increase in importance.
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2.4 Discussion
The predicted fragile mechanisms in the control are molecular targets in current
anticoagulation preclinical development, clinical therapies, and clinical trials.
Four of the top five fragile mechanisms involved fX/FXa or the activation of
platelets by FIIa. Anti-fX/FXa and direct thrombin inhibitors (DTIs) are two
important classes of anticoagulants (see Table 2.4 for a sampling of current clin-
ical trials involving anti-fX/FXa strategies and DTIs). Fondaparinux, a 1.7 kDa
pentasaccharide which selectively binds ATIII, is approved for the prevention of
venous thromboembolism following hip fracture surgery, total hip replacement,
total knee replacement, and major abdominal surgery in addition to the initial
treatment of patients with deep venous thrombosis and pulmonary embolism
[118, 119, 120, 121, 122]. Fondaparinux increases the natural inhibitory effect of
ATIII against FXa approximately 300-fold [123, 124]; selective inhibition of FXa
by fondaparinux interrupts thrombin generation and clot formation without in-
activating thrombin itself [125, 126]. Elalamy and coworkers showed in a whole-
blood in vitro assay that fondaparinux prolonged the lag time of prothrombin
activation for all concentrations explored, and for physiologically relevant con-
centrations (0.110.28 anti-FXa IU/ml), reduced the maximal rate of thrombin
formation to approximately 47%55% of its nominal value [127]. Herbert and
colleagues explored fondaparinux and the sulfated analog SANORG 32701 in
in vivo mouse, rat, and rabbit coagulation models [128, 129]; SANORG 32701
has a high affinity for ATIII (Kd = 3.7 0.7 nM) and shows more potent anti-FXa
activity (1,100 31 versus 850 21 U/mg for fondaparinux). DTIs have also been
explored as anticoagulants [130]. Thrombin activity is mediated by three protein
domains; an active site catalyzing protease activity and two exosites controlling
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Table 2.4: Ten example clinical trial for FXa and DTIs.3
Trial Identifier Treatment Purpose Target Mechanisms
NCT00412464 Fondaparinux Dose/PK study in thrombotic children ATIII-dependent FXa inhibitor
NCT00413374 Enoxaparin Outpatient treatment for DVT and/or PE ATIII-dependent FXa inhibitor
NCT00423683 Arixtra Clot prevention in cancer patients ATIII-dependent FXa inhibitor
NCT00245856 Fragmin Treatment of upper extremity DVT ATIII-dependent FXa/FIIa inhibitor
NCT00353678 YM150 Prevention of clot formation following HRS Direct FXa inhibitor
NCT00371683 Apixaban Prevention thrombosis following KRS Direct FXa inhibitor
NCT00180674 Ximelagatran Anticoagulation in liver fibrosis Direct II/IIa inhibitor
NCT00334464 Warfarin Establish pharmacogenetic warfarin dosing FVII, IX, X, and II inhibitor
NCT00206089 Melagatran Safety and efficacy of combination treatment Direct II/IIa inhibitor
NCT00206063 Ximelagatran Long-term tolerability of ximelagatran Direct II/IIa inhibitor
substrate binding [131]. Our sensitivity analysis predicts thrombin activation
of platelets is a key mechanism; Sarich et al. have explored the DTI ximelaga-
tran in healthy male volunteers [132]. Thrombin generation, platelet activation,
and the thrombinantithrombin complex were monitored in shed blood collected
from skin incisions in 120 healthy male volunteers following oral administration
of ximelagatran. Oral ximelagatran showed a rapid and statistically significant
decrease in all endpoints relative to control. When taken together, the fonda-
parinux, SANORG 32701, and ximelagatran results present a clinical basis in
both in vitro and in vivo coagulation studies for the prediction that fX/FXa and
IIa are fragile components of the coagulation architecture.
Mechanisms involving fIX/FIXa, consistent with multiple lines of experi-
mental evidence, were predicted to be moderately robust. Feuerstein et al. ex-
3Clinical trial information was assembled on May 15, 2007, from http://ClinicalTrials.gov
using the search terms thrombosis and thromboembolism, where both open and closed trials were
accepted; the search generated 215 clinical trials for thrombosis and 51 studies for thromboem-
bolism. DVT, deep venous thrombosis; HRS, hip replacement surgery; KRS, knee replacement
surgery; PE, pulmonary embolism.
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plored inhibition of fIX/FIXa using a murine anti-fIX/FIXa antibody (BC2) in
a male Sprague-Dawley rat model [133]. The fIX/FIXa activity and the acti-
vated partial thromboplastin time (aPTT) endpoints were monitored ex vivo
following intravenous infusion of the BC2 antibody. Feuerstein et al. found that
fIX/FIXa activity could be reduced by as much as 2.5-fold before any significant
change in the aPTT was observed; only after > 90% of the fIX/FIXa activity was
eliminated was there a 3.5- to 4-fold increase in aPTT. Benedict et al. explored
the contribution of fIX/FIXa to intravascular thrombosis in a canine coronary
thrombosis model [134]. Animals received an intravenous bolus of saline (vehi-
cle), bovine glutamyl-glycyl-arginyl-FIXa (FIXai; a competitive inhibitor which
prevents the assembly of the FVIIIa-FIXa complex [135, 136, 137]), bovine fIX, or
heparin. Animals that received saline or bovine fIX developed a coronary occlu-
sion due to a fibrin/platelet thrombus in approximately 1 h; conversely, FIXai
decreased coronary thrombus occlusion in a dose-dependent manner. However,
FIXai administration was not accompanied by increased bleeding at abdominal
and chest-wall incision sites, leading Benedict et al. to conclude, consistent with
the earlier work of Weiss and Lages [138], that direct TF-FVIIamediated activa-
tion of fX may be the primary mechanism of fX activation in blood obtained
from bleeding wounds. While our prediction that FVIIIa-FIXamediated fX ac-
tivation is robust is consistent with Benedict et al., the robustness of fIX mech-
anisms should be further explored using in vivo animal models or cell-based
assays to control for artifacts introduced by the synthetic plasma model.
Overall state sensitivity coefficients and shifts in sensitivity provide insight
into the potential method of action of coagulation inhibitors, including synergis-
tic effects, but are not predictors of clinical performance. The naive perspective
that a specific inhibitor influences only its target and nothing else is not con-
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sistent with our sensitivity analysis. Consider the sensitivity results for TFPI;
13 different mechanisms were predicted to change significantly relative to the
control. These shifts included not only the direct interactions of TFPI with FXa
and TF-FVIIa, but also secondary effects like FXa interaction with fluid phase
fIX. Moreover, the direction of shift, i.e., toward sensitivity or robustness, gives
insight into the mechanism of action and the response of the network to the
anticoagulant. In the case of TFPI, parameters associated with fluid phase FXa
activity became more robust relative to the control, indicating these mechanisms
were of decreased importance. Conversely, the off rate governing the disassoci-
ation of surface-bound FXa became more fragile relative to the control; keeping
FXa bound became important as only fluid phase FXa binds TFPI in our model.
However, while shifts in sensitivity coefficients might be a useful predictor of
the network response, they are not predictors of clinical performance. No infor-
mation about practical issues in patients, e.g., bioavailability, therapeutic win-
dow, unexpected toxicities, etc., was gained from sensitivity analysis of the net-
work in isolation. Perhaps embedding the network into a pharmacokinetic or
physiologically based pharmacokinetic (PBPK) model and then exploring the
sensitivity profile of the augmented system could give insight into factors such
as bioavailability and therapeutic window.
Despite parametric and structural uncertainty, the model captured the bulk
of the thrombin generation dynamics resulting from TF-FVIIainitiated coagula-
tion in the presence and absence of natural anticoagulants. However, several
challenges remain before the model is relevant to in vivo phenomena. First, pro-
and antiplatelet activation mechanisms operating on the endothelium should
be refined and/or included in the model. Predicted thrombin and APC concen-
trations in the presence of TM were not consistent with in vitro synthetic plasma
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measurements for TM concentrations > 10 nM. The discrepancy between IIa
and APC values remained despite changes in parameters indicating a potential
structural issue with the model. Also not considered was the active role played
by the endothelium; endothelial cells secrete anticoagulants (e.g., nitric oxide
[NO] and prostacyclin) and express surface proteins (e.g., CD39). CD39 inhibits
platelet activation by converting adenosine diphosphate, a potent inducer of
platelet activation, into adenosine monophosphate [139]; however, CD39 may
play a dual role, as Eniyoji et al. showed ∆CD39 mice had prolonged bleeding
times and decreased platelet activation [140]. Second, the predicted fraction of
activated platelets and the concentration of key complexes on the platelet sur-
face need to be quantified under a variety of conditions. Initial simulations of si-
multaneous thrombin formation and platelet activation were consistent with the
cell-based assay of Roberts and coworkers [115] (after changing three parameter
values). However, these simulations and the cell-based assay were conducted
assuming no flow and no regulatory input from the endothelium. Moreover,
given the role that activated platelets play in the amplification of the throm-
bin signal, the predicted concentration of key complexes on the platelet surface,
e.g., the FVIIIaFIXa and FVaFXa complexes, need to be validated. Third, the cell
biology of coagulation and clot formation must be embedded in a description
of physics occurring in clot formation. Several researchers have explored the
role that blood flow plays upon the formation of clots. Antaki and coworkers
developed a 2-D model of platelet deposition and activation in flowing blood
[69]. The Antaki model was able to describe the axial platelet deposition on col-
lagen under parallel-plate Poiseuille flow for a range of wall shear rates [70].
Diamond and coworkers have produced a rich body of work exploring the re-
action complexity of human blood, cell aggregation and adhesion under flow,
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the formation of key complexes on the surface of activated platelets under flow
conditions, establishing high-throughput techniques for real-time monitoring
of coagulation dynamics and have done stochastic modeling of the initiation of
coagulation [141, 142, 143, 144, 145]. These literature sources (and others) will
form the basis of our future development.
2.5 Methods
2.5.1 Formulation of the Model Equations.
The reactions considered in the coagulation model have been compiled from
literature and are given in Appendix A Table A.3. Mass balance equations are
written around each protein or protein complex yielding the set of differential
equations (vector-form):
dx
dt
= Sr (x,k) x (to) = xo (2.1)
The symbol S denotes the stoichiometric matrix (92 × 148), while x denotes
the 92-dimensional concentration vector of proteins or protein complexes and
r (x,k) denotes the 148-dimensional vector of reaction rates. Each row in S de-
scribes a particular protein or protein complex, while each column describes
the stoichiometry associated with a specific interaction in the network. Thus,
the (i, j) element of S denoted by σi j, describes how protein i is connected to
rate process j. If σi j < 0, then protein i is consumed in r j; conversely, if σi j > 0,
protein i is produced by r j, and if σi j = 0, there is no connection between pro-
tein i and rate j. We have assumed mass action kinetics for each interaction in
Appendix A Table A.3; under the mass action assumption the rate expression
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for the general reaction q:
∑
j∈{Rq}
σ jqx j →
∑
k∈{Pq}
σkqxk (2.2)
is given by:
rq
(
x, kq
)
= kq
∏
j∈{Rq}
x−α jqj (2.3)
where {Rq} denotes the set of reaction q, {Pq} denotes the product set for reaction
q, kq denotes the rate constant governing the qth reaction, and σ jq, σkq denote
stoichiometric coefficients (elements of the matrix S). We have treated every
rate as nonnegative; all reversible reactions in Appendix A Table A.3 were split
into two irreversible reaction steps. Thus, every element of the reaction rate
vector r(x,k) takes the form shown in Equation 2.3.
The model equations were solved using the LSODE routine of the OCTAVE
programming environment (v2.1.71) on an Apple Computer MacOSX (Cuper-
tino, CA; v10.4.8) workstation. Model parameters and structure were compiled
from literature; see Appendix A Table A.3 and [52, 54, 60, 52, 146, 9, 8, 53]. Ini-
tial conditions were taken from each experiment and roughly correspond to in
vivo physiological conditions (see Appendix A Table A.2). While the model pre-
sented here was developed from literature (including other models), it is, to the
best of our knowledge, the only coagulation model to simultaneous describe
all 21 datasets, including coupled platelet and thrombin activation and the ac-
tivity of three different anticoagulants, using only minimal parameter variation
(three-parameter change for a single case).
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2.5.2 Error Analysis of the Coagulation Simulations.
The correlation between model simulations and experimental data and the
scaled standard error were used to quantify the simulation uncertainty. The
correlation between simulation and experimental observation was calculated
using the relationship:
r2 =
∑NT
k=1
(
Ym (tk) − Y¯
)2
∑NT
k=1
(
Y¯ (tk) − Ym (tk)
)2
+
∑NT
k=1
(
Ym (tk) − Y¯
)2 (2.4)
where Ym (tk) denotes the model value at time point k, Y¯ denotes the global av-
erage experimental value (average of experimental measurements over time),
Y¯ (tk) denotes the average experimental value at time point k (average of exper-
imental trials at single time point), and NT denotes the number of time points.
The numerator of Equation 5.4 is the variation in the experimental data ex-
plained by the model, while the denominator is the total variation; thus, Equa-
tion 5.4 describes the fraction of the dynamics explained by the model across all
time points. In addition to correlation, the scaled standard error was used to
measure the agreement between the model and the experiment:
sE =
1
maxk
(
Y¯ (tk)
)

∑NT
k=1
(
Y¯ (tk) − Ym (tk)
)2
NT

1/2
(2.5)
Both error metrics were taken from Spiegel [147].
2.5.3 Computation of the OSSCs.
The sensitive or fragile elements of the coagulation architecture were determined
by computing OSSCs [89]. Because each parameter corresponds directly to
a particular molecular interaction in the cascade, OSSC values were used to
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gauge which elements of the architecture influence thrombin formation; large
OSSC values for parameters relative to their peers indicates fragility or sensitiv-
ity, while small OSSC values indicates robustness. OSSC values were calculated
by first calculating the first-order sensitivity coefficients:
σi j (tk) =
∂xi
∂p j
∣∣∣∣∣∣
tk
(2.6)
which are solutions of the matrix differential equation:
ds j
dt
= A (t) s j + b j (t) j = 1, 2, , P (2.7)
subject to the initial condition s j(t0) = 0. In Equation 5.8, the quantity j denotes
the parameter index, P denotes the number of parameters, A denotes the Jaco-
bian matrix, and bj denotes the jth column of the matrix of first-derivatives of
the mass balances with respect to the parameter values (B) are given by:
A =
∂f
∂x
∣∣∣∣∣∣
(x∗,p∗)
B =
∂f
∂p
∣∣∣∣∣∣
(x∗,p∗)
(2.8)
where (x∗,p∗) denotes a point along the nominal or unperturbed system solution.
We solved Equation 5.8 for each parameter using the ODE15s routine of MAT-
LAB 2006b (The Mathworks, http://www.mathworks.com). The matrices A
and B were estimated at each time step using a generalized gradient algorithm
[148]. The OSSC value for parameter j defined as:
S o j (t) =
p∗j
Ns
( NT∑
k=1
Ns∑
i=1
[
1
x∗i
∂xi
∂p j
∣∣∣∣∣∣
tk
]2)1/2
(2.9)
were computed using the scaled first-order sensitivities. The quantity NT de-
notes the number of time points used in the simulation, while Ns denotes the
number of proteins/protein complexes in the model. To account for parametric
uncertainty, the OSSC values (S o j) were calculated over a family of random pa-
rameter sets; we randomly perturbed each nominal parameter by up to ±50%,
then solved the sensitivity balances for each family member.
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2.5.4 Statistical analysis of the shifts in OSSCs.
Two different statistical tests were performed to identify large statistically sig-
nificant shifts in the OSSC values between treatment cases. A Welch t-test [149]
was used to find all statistically significant shifts resulting from the different
treatments, and then a secondary test on the z-score of each shift was preformed
to find only the most prominent significant shifts. The OSSC values calculated
over the family of random parameter sets were assumed to follow normal dis-
tributions in each treatment case. The standard test to determine if the means
of normal distributions are equal is the student t-test; however, the student t-
test assumes the two distributions in question have equal variances. We cannot
a priori guarantee this is true for the OSSC distributions in different treatment
cases; thus, we have chosen the Welch t-test. The Welch t-test is very similar to
the student t-test, with the exception that the two distributions being compared
are not required to have equal variances. The statistical significance of shifts in
OSSC values for each treatment case relative to the control were determined by
performing a Welch t-test with the null hypothesis that the means of the OSSC
values were equal at a 1% significance level. The list of significant OSSC val-
ues was further restricted to only those shifts with a magnitude larger than a
specified z-score (0.1) away from the squared mean displacement over the sig-
nificant OSSC values. We defined the displacement of an OSSC value relative to
the control as:
d j,q =
(
S¯ qo j − S¯ co j
)2
, j = 1, 2, , 148 (2.10)
where S¯ co j denotes the mean OSSC value over the family of random parame-
ter sets for parameter j in the control, while S¯ qo j denotes the same quantity for
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treatment case q. A significant shift in OSSC value is accepted if:
d j,q > zσdq + µdq (2.11)
where z denotes a desired z-score, σd j denotes the standard deviation of the total
displacement over all significant OSSC values for the qth treatment case, and µdq
denotes the mean of the significant displacements for treatment case q.
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CHAPTER 3
FALSE NEGATIVE STRUCTURAL UNCERTAINTY DESTROYS THE
ABILITY TO ASSESS THE ROBUSTNESS AND FRAGILITY OF
MOLECULAR INTERACTIONS IN A HUMAN CASCADE
3.1 Abstract
Mechanistic mathematical modeling has not played a significant role in the de-
velopment of new therapies for cancer, cardiovascular diseases or the treatment
of acute events such as thrombosis during or after surgery. A critical issue often
cited for the lack of modeling has been uncertainty. The conventional wisdom
is that the data requirement to fully identify and validate mechanistic models
is too large. One tool that could potentially extract qualitative properties about
interactions in molecular networks, despite model uncertainty, is monte-carlo
sensitivity analysis. In this study, we explored two critical open questions sur-
rounding sensitivity-based knowledge discovery, namely, the impact of para-
metric sampling strategies and network structural uncertainty upon the assess-
ment of the qualitative importance of molecular interactions in an archetype
human network. We tested the working hypothesis that the determination of
fragile and robust mechanisms using sensitivity analysis and uncertain mech-
anistic models was independent of parameter sampling strategy but strongly
dependent upon network structural uncertainty. We tested our working hy-
pothesis by analyzing a mechanistic model of the well-studied human extrinsic
coagulation cascade. Overall state sensitivity coefficients generated using ran-
dom and Latin Hypercube Sampling (LHS) were compared for two different
perturbation sizes. Random and LHS sampling produced a qualitatively simi-
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lar ranking of coagulation mechanisms as measured by the Spearman rank cor-
relation for both small and large parameter perturbations. Sensitivity analysis
of structurally defective coagulation networks was strongly influenced by false
negative structural defects but tolerant to false positive errors. Surprisingly,
no relationship was observed between network connectivity and the impact of
structural errors. However, there was a linkage between the biological function
of proteins and the impact of missing network structural information. When
taken together, these results indicate that while parametric uncertainty can be
partially overcome by sampling feasible parameter regions using one of several
strategies, structural uncertainty remains a critical determinant of our ability to
classify mechanisms as fragile or robust in networks relevant to human health.
3.2 Introduction
The role that mechanistic mathematical modeling and systems biology will play
in molecular medicine and clinical development remains uncertain. Kitano sug-
gested that understanding of critical questions in biology requires the integra-
tion of experimental and computational research [73]. Assmus et al., and oth-
ers maintain that analysis of the dynamics of human relevant networks using
predictive computer models and high-throughput data generation will play an
increasingly important role in medical research and the elucidation of disease
mechanisms [76, 77]. However, mechanistic mathematical modeling at the cel-
lular or network level has not been widely adopted as a data integration or
knowledge generation platform in cell-biology, despite thoughtful discussion
to the contrary [150]. The primary issue limiting the use of mathematical mod-
eling in molecular medicine is uncertainty. The conventional wisdom is that
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the data requirement to fully identify and validate mechanistic models is too
large. Two schools of thought have emerged on the manner in which uncer-
tain mechanistic models can be used to gain qualitative insight into the func-
tion of protein-protein and protein-DNA networks. Bailey hypothesized that
critical qualitative properties of metabolic or signaling networks and perhaps
even entire cells could be determined largely on the basis of network structure
[151]. Certainly, there is literature evidence to support the Bailey hypothesis in
metabolic networks [152, 153, 154, 155] and studies focused upon identifying
the modularity of networks [85, 156, 157] have identified recurrent motifs that
perhaps betray natural design principles. More recently, a second line of in-
quiry in the computational and systems biology community has focused upon
extracting qualitative information about networks, for example the robustness
of network interactions, using uncertain models and sensitivity analysis.
Sensitivity analysis is an enabling tool for the investigation of robustness and
fragility in networks relevant to human health and more generally for model-
based knowledge discovery. Robustness, a long-recognized property of living
systems and networks, allows function in the face of uncertainty while fragility,
i.e., extreme sensitivity, can potentially lead to catastrophic failure following
seemingly innocuous perturbations [85, 158, 159, 160, 84]. Several researchers
have used sensitivity analysis to better understand the robustness and fragility
of metabolic and signalling networks [86, 87, 80, 89, 88, 161]. In the context
of molecular medicine, sensitivity analysis has been used to predict fragile in-
teractions involved in coagulation [162] and mammalian cell-cycle [163] where
these fragile interactions were shown to be consistent with anti-coagulation and
anti-cancer therapeutic strategies. The link between fragility and possible novel
therapeutics has also been suggested by Kitano [164]. Sensitivity analysis has
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also been used to integrate model identification and discrimination with opti-
mal experimental design. Several optimal experimental design and model iden-
tification studies are resident in the literature [100, 101, 103, 104, 105, 165, 166]
along with many techniques to estimate sensitivity coefficients for models com-
posed of ordinary differential equations, differential algebraic and stochastic
equations [167, 168, 169, 170, 171, 172, 173, 174, 175, 176].
In this study, we explore two open questions surrounding sensitivity-based
knowledge discovery using uncertain network models, namely, the impact of
parametric sampling strategies and the influence of network structural uncer-
tainty on the determination of the qualitative importance of mechanisms in-
volved in networks relevant to human health. We explore the working hy-
pothesis that the determination of fragile and robust mechanisms using sen-
sitivity analysis and uncertain mechanistic models is independent of the pa-
rameter sampling strategy but strongly dependent upon the fidelity of the net-
work structure. We test our working hypothesis by analyzing a mechanistic
model of the well-studied human extrinsic coagulation cascade developed and
validated from literature [162] using two-different parameter sampling strate-
gies in combination with sensitivity studies of structurally defective coagula-
tion networks in which we systematically remove structural knowledge from
the cascade. While the current development is restricted to coagulation, the
broader strategy and conclusion drawn from this study may be applicable to
other molecular networks with a similar cascade architecture, e.g., the MAPK
cascade, Caspase activation cascade or the human complement system.
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3.3 Results
The mechanistic extrinsic coagulation cascade model of Luan et al., [162], used
in this study, consisted of 92 proteins and 148 protein-protein interactions (Fig.
2.2.1 and Supplemental Materials). The Luan et al., coagulation model was
formulated using literature parameter values and was validated using 21 dif-
ferent in-vitro data sets taken from two different in-vitro coagulation models
[116, 108, 115]. The robustness and fragility of mechanisms involved in TF-FVIIa
initiated coagulation was determined by computing Overall State Sensitivity
Coefficients (OSSCs) over a family of parameter sets constructed by randomly
perturbing the published parameter set by up to ±50% (N=100, unless otherwise
noted). To control for possible artifacts introduced because of random sampling
and the choice of the perturbation size, we performed two sets of computational
experiments in which the size of the parameter perturbation was varied along
with the method used to generate the family of parameter sets explored. The
role of structural uncertainty was explored by introducing structural defects into
the coagulation network and then quantifying the shifts in the sensitivity rank-
ing of interactions relative to the unperturbed control. The network structure
was perturbed by the addition of single and multiple false positive and false
negative defects. In the nominal network, sensitivity analysis of TF-FVIIa initi-
ated coagulation predicted two key coagulation factors, FXa and FIIa, mediated
the majority of fragile mechanisms while other coagulation factors, such as FIXa
activity, were found to be moderately robust. These results were found to be in-
dependent of both the size of perturbation and the strategy used to generate the
family of parameter sets sampled. Conversely, the ability to estimate the relative
importance of interactions in the coagulation network was found to be strongly
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dependent upon structural knowledge. While false positive defects had little
effect, the introduction of false negative interactions, i.e., connections present
in the control but missing in the defective networks, significantly impacted our
ability to forecast the qualitative significance of mechanisms.
3.3.1 FXa and FIIa mediate fragile mechanisms in TF-FVIIa ini-
tiated coagulation.
Fragile mechanisms for TF-FVIIa initiated coagulation were previously reported
by Luan et al., [162] and are shown in Fig. 3.3.2A; four of the top five fragile
mechanisms involved the binding or activation of fX/FXa with the fifth being
platelet activation by FIIa. Other sensitive mechanisms included the formation
of the FVa-FXa surface complex, the activation of thrombin by the FVa-FXa com-
plex and the activation of surface or fluid phase fIX and fV. Fragility was spread
across initiation and amplification mechanisms; 14/25 fragile mechanisms were
upstream of the FVa-FXa or FVIIIa-FIXa surface complexes while the remaining
11/25 involved platelet activation, FVa-FXa activity and IIa inactivation. Bind-
ing interactions were found to be the majority of fragile mechanisms; 21/25 of
the top fragile mechanisms were binding interactions. Six paired binding inter-
actions were found to be sensitive indicating affinity was controlling in these
cases; the exception was the TF-FVIIa-X and Va-P5s-Xa-P10s complexes where
on-rate, catalytic turnover and off-rate were all found to be sensitive. Of the
predicted robust mechanisms, the most non-intuitive were the formation and
activity of the FVIIIa-FIXa surface complex responsible for FXa amplification.
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3.3.2 The qualitative assessment of fragile and robust coagu-
lation mechanisms was invariant to parameter sampling
methodology.
The coagulation model parameters, although derived experimentally, do not
equally well describe each of the 21 in-vitro data sets used to validate the model.
Thus, a family of parameter sets, generated from the nominal set by random
perturbation, was used to estimate the OSSC distributions shown in Fig. 3.3.2A.
There were at least two potential drawbacks to random parameter sampling;
first, there was no guarantee that all of the interesting behavior was sampled
and similar behavior was likely oversampled and; second, perhaps a quali-
tatively different picture of how the TF-FVIIa initiated coagulation response
varies with model parameters would have emerged if we employed a larger
perturbation size, more parameter sets, etc.
We tested the working hypothesis that the determination of important in-
teractions in coagulation using sensitivity analysis and uncertain mechanistic
models was independent of the parameter sampling strategy. We compared
the results of random sampling with Latin Hypercube Sampling (LHS) [177],
which generates a distribution of plausible collections of parameter values from
a multidimensional distribution, for two different perturbation sizes. OSSC val-
ues calculated using random parameter families constructed by perturbing the
nominal parameter set by < ±50% (N=100; control-small) and < ±2-orders of
magnitude (N=100; control-large) were compared with OSSCs generated us-
ing LHS over the same parameter ranges (maximum/minimum perturbation
±50% and ±2-orders of magnitude, Fig. 3.3.2B and 3.3.2C). Random and LHS
54
0 0.25 0.5 0.75 1
OSSC Random Sampling (control-large)
0
0.25
0.5
0.75
1
O
SS
C
 
La
tin
 
H
yp
e
rc
u
be
 
Sa
m
pl
in
g 
(la
rg
e
)
0 0.25 0.5 0.75 1
OSSC Random Sampling (Small)
0
0.25
0.5
0.75
1
O
SS
C
 
R
a
n
do
m
 
Sa
m
pl
in
g 
(L
a
rg
e
)
0 25 50 75 100 125 150
Parameter index (k)
0
0.2
0.4
0.6
0.8
1
O
v
e
ra
ll 
St
at
e 
Se
n
s
iti
v
ity
 
Co
e
ffi
c
ie
n
ts
 
(O
SS
C)
0 0.5 1
OSSC Random Sampling (control-small)
0
0.5
1
O
SS
C 
La
tin
 
H
yp
e
rc
u
be
 
Sa
m
pl
in
g 
(sm
a
ll)(A) (B)
(C)
(D)
Figure 3.1: Parametric uncertainty studies using random and latin hyper-
cube sampling strategies. (A) OSSC values for TF-FVIIa initi-
ated coagulation generated using the random sampling over
the small perturbation family (N=100;±50%). (B) Comparison
of OSSC results for TF-FVIIa initiated coagulation for random
versus latin hypercube sampling strategies for the small pertur-
bation family (N=100;±50%). (C) Comparison of OSSC results
for TF-FVIIa initiated coagulation for random versus latin hy-
percube sampling strategies for the large perturbation family
(N=100;±2-orders of magnitude). (D) Comparison of OSSC re-
sults for TF-FVIIa initiated coagulation for small versus a large
random sampling strategy (N=100)
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sampling generated a qualitatively similar ranking of fragile and robust mech-
anisms with a Spearman rank of 0.98 (Fig. 3.3.2B) for the small-perturbation
and 0.89 for the large-perturbation (Fig. 3.3.2C) when compared to the con-
trol, respectively. The small-versus large random-random perturbation had a
Spearman rank of 0.96 (Fig. 3.3.2D) indicating that perturbation size was not a
factor for the coagulation network. When taken together, the sampling results
indicate, at least for the extrinsic coagulation network explored here, that the
qualitative ranking of the importance of coagulation interactions was indepen-
dent of the size and method of the perturbation used to generate the family of
parameter sets sampled. These results were consistent with previous work by
Stelling et al., which showed similar ranking of parameters in models of circa-
dian rhythm between exhaustive and random sampling [89].
3.3.3 The qualitative assessment of fragile and robust coagula-
tion mechanisms was sensitive to false negative but ro-
bust to false positive interactions.
We tested the working hypothesis that the prediction of fragile and robust in-
teractions in molecular networks was dependent upon structural fidelity by
performing monte-carlo sensitivity analysis on four classes of structurally per-
turbed coagulation networks containing both false positive and negative inter-
actions. In each of the structurally perturbed networks, unless otherwise noted,
the nominal parameter set reported by Luan et al., was used to generate a family
of parameter sets (N = 50) by randomly perturbing each nominal parameter by
< ±50%. OSSCs were calculated for each of the structurally perturbed networks
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and compared with the unperturbed parent network (control) by calculating the
Spearman rank correlation.
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Figure 3.2: Impact upon the qualitative classification of interactions be-
cause of single and multiple false-positive structural defects.
(A) Protein connectivity versus the Spearman rank correlation
between structurally perturbed and control networks as a func-
tion of the number of false positive interactions. (B) Protein
connectivity versus the Spearman rank correlation between
structurally perturbed and control networks as a function of
protein species for 30 false positive interactions.
Single and multiple false positive interactions in the coagulation network
had a limited impact upon the classification of mechanisms as fragile or robust.
The addition of single pairwise false positive binding interactions for 100 ran-
domly generated defective networks (see methods) resulted in Spearman rank
coefficients ranging from 0.96 to 1 (data not shown) when compared to the nom-
inal network (control). Moreover, for multiple false positive interactions, the
Spearman rank correlation was invariant to the number of structural defects in-
troduced into the cascade. Over the top ten connected species, the Spearman
rank between the perturbed and unperturbed networks showed small variation
(< 0.02) within individual species as the number of defects increased from 1 to
30, with the exception of IIa and IIa-P2s (Fig 3.3.3A). Conversely, large varia-
tion in the spearman rank was observed between different species; the average
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spearman rank over all defects for free and bound thrombin was 0.94 and 0.88,
while the inhibitors, ATIII and APC, showed 0.50 and 0.80 correlation, respec-
tively. While no obvious relationship was observed between the spearman rank
and the connectivity of the species in false-positive networks (Fig. 3.3.3B), a
correlation between the biological function and shift in spearman rank was ob-
served. Structural uncertainty in initiation factors such as TF-FVIIa, resulted in
average spearman rank over all trials of 0.69 ± 0.004, and the spearman rank
coefficients for control elements such as ATIII and APC were 0.50 ± 0.023 and
0.80 ± 0.042, respectively. On the other hand, components involved in the ampli-
fication of the thrombin signal, e.g., IIa, IIa-P2s, Va-P5s, or VIIIa-P8s were less
effected with an average spearman rank of 0.82. Thus, structural uncertainty
in mechanisms mediating the initiation of coagulation and control elements re-
straining the cascade was more influential than uncertainty in amplification in-
teractions.
Single and multiple simultaneous false-negative structural defects hindered
or destroyed the ability to correctly classify coagulation interactions as fragile or
robust. OSSC values calculated for 15 different coagulation networks corrupted
with single pairwise false-negative defects (see methods) were compared to the
unperturbed network using the Spearman rank correlation over a family of ran-
dom parameters sets (N=50, ±50%). While the influence of single false-negative
interactions was dependent upon which proteins or protein complexes were
affected, no obvious connection with reaction connectivity was observed (Fig.
3.3). The largest shift in Spearman rank occurred when platelet activation was
disrupted (correlation of 0.68) while the other 14 mechanisms selected had an
average Spearman rank of 0.89 ± 0.04, indicating that on average 90% of the
mechanisms would have been classified correctly in the structurally defective
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Figure 3.3: Impact upon the classification of coagulation interactions fol-
lowing the introduction of single pairwise false-negative struc-
tural defects.
networks. Although single pairwise false-negative defects had a limited im-
pact upon the classification of coagulation mechanisms, multiple simultaneous
false-negative interactions destroyed the ability to classify mechanisms as frag-
ile or robust. OSSC values generated for 2- (Fig. 3.3.3A), 4- (Fig. 3.3.3B) and
8- (Fig. 3.3.3C) partitions showed statistically significant deviation from the un-
partitioned control, where the Spearman rank correlation for the partitioned
networks was found to be inversely proportional to the number of partitions
(Fig. 3.3.3D). Partitioned subnetworks, independent of parameter values, dis-
played a similar fracture pattern versus the control where mechanisms impor-
tant in the control were no longer sensitive in the subnetwork and vice-versa.
Consider the 4-partitioned case (Fig. 3.3.3B). The 4-partitioned subnetworks
(37 ± 5 interactions in each partition) had a global cut of 8 proteins, including
TF-FVIIa, FXa and FIIa. Interestingly, only 30% of the statistically significant
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Figure 3.4: Impact of multiple false-negative structural defects upon the
qualitative classification of interactions in the network. The
coagulation cascade was partitioned into 2, 4 or 8 connected
subnetworks using hMetis and screened for fragile and robust
mechanisms using a random parameter family (N=100; ±50%
perturbation). The partitioned subnetworks were compared to
the unpartitioned control over the same family of random pa-
rameter sets; the 45o dashed-line indicates perfect correlation.
(A) OSSC values for the unpartitioned control versus the 2-
partitioned subnetwork. (B) OSSC values for the unpartitioned
control versus the 4-partitioned subnetwork. (C) OSSC values
for the unpartitioned control versus the 8-partitioned subnet-
work. (D) Spearman rank correlation as a function of the num-
ber of partitions.
fractured interactions involved cut proteins as reactants, thus, more complex
interactions were responsible for up- or downplaying the importance of signif-
icant mechanisms. Conversely, a core subset of interactions were predicted to
be important in both partitioned and unpartitioned networks, e.g., interactions
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involving TF-FVIIa activity. However, the persistence of these key interactions
as fragile mechanisms across 2-, 4- and 8-partitions could have been an artifact
of the partitioning as hMetis solutions are not deterministic.
To test for partitioning artifacts, ten different 4-partitioned subnetworks
were constructed and OSSC values were calculated over the same random pa-
rameter family as the original partitioning studies (Fig. 3.5). The average Spear-
man rank for the family of 4-partitioned subnetworks when compared to the
original was 0.87 ± 0.07 indicating that on average 80 - 94% of the mechanism
ranking was conserved across different partitioning trials. The persistent in-
teractions associated with TF-FVIIa activity appeared on average 70% ± 19%,
indicating these interactions were independent of partitioning.
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Figure 3.5: Pairwise Spearman Rank Correlation for the estimated OSSC
distributions calculated for ten different 4-partitioned coagula-
tion networks over the same family of random parameter sets.
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3.4 Discussion
Consistent with the conclusions drawn by Nayak et al., [163] and the hypoth-
esis of Kitano [164], the predicted fragile mechanisms in TF-FVIIa initiated co-
agulation are molecular targets in current anticoagulation preclinical develop-
ment, clinical therapies and clinical trials. Four of the top five fragile mech-
anisms involved fX/FXa or the activation of platelets by FIIa. Anti-fX/FXa
and Direct Thrombin Inhibitors (DTIs) are two important classes of anticoag-
ulants. Fondaparinux, a 1.7 kDa pentasaccharide which selectively binds ATIII,
is approved for the prevention of venous thromboembolism following hip frac-
ture surgery, total hip replacement, total knee replacement and major abdom-
inal surgery in addition to the initial treatment of patients with Deep Venous
Thrombosis (DVT) and Pulmonary Embolism (PE) [118, 119, 120, 178, 121, 122].
Fondaparinux increases the natural inhibitory effect of ATIII against FXa ap-
proximately 300-fold [123, 124]; selective inhibition of FXa by fondaparinux in-
terrupts thrombin generation and clot formation without inactivating thrombin
itself [125, 126]. Elalamy and coworkers showed in a whole blood in-vitro as-
say that fondaparinux prolonged the lag time of prothrombin activation for all
concentrations explored, and for physiologically relevant concentrations (0.11 -
0.28 anti-FXa IU/ml), reduced the maximal rate of thrombin formation to ap-
proximately 47 - 55% of its nominal value [127]. Herbert and colleagues ex-
plored fondaparinux and the sulfated analog SANORG 32701 in in-vivo mouse,
rat and rabbit coagulation models [128, 129]; SANORG 32701 has a high-affinity
for ATIII (Kd = 3.7 ± 0.7 nmol/L) and shows more potent anti-FXa activity
(1100 ±31 versus 850 ± 21 U/mg for fondaparinux). Direct Thrombin Inhibitors
(DTIs) have also been explored as anticoagulants [130]. Thrombin activity is
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mediated by three protein domains; an active site catalyzing protease activity
and two exosites controlling substrate binding [131]. Our sensitivity analysis
predicts thrombin activation of platelets is a key mechanism; Sarich et al., have
explored the DTI ximelagatran in healthy male subjects [132]. Thrombin gen-
eration, platelet activation and the thrombin-antithrombin complex were mon-
itored in shed blood collected from skin incisions in 120 healthy male volun-
teers following oral administration of ximelagatran. Oral ximelagatran showed
a rapid and statistically significant decrease in all endpoints relative to control.
When taken together, the fondaparinux, SANORG 32701 and ximelagatran re-
sults present a clinical basis in both in-vitro and in-vivo coagulation studies for
the prediction that fX/FXa and IIa are fragile components of the coagulation
architecture.
Mechanisms involving fIX/FIXa, consistent with multiple lines of experi-
mental evidence, were predicted to be moderately robust. Feuerstein et al., ex-
plored inhibition of fIX/FIXa using a murine anti-fIX/FIXa antibody (BC2) in a
male sprague-dawley rat model [133]. The fIX/FIXa activity and the Activated
Partial Thromboplastin Time (aPTT) endpoints were monitored ex-vivo follow-
ing IV-infusion of the BC2 antibody. Feuerstein et al., found that fIX/FIXa activ-
ity could be reduced by as much as 2.5-fold before any significant change in the
aPTT was observed; only after > 90% of the fIX/FIXa activity was eliminated
was there a 3.5 - 4 fold increase in aPTT. Benedict et al., explored the contribu-
tion of fIX/FIXa to intravascular thrombosis in a canine coronary thrombosis
model [134]. Animals received an IV-bolus of saline (vehicle), bovine glutamyl-
glycyl-arginyl-FIXa (FIXai; a competitive inhibitor which prevents the assembly
of the FVIIIa-FIXa complex [136, 135, 137]), bovine fIX or heparin. Animals
that received saline or bovine fIX developed a coronary occlusion due to a fib-
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rin/platelet thrombus in approximately 1 hr, conversely, FIXai decreased coro-
nary thrombus occlusion in a dose dependent manner. However, FIXai admin-
istration was not accompanied by increased bleeding at abdominal and chest-
wall incision sites leading Benedict et al., to conclude, consistent with the earlier
work of Weiss and Lages [138], that direct TF-FVIIa mediated activation of fX
may be the primary mechanism of fX activation in blood obtained from bleeding
wounds. While our prediction that FVIIIa-FIXa mediated fX activation is robust
is consistent with Benedict et al., the robustness of fIX mechanisms should be
further explored using in-vivo animal models or cell-based assays to control for
artifacts introduced by the synthetic plasma model.
The capability to gather cellular protein-protein and protein-DNA interac-
tion data has far outstripped our ability to understand it. Transforming large-
scale interaction data sets e.g., the B-cell interactome compiled by Califano and
coworkers [179], into a better cell or a new therapy requires tools to extract the
qualitatively significance of protein-protein and protein-DNA interactions. The
sampling and structural fidelity studies reported here support the Bailey hy-
pothesis that network structure is a critical factor in our ability to extract qual-
itative information about a network or system. The sampling results suggest
that given even an approximate parameter set it is possible to overcome para-
metric uncertainty by sampling regions of parameter space with one of many
possible strategies. Clearly, the more critical issue is structural uncertainty. Sin-
gle false positive and false negative structural defects were shown to have little
impact. Moreover, multiple false positive interactions appeared to have limited
influence with exception of particular inhibitors. However, multiple false nega-
tive structural defects made it impossible to infer the qualitative significance of
interactions. Unfortunately, protein-protein and protein-DNA interactions de-
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rived both computationally and experimentally are prone to both false positive
and false negative errors. The Yeast Two-Hybrid (Y2H) system [180, 181, 91, 92],
Fluorescence Resonance Energy Transfer (FRET) [182], quantitative Mass Spec-
trometry (MS) proteomic or Chromatin Immunoprecipitation (ChIP)-DNA mi-
croarray techniques [183, 93, 94, 95] have all been used to identify in-vivo bind-
ing interactions. Computational techniques have also contributed significantly
to network identification [184, 185]. However, Y2H assays are prone to false-
positive predictions e.g., in some cases >50% of the reported interactions are
false positives [185]. Moreover, Bork reported that none of the genomics meth-
ods for detecting connections cover more than 60% of the proteins in the yeast
genome and most are biased toward evolutionarily old, highly abundant pro-
teins that are localized in specific subcellular locations [186]. Bader and cowork-
ers have estimated that in yeast 25 - 45% of the reported interactions are likely
false positives and the false negative rates for worm and fly are possibly as high
as 75% and 90%, respectively [187]. When taken together, our results suggest
that using monte-carlo sensitivity analysis to explore large structurally uncer-
tain networks, especially networks corrupted with false negative interactions,
is likely to produce a small number of correct classifications dispersed among
many false results. Until interaction identification tools produce interaction
maps with a higher degree of fidelity, sensitivity analysis will likely have to
be limited to hand annotated networks.
3.5 Conclusions
In this study, we explored two open questions surrounding sensitivity-based
knowledge discovery using uncertain network models, namely the impact of
65
parametric sampling strategies and the influence of network structural uncer-
tainty. We showed that conclusions drawn from monte-carlo sensitivity analysis
of the human coagulation cascade were largely invariant to the method used to
generate the family of parameter sets sampled and the size of the parameter
perturbation used. However, structural defects strongly influenced the quali-
tative conclusions drawn from sensitivity analysis. The introduction of single
and multiple false positive defects showed limited impact on the classification
of mechanisms as fragile or robust. Moreover, the introduction of single false
negative structural defects did not have a great influence upon the classification
of interactions in the control. However, multiple simultaneous false negative
interactions introduced by partitioning the coagulation network into 2-, 4- and
8-partitions greatly altered conclusions drawn from our analysis. Thus, these
results indicated that while parametric model uncertainty can be partially over-
come by sampling feasible parameter regions using one of several strategies,
structural uncertainty remains a critical determinant of our ability to classify
mechanisms as fragile or robust.
3.6 Methods
3.6.1 Formulation of the model equations.
The human extrinsic coagulation model of Luan et al., composed of 92 proteins
and 148 protein-protein interactions, was used in this study [162]. Mass balance
equations were written around each protein or protein complex yielding the set
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of differential equations (vector-form):
dx
dt
= Sr (x,k) = g (x,k) x (to) = xo (3.1)
The symbol S denotes the stoichiometric matrix, x denotes the concentration
vector of proteins or protein complexes, r (x,k) denotes the vector of interaction
rates and k denotes the parameter vector. Each row in S describes a particular
protein or protein complex while each column describes the stoichiometry as-
sociated with a specific interaction in the network. Thus, the (i, j) element of S,
denoted by σi j, describes how protein i is connected to rate process j. If σi j < 0,
then protein i is consumed in r j, conversely, if σi j > 0 protein i is produced by
r j and if σi j = 0 there is no connection between protein i and rate process j. We
have assumed mass action kinetics for each interaction in the network; under
the mass action assumption the rate expression for protein-protein interaction
q: ∑
j∈{Rq}
σ jqx j →
∑
p∈{Pq}
σpqxp (3.2)
is given by:
rq
(
x, kq
)
= kq
∏
j∈{Rq}
x−σ jqj (3.3)
where
{
Rq
}
denotes the set of reactants for reaction q,
{
Pq
}
denotes the prod-
uct set for reaction q, kq denotes the rate constant governing the qth interaction
and σ jq, σpq denote stoichiometric coefficients (elements of the matrix S). We
have treated every protein-protein interaction and catalytic mechanism as non-
negative. All reversible interactions were split into two irreversible steps, thus,
every element of the reaction rate vector r (x,k) took the form shown in Eqn. 5.3.
The model equations were solved using the LSODE routine of the OCTAVE pro-
gramming environment (v2.9.9; www.octave.org) on an Apple Computer Ma-
cOSX (Cupertino, CA; v10.4.8) workstation.
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3.6.2 Computation of overall state sensitivity coefficients.
The sensitive or fragile interactions of the coagulation architecture were deter-
mined by computing Overall State Sensitivity Coefficients (OSSC) [89]. Because
each parameter corresponds directly to a particular molecular interaction in the
cascade, OSSC values were used to gauge which interactions were qualitatively
important. Large OSSC values for interactions relative to their peers indicated
fragility or sensitivity while small OSSC values indicated robustness. The OSSC
value for interaction j was defined as:
O j (t) =
k∗j
NS
( NT∑
h=1
NS∑
i=1
[
1
x∗i
∂xi
∂k j
∣∣∣∣∣∣
th
]2)1/2
(3.4)
where NT denotes the number of time points used in the simulation while NS
denotes the number of proteins/protein complexes in the model. The first-order
sensitivity coefficients:
si j (th) =
∂xi
∂k j
∣∣∣∣∣∣
th
(3.5)
were computed by solving the differential equation:
ds j
dt
= A (t) s j + b j (t) j = 1, 2, ,NP (3.6)
subject to the initial condition s j(t0) = 0. In Eqn. 5.8, the quantity j denotes the
parameter index, NP denotes the number of parameters, A denotes the Jacobian
matrix of the model equations and b j denotes the jth column of the matrix B,
which contains first-derivatives of the mass balances w.r.t. the parameter val-
ues. The quantity s j denotes the vector of first-order sensitivity coefficients w.r.t
parameter j. The Jacobian matrix (A) and the matrix of first-derivatives of the
mass balances w.r.t the parameter values (B) are given by:
A =
∂g
∂x
∣∣∣∣∣∣
(x∗,k∗)
B =
∂g
∂k
∣∣∣∣∣∣
(x∗,k∗)
(3.7)
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where (x∗,k∗) denotes a point along the nominal or unperturbed system solu-
tion. The matrices A and B were numerically estimated at each time step us-
ing a generalized gradient algorithm [148] while the sensitivity balances were
solved using the LSODE routine of the OCTAVE programming environment
(v2.9.9; www.octave.org) on an Apple Computer MacOSX (Cupertino, CA;
v10.4.8) workstation.
3.6.3 Statistical analysis of the shifts in overall state sensitivity
coefficients.
Three different tests were performed to identify large statistically significant
shifts in OSSC values between defective networks and the control. A Welch
t-test [149] was used to find all statistically significant shifts resulting from the
different structural perturbations and then a secondary test on the z−score of
each shift was preformed to find only the most prominent. The OSSC values
calculated over the family of parameter sets were assumed to follow normal
distributions for all cases. The statistical significance of shifts in OSSC values
relative to the control were determined by performing a Welch t-test with the
null hypothesis that the means of the sensitivity coefficients were equal at a
1% significance level. The Welch t-test is similar to the student t-test with the
exception that the two distributions being compared are not required to have
equal variances. The list of significant OSSC values was further restricted to
only those shifts with a magnitude larger than a specified z-score (0.1) away
from the squared mean displacement relative to the control:
d j,q =
(
O¯qj − O¯cj
)2
, j = 1, 2, ,NP (3.8)
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where O¯cj denotes the mean OSSC value over the family of parameter sets for
parameter j in the control while O¯qj denotes the same quantity for defective case
q. A significant shift in OSSC value was accepted if:
d j,q > zσdq + µdq (3.9)
where z denotes a desired z-score, σd j denotes the standard deviation of the total
displacement over all significant OSSC values for the qth defective case and µdq
denotes the mean of the significant displacements for the structurally defective
case q.
A large statistically significant shift in OSSC value, while indicative of the
shifting importance of an interaction, does not guarantee that an interaction
is ranked differently between cases. To this end, we used the Spearman rank
correlation denoted by ρ and defined as:
ρ = 1 − 6
∑NP
i=1 d
2
i
N
(
N2 − 1) (3.10)
to measure the difference in qualitative ranking between cases. The quantity
di denotes the difference in the ordinal rank of interaction i between a struc-
turally defective network and the control, N denotes the number of pairs of
values and NP denotes the number of parameters considered. The Spearman
rank is bounded by −1 ≤ ρ ≤ 1; a Spearman rank of one indicates that two
ranked lists are identical, a Spearman rank equal to negative one indicates that
two ranked lists are perfectly negatively correlated, while a Spearman rank of
zero indicates that two ranked lists are uncorrelated.
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3.6.4 Generation of structurally perturbed coagulation net-
works.
Single pairwise false positive binding interactions were added to the coagula-
tion model by generating a single binding connection between two randomly
selected proteins. A family of structurally defective models was constructed
(N=100), where each model contained a single false-positive interaction. Sen-
sitivity analysis was conducted on each of the models using only the nomi-
nal parameter set. The Spearman rank correlation between each of the struc-
turally perturbed networks and the control was calculated to estimate the effect
of adding the false-positive interaction. The 10 models with the lowest Spear-
man rank, i.e., the largest degree of disruption were then selected for further
study. To control for possible artifacts stemming from the use of only the nomi-
nal parameter set, a parameter set family (N=50) was constructed by randomly
perturbing each of the nominal parameters by < ±50%. Sensitivity analysis was
conducted using the worst 10 models where sensitivity coefficients were com-
puted for each model and parameter set.
Multiple false positive binding and catalytic errors were introduced into the
coagulation network by randomly modifying the mass balance equations of the
ten most connected proteins. The connectivity of the top ten connected proteins,
free and bound thrombin, two inhibitors (ATIII and APC), five upstream coag-
ulation factors (free FIXa and FXa and bound FVa, FVIIIa, and FXa), and one
initiating complex (FVIIa-TF), was manipulated by adding either 1, 5, 7, 10, 15
or 30 false positive interactions to the stoichiometric matrix. The same monte-
carlo procedure was used for each of the connected species. First, a species was
selected from the list of connected proteins (row i) along with a random interac-
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tion in the network (column j). Second, a discrete number of randomly selected
zero stoichiometric coefficients (σi j) in column j were flipped from 0 to 1 where
different columns were selected for each number of false positives. For exam-
ple, if column j1 was selected and stoichiometric coefficients were flipped, then
column j2 , j1 would be selected for the next iteration of the algorithm. Because
our sampling protocol connected multiple previously unconnected proteins to-
gether via random interactions, we did not consider cases where the mass bal-
ance of more than one of the connected proteins was explicitly manipulated
simultaneously. Sensitivity analysis was conducted on each of the structurally
perturbed models using the nominal parameter set only.
Networks with single false negative structural errors were constructed by
removing a single protein-protein interaction from the network. Each of the 148
interactions were removed, in turn, and sensitivity analysis was conducted, us-
ing the nominal parameter set, on each of the structurally defective networks.
The difference in the ranking of interactions between the structurally perturbed
networks and the control was quantified using the Spearman rank correlation.
The 15 networks with the lowest Spearman rank, i.e., the largest degree of dis-
ruption were then selected for further study. To control for possible artifacts
stemming from the use of only the nominal parameter set, a parameter set fam-
ily (N=50) was constructed by randomly perturbing each of the nominal param-
eters by < ±50%. Sensitivity analysis was conducted using the worst 15 models
where sensitivity coefficients were computed for each model and parameter set.
Simultaneous false negative errors were investigated by partitioning the
extrinsic coagulation network into 2-, 4- and 8-partitions using hMetis [188].
hMetis partitioned the coagulation network by minimizing the number of
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shared proteins or protein complexes employed across partitions where any
given protein-protein interaction was resident in a single partition. Thus, the
partitioned subnetworks represent cases where defects, i.e., missing structural
information, has been introduced into the network; the larger the number of
partitions the more defects in the network. Sensitivity analysis was conducted
on each partitioned subnetwork in isolation using a random parameter set fam-
ily (N=50) where each of the nominal parameters was perturbed by < ±50%.
3.6.5 Calculation of protein and interaction connectivity.
The connectivity of the ith protein or protein complex, denoted by Cxi , was cal-
culated by summing the absolute values of the stoichiometric coefficients (σi j)
from the corresponding row of the stoichiometric matrix:
Cxi =
NS∑
j=1
∣∣∣σi j∣∣∣ i = 1, 2, ,NS (3.11)
The connectivity of reaction j, denoted by Cr j , was taken to be the average con-
nectivity of the proteins or protein-complexes involved in the reaction:
Cr j =
1
Nr j
∑
i∈{R j∪P j}
Cxi j = 1, 2, ,NR (3.12)
where Nr j denotes the total number of reactants and products associated with
reaction j and NR denotes the number of interactions in the network.
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CHAPTER 4
A MATHEMATICAL MODEL SUCCESSFULLY PREDICTS THROMBIN
GENERATION IN PATIENT-DERIVED PLASMA
4.1 Abstract
The complex system regulating hemostasis, as well as an increasing number
of inherited and acquired conditions associated with their dysregulation, need
to be understood fully before meaningful clinical development can take place.
Mechanistic mathematical modeling plays a significant role in the develop-
ment of new therapies for a number of diseases. In this study, a mechanistic
model, composed of 193 proteins and 301 protein-protein interactions, was built
to describe the complex hemostatic system. A family or ensemble of probable
parameter sets were estimated using nine experimental data sets from a cell-
based model. The model and the parameter ensemble was used to predict the
thrombin generation in experiments using patient-derived plasma from coro-
nary artery and hemophilia A patients. In experiments, thrombin generation in
platelet-rich plasma from 4 coronary artery patients who are on aspirin treat-
ment and in platelet-poor plasma from healthy and hemophilia A patients was
initiated by the addition of tissue factor. The mean model predictions over the
parameter ensemble were generally consistent with the experimental observa-
tions with a normalized standard error less than 30% and a correlation greater
than 0.66. Furthermore, in order to study the initiating effects of TF-FVIIa and
FVIIa only, the model was used to predict thrombin concentrations following
the addition of 25 pM TF-FVIIa or 120 nM FVIIa to the synthetic plasma with
platelets. The mean model predicted values agreed well with the experiments
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as proved by a normalized error of less than 22 % and a correlation greater than
0.85. Sensitivity analysis revealed that the propagation of thrombin could be
highly influenced by the perturbation in the parameter values in the TF-FVIIa
initiating case, while the initiation of thrombin generation were profoundly af-
fected by the perturbation in the parameter values in the FVIIa initiating case.
4.2 Introduction
Factor VIII (fVIII) and factor IX (fIX) are the X-chromosomally encoded coagu-
lation factors which are deficient in hemophilia A and B, respectively [24]. The
frequency of hemophilia A is often stated to be 1 in 5,000-10,000 male births;
while hemophilia B occurs at about 1 in about 35,000-50,000 male births [25].
The existence of hemophilia was noted very early in the medical literature, and
has been a prime stimulus for attempts to understand the mechanism of blood
coagulation. Bleeding in hemophilia A and B correlates well with the residual
level of the coagulation activity in the patient’s plasma [25]. A hemophilia pa-
tient do not bleed more intensely than a normal person, but for a much longer
amount of time. In severe hemophiliacs even a minor injury could result in
blood loss lasting days, weeks, or not ever healing completely. The critical risk
here is with normally small injuries which, due to missing coagulation factors,
take long times to heal. In areas such as the brain or inside joints this can be
fatal or permanently debilitating. The bleeding with external injury is normal,
but incidence of late re-bleeding and internal bleeding is increased, especially
into muscles, joints, or bleeding into closed spaces. Major complications include
hemarthrosis, hemorrhage, gastrointestinal bleeding, and menorrhagia.
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Though there is no cure for hemophilia, it can be controlled with regular
infusions of the deficient clotting factor, i.e. fVIII in hemophilia A or fIX in
hemophilia B. Replacement therapy markedly improves the management of
bleeding of most patients with hemophilia. However, fVIII and fIX inhibitors
have developed in 18-32% and 2-3% of hemophiliacs A and B in response to
fVIII and fIX, respectively [28] and those inhibitors make the subsequent man-
agement of patient, using coagulation factor concentrates, difficult. In the 1980s,
activated prothrombin complex concentrates (aPCC) from pooled plasma were
developed for hemophiliacs with inhibitors, assuring ‘fVIII bypassing activity’
[29, 30]. However, aPCCs induce disseminated intravascular coagulation syn-
dromes or acute myocardial infarction [31]. Recently, recombinant factor VIIa
(rFVIIa) was developed as a new bypassing agent, and its clinical efficacy and
safety have been established [32, 33]. Hemophilia patients with inhibitors most
frequently bleed in the joints. Clinical data have demonstrated that rFVIIa has
a response rate of 91% in joint bleeds and 86% in muscle bleeds in as few as 5
hours [189]. rFVIIa has also been shown to effectively control bleeding during
surgical procedures in people with inhibitors. Four separate studies involv-
ing more than 200 procedures showed that rFVIIa was effective and safe [189].
However, because of its short half-life, therapy with rFVIIa requires frequent ad-
ministration (at intervals of 2-3 h) to achieve hemostasis and therapeutic dose
of rFVIIa is not always predictable [28].
Both bypassing products (aPCC and rFVIIa) have been shown to be effec-
tive, to some extend, in treating hemophilia with inhibitors [190]. Yet their
hemostatic efficacy can be difficult to predict [28] and does not reach the overall
success rates obtained with replacement therapy in patients without inhibitors
[191]. Furthermore, responsiveness to bypassing therapy may change from one
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bleed to the next in the same patient and even from hour to hour during the
course of a single bleeding event. Thus, sequential use of bypassing agents was
proposed to treat bleeding disorder, especially refractory bleeds [192, 193, 194].
However, increased risk for thrombosis is often a concern of using such therapy;
this aggressive therapy was recommended to use only in the inpatient setting
with careful monitoring of the physical examination and frequent laboratory
screening to assess for thrombosis [195, 30].
Given all the difficulties faced in treating hemophiliacs, the lack of under-
standing the principal mechanism of action of all these agents could be one of
the obstacles in developing effective treatment regimes. For example, it is gen-
erally believed that the mechanism of action of rFVIIa is either TF-dependent or
TF-independent. Both mechanisms have their experimental evidence; throm-
bin generation could be activated by small amount of TF-FVIIa or large amount
of FVIIa only [196, 197, 198, 199, 200, 32, 115, 201]. Thus the understanding of
mechanism of action of rFVIIa could provide some insights into determining
the therapeutic dosages in different pathological conditions. Furthermore, the
potential synergy of rFVIIa and APCCs is proposed to treat hemophilia in more
complex conditions [194].
In order to study the complex system regulating hemostasis, our group pre-
viously built a mechanistic model with 92 proteins and 148 protein-protein in-
teractions [162]. The model was validated using published datasets generated
from synthetic plasma and a cell-based model. However, in order to fit datasets
from both experiments, 3 kinetic parameters were modified. Here in the study,
we modified our previous model using more realistic interactions for platelet
activation and more involving proteins. The new model, with 193 protein and
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301 protein-protein interactions, was trained using nine cell-based experiment
measurements that were more representative to the in vivo conditions.
4.3 Results
The mechanistic model was formulated based on our previous coagulation
model [162] with additional interactions describing platelets activation via
PARs, the intrinsic pathway, etc (see supplementary table). A family or ensemble
of probable parameter sets (N = 437) were estimated using nine experimental
data sets from a cell-based model [29]. The model predictions and the training
data sets were shown in Figure 4.1. As the results of training with the experi-
ment data, a normalized standard error less than 30% and a correlation greater
than 0.66 (Table 4.1) were observed for the mean model predictions over the
parameter ensemble. The model and the parameter ensemble was used to pre-
dict the thrombin generation in experiments using patient-derived plasma for
coronary artery and hemophilia A patients. In experiment, thrombin genera-
tion in platelet-rich plasma from 4 coronary artery patients who are on aspirin
treatment and in platelet-poor plasma from healthy and hemophilia A patients
was initiated by the addition of tissue factor. As shown in Figure 4.2, the model
successfully predicted thrombin generation in patient-derived plasma with the
error quantifications shown in Table 4.1. Furthermore, in order to study the initi-
ating effects of TF-FVIIa and FVIIa only, the model was used to predict thrombin
concentrations following the addition of 25 pM TF-FVIIa or 120 nM FVIIa to the
synthetic plasma with platelets. The mean model predicted values agreed well
with the experiments as proved by a normalized error of less than 22 % and a
correlation greater than 0.85. Sensitivity analysis revealed that the propagation
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of thrombin could be highly influenced by the perturbation in the parameter
values in the TF-FVIIa initiating case, while the initiation of thrombin genera-
tion were profoundly affected by the perturbation in the parameter values in
the FVIIa initiating case.
4.3.1 The model predicted thrombin generations in patient-
derived plasma.
Computational simulations and experimental observations from a cell-based
model [29] and from an analysis of patient plasma were shown in Figure 4.1
and Figure 4.2, respectively. To address uncertainty in the model parameters,
we estimated a family or ensemble of parameter sets that minimized errors be-
tween model simulations and the training data sets. Nine data sets with dif-
ferent concentrations of rFVIIa and prothrombin in the presence and absence
of fVIII and fIX from a cell-based model were selected to train the model (Fig-
ure 4.1). Parameter values were adjusted to minimize the squared error between
model simulations and experimental measurements. We obtained an ensemble
of parameter sets (N = 437).
In each figure, the dashed lines in each case denote the mean simulated val-
ues over the ensemble of model parameters while the shaded regions denote
one ensemble standard deviation (N = 437). A typical thrombin generation
consists of three phases: the initiation, the propagation and the termination
[202, 203]. It is generally believed the initially formed thrombin is produced
upon the cleavage of prothrombin by fluid phase activated factor X (FXa) [200].
The picomolar amount of initially formed thrombin activates cofactors factors
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Figure 4.1: Comparison of model simulations versus training data from
a cell-based model. The dashed lines in each case denote the
mean simulated value over the ensemble of model parame-
ters while the shaded regions denote one ensemble standard
deviation (N = 437). Experimental data are shown with error
bars (10% of the experimental values). The quantified errors
are shown in Table 4.1.
V and VIII (fV and fVIII) and platelets, resulting in the formation of surface
complexes tenase and prothrombinase. Massive prothrombin activation occurs
as the results of interactions on activated platelet surface during the propaga-
tion phase. This is followed by the termination phase in which the reactions
of the coagulation cascade subside and thrombin is consumed by the dynamic
inhibitor APC and the potent thrombin inhibitor ATIII.
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Table 4.1: Quantification of model errors. The nomarlized standard errors
(SE) and the correlation (defined in the text) were calculated for
the mean simulated values of the ensemble versus the experi-
mental measurements.
Simulation Normalized SE Correlation r2 Simulation Normalized SE Correlation r2
Figure 4.1 Figure 4.2
Panel A 0.13 0.84 Panel A 0.12 0.88
Panel B 0.22 0.66 Panel B 0.05 0.96
Panel C 0.22 0.68 Panel C 0.17 0.77
Panel D 0.19 0.82 Panel D 0.30 0.66
Panel E 0.13 0.90 Panel E 0.17 0.74
Panel F 0.18 0.75 Panel F 0.19 0.76
Panel G 0.15 0.84 Figure 4.4
Panel H 0.15 0.74 Panel A 0.22 0.85
Panel I 0.21 0.77 Panel B 0.08 0.94
Thrombin generations in normal and hemophilia cases with various concen-
trations of FVIIa and prothrombin and the training data sets generated using a
cell-based model [29] are shown in Figure 4.1. The standard errors and the cor-
relations between the mean simulated values and the experimental measure-
ments are shown in Table 4.1. On average, the model has a standard error of
18% and explained about 78% of the thrombin generation dynamics. In the nor-
mal case where physiological amounts of the plasma clotting factors, inhibitors
and platelets were present in the system (Figure 4.1A), a characteristic patten
of thrombin generation was observed. Little amount of thrombin was gener-
ated in the initiation phase and subsequently quantitative thrombin was formed
during propagation, followed by the termination of thrombin. Thrombin gener-
ation reached its maximum of about 120 nM at 45 min and our model predicted
a faster rate of thrombin formation. The normalized standard error in this case
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is 13% and the correlation between the model prediction and the training data
was 0.84. While in the hemophilia case (Figure 4.1B) when no fVIII and fIX were
present, the maximum thrombin generated was less than 20 nM at 120 min. The
normalized standard error in this case was 22% and a correlation of 0.66 was
observed. When a combination of 75 nM FVIIa and 150% level of prothrom-
bin were added, the normal thrombin generation was almost restored and we
termed this case as treatment case. In the treatment case, the concentration of
thrombin generated reached the normal maximum level at about 40 min and
further increase to about 140 nM at about a hour. Our model resulted a slower
thrombin generation rate and a lower maximum thrombin concentration with a
correlation of 0.68 as compared to the training data.
The thrombin concentrations following the addition of FVIIa (25, 50 or 75
nM) to synthetic plasma at 100% prothrombin level were constrained by the
in vitro training data sets (Figure 4.1D, E and F) and resulted in an average
correlation of 0.82. Both the rate and the peak of thrombin generation were
increased with the increase in the concentration of FVIIa. Thrombin genera-
tion has been shown to be influenced by concentrations of various clotting fac-
tors, especially prothrombin and ATIII [146, 111]. The increase of prothrombin
concentration form 100% to 150% would result in 72% to 121% increase in the
amount of thrombin generated [146, 111]. The model showed that when the
level of prothrombin varied over 50-150% of the physiological ranges at fixed
FVIIa concentrations of 25 nM (Figure 4.1G, D and H) or 75 nM (Figure 4.1I,
F and C), the maximal concentration of thrombin generated increased with the
increase in the level of prothrombin concentrations. However, discrepancies be-
tween the model prediction and the experimental training data were observed
in the first 20 min of all simulations.
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Figure 4.2: Predicted time course of thrombin generation versus exper-
imental measurements using patient-derived plasma. The
dashed lines in each case denote the mean simulated values
over the ensemble of model parameters while the shaded re-
gions denote one ensemble standard deviation. (A) The ex-
periments were conducted using plasma from 4 patients with
coronary artery disease (on aspirin); the generation of throm-
bin was initiated using 1 pM TF. Experimental data are shown
with error bars, which were calculated as one standard devia-
tion of the 4 different patient data sets. (B-F) The experiments
were conducted using plasma from healthy or hemophilia A
patients; the levels of fVIII concentration with respect to the
normal concentration (0.3 nM) were shown in the corner. The
generation of thrombin was initiated using 5 pM TF. Experi-
mental data are shown with error bars, which were 10% of the
experimental values.
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The model and the parameter ensemble was then used to predict the throm-
bin generation in experiments using patient plasma for coronary artery diseases
and hemophilia A. Platelet-rich and platelet-poor plasma were prepared using
the coronary artery and hemophilia A patients plasma, respectively. TF was
added to initiate the generation of thrombin. In the simulations, we assumed
TF binds with FVIIa immediately to form TF-FVIIa complex, which therefore
initiate the cascade. Platelet-rich plasma prepared using the blood drawn from
4 coronary artery patients who were on aspirin treatment was used in the ex-
periments. The profile of thrombin concentrations in time has shown the typical
characteristics of thrombin generation with a normalized standard error of 0.12
and a correlation of 0.88 (Figure 4.2 A and Table 4.1). The maximum thrombin
concentration was about 150 nM at 15 min, while our model predicted a higher
maximum of 220 nM at almost the same time point. Both the peak and rate of
thrombin generation in this case were much lower than those in the case with
106% fVIII (plasma from healthy volunteer, Figure 4.2 B), which was mostly
likely to be the results of the smaller amount of initiating TF used (1 pM in Fig-
ure 4.2 A and 5 pM Figure 4.2 B-F). The model gave the best prediction in the
case with 106% fVIII (Figure 4.2 B), as shown by the small standard error of 0.05
and a high correlation of 0.96. While decreasing in fVIII concentrations resulted
in decreases in both the peak and the rate of thrombin generation, the model
explained more than 67% of the thrombin generation dynamics (Figure 4.2 C-F
and Table 4.1). As we know, the level of coagulation factors is often related to
the severity of hemophilia [25]. When fVIII decreased, the bleeding time was
prolonged as a result of less and slower thrombin generation. The above results
proved that the mechanistic model, trained using nine experimental data sets
from an in vitro cell-based experiment, was able to predict thrombin generations
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in patient-derived plasma.
4.3.2 Sensitivity analysis revealed the bypassing activity of
rFVIIa.
The scaled OSSC values were clustered into three groups with high, medium
and low sensitivities using a k-mean algorithm (see Methods). The parameters
with high and medium sensitivities in the normal, hemophilia and treatment
cases (Figure 4.1 A, B and C) were shown in Table 4.2. In the normal, hemophilia
and treatment cases, the activation of platelets by ADP and TXA2 were clustered
as the top 2 most sensitive parameters. Although the inhibition of FXa by ATIII
(on rate), the formation and activity of prothrombinase, and the binding of FXa
on platelet active sites (off rate) were clustered in the medium sensitive group
in the treatment case, they showed similar ranks as those in the normal and
hemophilia cases. While the on rate of FXa binding and the on/off rates of fX
bindings showed similar ranks in the treatment and hemophilia cases, they were
much higher than those in the normal case. This indicated that the sensitivity
of fX/FXa bindings were generally higher in the case of hemophilia and treat-
ment. In addition, 11 fVIII/fIX mechanisms that were clustered in the medium
sensitive group in the normal case were shown to be robust in the hemophilia
and treatment cases; 6 fV/FVa mechanisms, 2 activated platelets mechanisms, 3
inhibitory mechanisms (by TFPI or ATIII) and the on rate of TF-FVIIa activating
fX were shown to have moderate sensitivity in the hemophilia and treatment
cases, but robust in the normal case. In general, comparing to the normal case,
the mechanisms related to fX/FXa and fV/FVa became more sensitive, while
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Figure 4.3: The normalized ranks of the OSSC values calculated over the
selected parameter ensemble (N = 100) were compared in pairs
among different cases.
the mechanisms related to fVIII/FVIIIa and fIX/FIX became more robust in the
treatment and hemophilia cases.
The statistically significant shifts were calculated using the Welch T-Test
among normalized ranks of the OSSC values in the normal, hemophilia, treat-
ment cases (Figure 4.3 A, B and C). Compare with the normal case, 24 and 23
statistically significant shifts were found in hemophilia and treatment cases, re-
spectively (data not shown). Except for the off-rate of fIX binding with platelet
active site, the remaining 23 shifts were identical in these two cases. And all
these shifts, related to fVIII and fIX activities, were shown to have increases sen-
sitivity in the normal case. This result proved that the treatment of hemophilia
using rFVIIa bypassed the activity of fVIII and/or fIX. It is reasonable as rFVIIa
is often used to treat hemophiliacs with inhibitors of fVIII and fIX. Compare to
the hemophilia case, 7 shifts were shown to have slightly increased sensitivities
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and 7 shifts were shown to have slightly reduced sensitivities in the treatment
case. Among the 7 decreased shifts, 4 of them were related to the activity of
tenase, which was probably due to the addition of the ‘by-passing’ agent rFVIIa
in the treatment case. The addition of rFVIIa is believed to activate fX when
fVIII and fIX were not available.
Table 4.2: Distribution of OSSCs for normal, hemophilia and treatment cases 4.
p-index normal hemophilia treatment Description
Cluster I
p-index Rank µ ± σ Rank µ ± σ Rank µ ± σ Description
172 4±4 0.91±0.13 7±7 0.78±0.22 2±2 0.98±0.04 TXA2 activates platelets (off)
175 6±7 0.78±0.14 4±5 0.90±0.14 3±3 0.76±0.15 ADP activates platelets (off)
126 5±3 0.71±0.23 3±1 0.70±0.20 – – ATIII inhibits FXa (on)
97 8±5 0.61±0.22 9 ±1 0.55±0.18 – – FXa binds FVa on platelet surface (on)
98 9±5 0.61±0.22 9±1 0.55±0.18 – – FXa binds FVa on platelet surface (off)
90 9±4 0.61±0.22 11±1 0.54±0.18 – – Prothrombinase activates fII (on)
50 5±4 0.69±0.24 6±2 0.67±0.22 – – FXa binds platelet active sites (off)
49 – – 5±2 0.67±0.22 – – FXa binds platelet active sites (on)
48 – – 4±2 0.68±0.22 – – fX binds platelet active sites (off)
47 – – 4±1 0.68±0.22 – – fX binds platelet active sites (on)
Cluster II
p-index Rank µ ± σ Rank µ ± σ Rank µ ± σ Description
126 – – – – 4±2 0.58±0.25 ATIII inhibits FXa (on)
97 – – – – 9±2 0.49±0.25 FXa binds FVa on platelets (on)
98 – – – – 10±1 0.49±0.25 FXa binds FVa on platelets (off)
90 – – – – 11±2 0.49±0.25 Prothrombinase activates fII (on)
50 – – – – 8±2 0.53±0.25 FXa binds platelet sites (off)
49 21±6 0.35±0.10 – – 6±2 0.53±0.25 FXa binds platelet sites (on)
Continued on next page
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Table 4.2 (Continued)
p-index normal hemophilia treatment Description
48 19±7 0.35±0.10 – – 6±1 0.53±0.25 fX binds platelet active sites (off)
47 19±6 0.35±0.10 – – 5±2 0.53±0.25 fX binds platelet active sites (on)
58 13±8 0.54±0.28 – – – – FVIIIa binds platelet sites (off)
57 15±7 0.54±0.28 – – – – FVIIIa binds platelet sites (on)
45 15±10 0.52±0.28 – – – – FIXa binds specific platelet sites (on)
46 16±10 0.52±0.28 – – – – FIXa binds specific platelet sites (off)
81 17±11 0.52±0.29 – – – – Tenase activates fX (on)
95 17±11 0.52±0.29 – – – – FIXa (specific) binds FVIIIa (on)
96 18±11 0.52±0.29 – – – – FIXa (specific) binds FVIIIa (off)
123 16±4 0.49±0.20 – – – – ATIII inhibits FIXa (on)
29 24±11 0.40±0.22 – – – – FXa activates fIX (on)
30 26±11 0.38±0.21 – – – – FXa activates fIX (off)
31 27±12 0.38±0.22 – – – – FXa activates fIX (catalytic)
284 35±16 0.23±0.14 22±10 0.31±0.21 23±12 0.23±0.12 FVIIa activates fX (catalytic)
282 34±12 0.22±0.13 21±7 0.30±0.18 22±9 0.23±0.11 FVIIa activates fX (on)
283 35±12 0.22±0.12 22±7 0.30±0.18 23±9 0.23±0.11 FVIIa activates fX (off)
165 16±11 0.47±0.18 14±9 0.43±0.18 10±7 0.46±0.15 Activate platelets secret TXA2
13 20±12 0.38±0.22 14±6 0.40±0.16 15±5 0.36±0.21 TF-FVIIa activates fX (catalytic)
121 25±12 0.30±0.12 17±5 0.38±0.15 18±4 0.22±0.15 TFPI inhibits X-VIIa-TF (on)
59 19±5 0.44±0.23 22±7 0.30±0.14 23±10 0.30±0.24 fII binds platelets sites (on)
60 19±5 0.44±0.23 23±7 0.30±0.14 23±10 0.30±0.24 fII binds platelets sites (off)
54 24 ±8 0.28±0.14 17±4 0.35±0.11 19±3 0.24±0.13 FVa binds platelet sites (off)
53 – – 21±3 0.31±0.12 21±3 0.23±0.13 FVa binds platelet sites (on)
52 – – 23±5 0.31±0.13 23±3 0.22±0.13 fV binds platelet sites (off)
51 – – 22±5 0.31±0.13 22±3 0.22±0.13 fV binds platelet sites (on)
23 – – 21±6 0.34±0.19 25±6 0.19±0.15 Thrombin activates fV (on)
24 – – 25±7 0.32±0.19 31±9 0.17±0.14 Thrombin activates fV (off)
25 – – 22±7 0.33±0.20 28±9 0.19±0.15 Thrombin activates fV (catalytic)
164 – – 23±9 0.27±0.11 20±7 0.23±0.07 Activate platelets secret ADP
Continued on next page
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Table 4.2 (Continued)
p-index normal hemophilia treatment Description
147 – – 34±26 0.21±0.14 26±14 0.21±0.11 FIIa activates PL (catalytic)
129 – – 22±5 0.32±0.16 27±5 0.19±0.11 ATIII inhibits thrombin (on)
133 – – 35±13 0.19±0.16 36±14 0.17±0.20 ATIII inhibits TF-FVIIa (on)
122 – – 29±6 0.20±0.09 25±5 0.21±0.14 TFPI inhibits X-VIIa-TF (off)
11 – – 32±8 0.17±0.13 29±8 0.17±0.16 TF-FVIIa activates fX (on)
In order to explore the dosage effect of rFVIIa, the ranks of OSSCs with
normal prothrombin and 25 nM or 75 nM rFVIIa were compared against each
other (Figure 4.3D). The sensitivities of almost all parameters were comparable
in these two cases, indicating that the parameter sensitivities were not depen-
dent on the dosage of rFVIIa. Similar analysis was conducted on the effect of
prothrombin level (50% fII vs 150% fII, 75 nM rFVIIa); the result was shown in
Figure 4.3E. The sensitivities of parameters were not related to the prothrombin
level (at least the levels we considerer here).
Figure 4.4F shows the comparison of the ranks of the OSSC values in the
cases with different amount of fVIII (106% vs 1% fVIII). There are 16 mecha-
nisms statistically significant changed when the level of fVIII changed (data not
shown). Among the 16 shifts, 11 fVIII/FVIIIa mechanisms became more robust
and the other 5 shifts, related to the activation of fVII and fV by thrombin, be-
came more fragile when fVIII was only 1% of the normal concentration (0.3 nM)
as compared to 106% fVIII. When fVIII is not enough to generate FXa, the al-
ternated pathway of thrombin generation, related to fVII and the formation of
prothrombinase, could become more important. This could be the reason why
fVII and fV mechanisms became more important in the 1% fVIII (hemophilia A)
4The OSSC values were clustered using a k-means algorithm into three parts. The most
fragile parameters were shown in Cluster I; the most robust ones were shown in Cluster III.
The mean OSSC value (µ) ± one standard deviation (σ) in Cluster I and II are reported. p-index
denotes the parameter index in the reaction file.
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case.
The ranks and the clustered OSSC values of the cases with 106% and 1% fVIII
(hemophilia A) are shown in Table 4.3. 5 fX/FXa mechanisms were shown to
have increased sensitivity, while 2 mechanisms related with activated platelets
became more robust when the level of fVIII was reduced to 1% from 106%. In
addition, 2 FXIa mechanisms, 6 fV/FVa mechanisms, 3 inhibitory mechanisms
by TFPI or ATIII, 3 fI mechanisms and 2 TF mechanisms were more sensitive
when only 1% fVIII was present. As the concentration of fVIII reduced, the
pathway of FXa activation by tenase was shut down, the activation of FXa by
other mechanisms, e.g. by TF-FVIIa, became more important. This could pos-
sibly explain why the TF mechanisms and fX/FXa activities became important
when the fVIII was only 1% of the normal level.
Table 4.3: The distribution of the OSSCs for 106% and 1% fVIII cases.
p-index 106% fVIII (µ ± σ) 1% fVIII (µ ± σ) Description
Cluster I
p-index Rank µ ± σ Rank µ ± σ Description
178 5±8 0.81±0.28 – – TXA2 activates platelets (catalytic)
165 14±17 0.52±0.25 – – Activate platelets secret TXA2
50 5±6 0.62±0.26 4±1 0.87±0.10 FXa binds platelet active sites (off)
49 5±4 0.56±0.25 4±2 0.86±0.10 FXa binds platelet active sites (on)
48 7±4 0.56±0.24 5±2 0.86±0.10 fX binds platelet active sites (off)
47 6±4 0.56±0.24 5±1 0.86±0.10 fX binds platelet active sites (on)
126 – – 3±2 0.93±0.12 ATIII inhibits FXa (on)
13 – – 3±2 0.88±0.11 TF-FVIIa activates fX (catalytic)
97 – – 9±2 0.63±0.10 FXa binds FVa (on)
98 – – 10±2 0.63±0.11 FXa binds FVa (off)
Continued on next page
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Table 4.3 (Continued)
p-index 106% fVIII (µ ± σ) 1% fVIII (µ ± σ) Description
90 – – 11±2 0.62±0.11 Prothrombinase activates fII (on)
Cluster II
p-index Rank µ ± σ Rank µ ± σ Description
178 – – 17±17 0.55±0.27 TXA2 activates platelets (catalytic)
165 – – 21±12 0.41±0.17 Activate platelets secret TXA2
126 8±6 0.44±0.11 – – ATIII inhibits FXa (on)
13 10±5 0.41±0.10 – – TF-FVIIa activates fX (catalytic)
97 12±6 0.38±0.13 – – FXa binds FVa (on)
98 14±6 0.35±0.11 – – FXa binds FVa (off)
90 12±4 0.37±0.10 – – Prothrombinase activates fII (on)
92 36±25 0.24±0.27 – – Prothrombinase activates fII (catalytic)
58 25±10 0.19±0.13 – – FVIIIa binds platelet active sites (off)
176 17±12 0.32±0.12 35±15 0.24±0.12 TXA2 activates platelets (on)
177 19±11 0.30±0.11 36±15 0.22±0.11 TXA2 activates platelets (off)
175 16±10 0.35±0.18 14±8 0.54±0.22 ADP activates platelets (off)
164 27±15 0.21±0.10 38±14 0.20±0.11 Activate platelets secret ADP
11 15±6 0.32±0.09 15±6 0.48±0.12 TF-FVIIa activates fX (on)
12 20±6 0.25±0.07 20±6 0.37±0.08 TF-FVIIa activates fX (off)
14 25±7 0.19±0.09 37±12 0.19±0.09 TF-FVIIa activates fIX (on)
15 28±8 0.17±0.08 41±12 0.17±0.08 TF-FVIIa activates fIX (off)
72 19±7 0.28±0.14 31±14 0.25±0.11 FXa activates fV (on)
54 14±5 0.34±0.12 13±2 0.52±0.07 FVa binds platelet active sites (off)
62 19±6 0.25±0.12 37±12 0.19±0.08 FIIa binds platelets active sites (off)
59 27±10 0.20±0.14 24±9 0.32±0.10 fII binds platelets active sites (on)
60 27±10 0.20±0.14 24±9 0.32±0.10 fII binds platelets active sites (off)
204 31±13 0.16±0.08 40±13 0.18±0.07 Thrombin activates fXI (on)
197 – – 21±11 0.42±0.23 FXIa self-activation (on)
199 – – 26±11 0.34±0.16 FXIa self-activation (catalytic)
Continued on next page
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Table 4.3 (Continued)
p-index 106% fVIII (µ ± σ) 1% fVIII (µ ± σ) Description
121 – – 22±7 0.35±0.15 TFPI inhibits X-VIIa-TF (on)
53 – – 25±15 0.34±0.16 FVa binds platelet active sites (on)
52 – – 27±15 0.34±0.16 fV binds platelet active sites (off)
51 – – 25±14 0.34±0.16 fV binds platelet active sites (on)
23 – – 29±12 0.28±0.14 Thrombin activates fV (on)
24 – – 34±16 0.26±0.14 Thrombin activates fV (off)
25 – – 31±15 0.28±0.19 Thrombin activates fV (catalytic)
129 – – 29±13 0.28±0.16 ATIII inhibits thrombin (on)
123 – – 32±14 0.25±0.16 ATIII inhibits FIXa (on)
166 – – 34±13 0.22±0.09 Activate platelets secret fibrinogen
179 – – 35±12 0.21±0.09 Thrombin activates fibrinogen (on)
180 – – 36±12 0.21±0.08 Thrombin activates fibrinogen (off)
2 – – 32±7 0.22±0.08 TF binds fVII (off)
4 – – 41±18 0.20±0.14 TF binds FVIIa (off)
4.3.3 TF-FVIIa is a more potent activator of thrombin genera-
tion than FVIIa only.
In order to study the initiating effects of TF-FVIIa and FVIIa in the generation
of thrombin, our model was used to predict thrombin concentrations following
the addition of 25 pM TF-FVIIa or 120 nM FVIIa to the synthetic plasma with
platelets (Figure 4.4A and B). The model predictions were generally consistent
with in vitro observations as proved by correlations of 0.85 and 0.94, resepec-
tively (Table 4.1). The initiation (lag) phase was about 5 minutes in the TF-FVIIa
initiating case, which is much shorter than that in the FVIIa case. In addition,
both the rate and the peak of thrombin generation in the TF-FVIIa case were
larger than those in the FVIIa case, which was consistent with the theory that
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the initiating potential of FVIIa was much smaller than TF-FVIIa [200]. It is clear
that TF-FVIIa has a much greater effect in initiating the coagulation cascade than
FVIIa only. In addition, TF also helps in the localization of the blood clot to the
wound site in physiological conditions.
Sensitivity analysis using ensembles of mechanistic models could be used
to robustly rank-order the fragility of proteins in the network. In order to ex-
plore the differences in the mechanism of action by TF-FVIIa and FVIIa, the
normalized ranks of the OSSC values and the species sensitivity results for the
TF-FVIIa versus FVIIa cases were shown in Figure 4.4C and D. Statistically sig-
nificant shifts between these two cases were calculated using Welch T-test (data
not shown). In Figure 4.4C, among the 24 statistically significant shifts, 3 shifts
that have increased sensitivity in the FVIIa case than the TF-FVIIa case are re-
lated to the activation of fX and fIX by FVIIa; the other shifts were shown to be
less sensitive in the FVIIa case and amongst them, 16 shifts related to TF/TF-
FVIIa activities, and the other 5 were inhibitory mechanisms related to TFPI,
APC and ATIII. In Figure 4.4D, among the 10 significantly shifted species, fX-
FVIIa complex has shown to be more sensitive in the FVIIa case; the other 9
species, including 7 TF related complexes and 2 tenase complexes, were more
sensitive in the TF-FVIIa case. These results show that fluid phase activation of
fIX and fX by FVIIa was the more important in the FVIIa case while the surface
interactions of tenase were more important in the TF-FVIIa case.
Because the above results do not clearly state the differences in the mech-
anism of action for TF-FVIIa and FVIIa, we further analyzed the sensitivities
in different phases of thrombin generation. The different phases were noted in
Figure 4.4 A and B, and the OSSC values were calculated as summing over the
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Figure 4.4: Model prediction and sensitivity analysis of TF-FVIIa and
FVIIa initiated thrombin generation. (A) and (B): Predicted
time course of thrombin generation versus in vitro experimen-
tal measurements [200]. Thrombin generation was initiated
either by 25 pM TF-FVIIa (we assumed TF binds with FVIIa
to form TF-FVIIa complex immediately) or by 120 nM FVIIa
in the presence of physiological concentrations of pro- and
anti-coagulants. Different phases of thrombin generation were
noted: Phase I: initiation; Phase II: propagation; Phase III:
degradation. The dashed lines in each case denote the mean
simulated values over the ensemble of model parameters while
the shaded regions denote one ensemble standard deviation
(N = 437). Experimental data are shown with error bars (10%
of the experimental values). (C) The normalized ranks of the
OSSC values calculated over the selected parameter ensemble
(N = 100) were compared between TF-FVIIa and FVIIa cases.
(D) The normalized ranks of the species sensitivity values cal-
culated over the selected parameters ensemble (N = 100) be-
tween TF-FVIIa and FVIIa cases.
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Figure 4.5: Comparisons of the parameter sensitivities (the normalized
ranks of the OSSC values) in different phases with respect to
that of the whole time span. (A-C) Normalized ranks of the
OSSC values in different phases in thrombin generation versus
that of the whole time span for TF-FVIIa case. (D-F) Normal-
ized ranks of the OSSC values in different phases in thrombin
generation versus that of the whole time span for FVIIa case.
first order sensitivity coefficients within the time span for separated phases. The
comparison of rank-ordered OSSC values in individual phases versus the whole
were shown in Figure 4.5. It is interesting to note that in the TF-FVIIa case, the
OSSC ranks of the parameters in the propagation phase were the most repre-
sentative across the whole time; while in FVIIa case, the OSSCs in the initiation
phase were more representative to those of the whole time span.
Compare to the TF-FVIIa whole time case, 21, 12 and 23 statistically signifi-
cant shifts were observed in the initiation, propagation and termination, respec-
tively (data not shown). In the initiation phase, all shifts showed reduced sensi-
tivity; 14 of them were related to the activity of PC/APC, 1 TF-fVII dissociation,
95
1 fVIII binding on platelet surface (on-rate), 2 related to the formation of tenase,
1 activation of PL by thrombin, 1 fibrin formation and 1 thrombin inhibition. In
the propagation phase, 2 shifts, 1 fV activation by thrombin and 1 thrombin acti-
vation by prothrombinase, showed slightly increased sensitivity; while the other
10 shifts, including 1 TF-fVII dissociation,1 fVIII activation by FXa, 3 APC ac-
tivity, 1 ATIII inhibition of thrombin, 2 activation of PL/PL-sub by thrombin, 2
fibrin activities, were less sensitive. In the termination phase, all shifts showed
reduced sensitivity; 9 fluid phase activation of fV/fVIII by FXa/thrombin, 3
surface phase activation of fV/fVIII by FXa (surface), 7 platelets activation by
thrombin/subendothelium, 3 fXI activities and 1 binding interaction of FVa.
Table 4.4: The distribution of the OSSCs for TF-FVIIa and FVIIa cases.
p-index TF-FVIIa (µ ± σ) FVIIa (µ ± σ)
Cluster I
p-index Rank µ ± σ Rank µ ± σ Description
178 28±31 0.39±0.26 – – TXA2 activates platelets (catalytic)
172 2±1 0.86±0.13 5±4 0.87±0.16 TXA2 activates platelets (off)
165 5±8 0.75±0.28 5±6 0.72±0.25 Activate platelets secret TXA2
284 – – 3±1 0.81±0.17 FVIIa activates fX (catalytic)
282 – – 5±1 0.76±0.16 FVIIa activates fX (on)
283 – – 7±1 0.74±0.15 FVIIa activates fX (off)
126 – – 6±2 0.74±0.16 ATIII inhibits FXa (on)
50 – – 8±4 0.76±0.19 FXa binds platelet active sites (off)
49 – – 9±2 0.67±0.14 FXa binds platelet active sites (on)
48 – – 8±2 0.67±0.14 fX binds platelet active sites (off)
47 – – 8±2 0.67±0.14 fX binds platelet active sites (on)
97 – – 14±4 0.53±0.16 FXa binds FVa (on)
98 – – 15±3 0.52±0.16 FXa binds FVa (off)
Continued on next page
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Table 4.4 (Continued)
p-index TF-FVIIa (µ ± σ) FVIIa (µ ± σ)
90 – – 15±3 0.52±0.16 Prothrombinase activates fII (on)
Cluster II
p-index Rank µ ± σ Rank µ ± σ Description
178 – – 22±23 0.33±0.21 TXA2 activates platelets (catalytic)
126 5±2 0.58±0.15 – – ATIII inhibits FXa (on)
50 5±3 0.57±0.16 – – FXa binds platelet active sites (off)
49 8±2 0.53±0.12 – – FXa binds platelet active sites (on)
48 6±3 0.54±0.12 – – fX binds platelet active sites (off)
47 6±2 0.54±0.12 – – fX binds platelet active sites (on)
97 12±2 0.40±0.11 – – FXa binds FVa (on)
98 13±2 0.40±0.11 – – FXa binds FVa (off)
90 13±2 0.40±0.11 – – Prothrombinase activates fII (on)
13 6±2 0.55±0.12 – – TF-FVIIa activates fX (catalytic)
12 16±4 0.35±0.09 – – TF-FVIIa activates fX (off)
11 10±4 0.45±0.13 – – TF-FVIIa activates fX (on)
14 17±5 0.31±0.10 – – TF-FVIIa activates fIX (on)
15 20±7 0.28±0.10 – – TF-FVIIa activates fIX (off)
175 21±11 0.32±0.17 19±10 0.36±0.20 ADP activates platelets (off)
164 28±11 0.24±0.12 18±9 0.24±0.11 Activate platelets secret ADP
25 36±17 0.20±0.18 57±29 0.24±0.18 Thrombin activates fV (catalytic)
129 28±12 0.23±0.13 50±6 0.16±0.13 ATIII inhibits thrombin (on)
59 26±8 0.22±0.10 23±8 0.27±0.10 fII binds platelets active sites (on)
60 27±8 0.22±0.10 23±8 0.27±0.10 fII binds platelets active sites (off)
54 18±2 0.31±0.07 15±1 0.43±0.12 FVa binds platelet active sites (off)
53 – – 28±11 0.29±0.14 FVa binds platelet active sites (on)
52 – – 26±9 0.29±0.13 fV binds platelet active sites (off)
51 – – 25±8 0.29±0.13 fV binds platelet active sites (on)
58 – – 62±30 0.18±0.09 FVIIIa binds platelet sites (off)
Continued on next page
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Table 4.4 (Continued)
p-index TF-FVIIa (µ ± σ) FVIIa (µ ± σ)
57 – – 68±26 0.17±0.08 FVIIIa binds platelet sites (on)
45 – – 59±27 0.17±0.07 FIXa binds specific platelet sites (on)
46 – – 60±27 0.17±0.07 FIXa binds specific platelet sites (off)
95 – – 76±36 0.15±0.08 FIXa (specific) binds FVIIIa (on)
96 – – 76±34 0.15±0.08 FIXa (specific) binds FVIIIa (off)
81 – – 76±35 0.15±0.08 Tenase activates fX (on)
72 – – 20±5 0.25±0.07 FXa activates fV (on)
166 – – 31±6 0.22±0.10 Activate platelets secret fibrinogen
29 – – 29±5 0.17±0.06 FXa activates fIX (on)
30 – – 30±5 0.16±0.06 FXa activates fIX (off)
31 – – 44±17 0.15±0.06 FXa activates fIX (catalytic)
23 – – 43±20 0.24±0.16 Thrombin activates fV (on)
24 – – 48±20 0.22±0.15 Thrombin activates fV (off)
20 – – 61±18 0.13±0.13 Thrombin activates fVII (on)
21 – – 63±17 0.12±0.13 Thrombin activates fVII (off)
22 – – 77±33 0.13±0.15 Thrombin activates fVII (catalytic)
179 – – 42±8 0.18±0.08 Thrombin activates fibrinogen (on)
180 – – 44± 8 0.17±0.08 Thrombin activates fibrinogen (off)
135 – – 59±19 0.14±0.07 Thrombin activated PC (on)
137 – – 78±27 0.12±0.07 Thrombin activated PC (catalytic)
170 – – 30±14 0.14±0.06 TXA2 activates platelets (on)
171 – – 31±14 0.13±0.05 TXA2 activates platelets (off)
176 – – 31±21 0.17±0.09 TXA2 activates platelets (on)
177 – – 33±22 0.16±0.08 TXA2 activates platelets (off)
Compare to the TF-FVIIa whole time case, no shifts found in the initiation
phase; while 21 and 29 shifts found in the propagation and termination phases,
respectively (data not shown). In the propagation phase, 11 shifts, related to
APC activities, showed increased sensitivity; while the other 10 shifts, includ-
ing 3 fluid phase activation of fVIII by FXa and 7 platelet activations by AP,
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subendothelium, thrombin and ADP, became more robust. In the termination
phase, 18 shifts, including 15 APC mechanisms, 1 activation of PL by thrombin,
1 fibrin formation and 1 thrombin inhibition, were more sensitive; while the
other 11 shifts, including 3 fluid phase activation of fVIII by FXa and 8 platelet
activations by AP, subendothelium, thrombin and ADP, became more robust.
In general, APC activities were more important in the propagation and ter-
mination phases than in the initiation phase, which were reasonable as APC
was formed only after certain amount of thrombin was generated.
4.4 Discussion
In this study, we modeled thrombin generation in different conditions using the
mechanistic model with 193 proteins or protein complexes connected by 301
interactions. A family or ensemble of model parameters (N = 437) was estimated
using nine experimental training sets compiled from a cell-based experimental
model. Sensitivity analysis was then used, over the selected parameter sets from
the ensemble (N = 100), to estimate which parameters were critical globally and
key to specific model outputs (thrombin concentration).
Numerous wet experimental studies on the complex system regulating
hemostasis have been done using synthetic plasma or cell-based models [196,
111, 108, 115]. One of the most important aspects of our research is the choice
of a model, which determines to a large extent the view of physiological reality
that we develop. Our previous model [162] was mainly based on the experi-
ments using synthetic plasma. However, in vivo conditions most likely require
the presence of platelets. Thus in this study, we enriched our model with more
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details to simulate physiological reality; for example, the activation of platelets
through different G protein-coupled protease-activated receptors (PARs), the
intrinsic pathway, etc, were added. We then trained the model using nine cell-
based model data sets (Figure 4.1) and obtained an ensemble of parameters. Fur-
thermore, plasma from coronary artery and hemophilia A patients was used
in the measurements of thrombin generation; our model predictions using the
parameter ensemble correlated well with the experimental measurements (Fig-
ure 4.2). These results suggested our model could capture the generation of
thrombin in the environment as close to the physiological conditions as possi-
ble.
Factor VIII (fVIII) and factor IX (fIX) are the X-chromosomally encoded co-
agulation factors which are deficient in hemophilia A and B, respectively [24].
A hemophilia patient do not bleed more intensely than a normal person, but
for a much longer amount of time. The critical risk here is with normally small
injuries which, due to missing coagulation factors, take long times to heal. Al-
though replacement therapy markedly improves the management of bleeding
of most patients with hemophilia, the development of inhibitors during treat-
ment is always a challenge. rFVIIa, as a newly developed bypassing agent, is
often considered a universal hemostatic agent that used in treating hemophilas
with inhibitors. Our study confirmed that in the treatment of hemophilia with
rFVIIa and 150% level of prothrombin would restore normal thrombin genera-
tion. Further sensitivity analysis revealed the robust behavior of fVIII and fIX
in the treatment case, while fX/FXa mechanisms became more important. This
is consistent with the theory that rFVIIa or TF-FVIIa bypasses fVIII and fIX to
produce FXa, which then restores thrombin production.
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Given all the difficulties faced in treating hemophiliacs, the lack of un-
derstanding the principal mechanism of action of all these agents could be
one of the obstacles in developing effective treatment regimes. For example,
it is generally believed that the mechanism of action of rFVIIa is either TF-
dependent or TF-independent. Both mechanisms have their experimental evi-
dence [196, 197, 198, 199, 200, 32, 115, 201]. It is generally believed that TF-FVIIa
is a more potent activator than FVIIa only. TF-FVIIa activates fX at a 4-fold
higher rate than that of FVIIa only [196, 200]. The sensitivity analysis was also
used to study differences in the initiating mechanisms of TF-FVIIa and FVIIa. As
mentioned above, thrombin generation can be divided into 3 phases [202, 203].
Our sensitivity analysis on the initiation, propagation and termination phases
revealed that TF-FVIIa initiating mechanism would highly influence thrombin
generation in the propagation stage, while FVIIa initiating mechanisms were
more important in the initiation region.
4.5 Materials and Methods
4.5.1 Formulation and solution of the model equations.
The reactions considered in the coagulation model have been compiled from
literature [162, 204, 113, 69, 17, 205, 206, 16, 15, 60, 52, 146, 9, 8, 53]. Mass balance
equations are written around each protein or protein complex yielding the set
of ordinary differential equations (ODEs):
dx
dt
= S · r (x,p) x (to) = xo (4.1)
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The symbol S denotes the stoichiometric matrix (193 × 301). The quantity x
denotes the species concentration (193 × 1). The term r (x,p) denotes the vector
of reaction rates (301 × 1). Each row in S described a species while each column
described the stoichiometry of network interactions. Thus, the (i, j) element of
S, denoted by σi j, described how protein i was involved in rate j. If σi j < 0, then
protein i was consumed in r j. Conversely, if σi j > 0, protein i was produced by
r j. Lastly, if σi j = 0, protein i was not involved in rate j.
We assumed mass-action kinetics for each interaction in the network. The
rate expression for protein-protein interaction or catalytic reaction q:∑
j∈{Rq}
σ jqx j →
∑
p∈{Pq}
σpqxp (4.2)
was given by:
rq
(
x, kq
)
= kq
∏
j∈{Rq}
x−σ jqj (4.3)
The set
{
Rq
}
denotes reactants for reaction q. The quantity
{
Pq
}
denotes the set
of products for reaction q. The kq term denotes the rate constant governing the
qth interaction. Lastly, σ jq, σpq denote stoichiometric coefficients (elements of
the matrix S). We treated every interaction in the model as non-negative. All re-
versible interactions were split into two irreversible steps. The mass-action for-
mulation, while expanding the dimension of the model, regularized the math-
ematical structure. The regular structure allowed automatic generation of the
model equations. Model parameters and structure, shown in Supplement Table
1, were taken from the literature [60, 52, 146, 9, 8, 53]. Initial conditions were
taken from each experiment and roughly correspond to in-vivo physiological
conditions. An ensemble of parameters (N = 437) were estimated to minimize
the objective functions that describe the errors between model simulations and
experimental data sets. Among the parameter ensemble, 100 parameter sets that
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resulted in a CV of 2 were selected for the sensitivity analysis.
4.5.2 Error Analysis of the Coagulation Simulations.
The correlation between model simulations and experimental data was calcu-
lated using the relationship:
r2 =
∑N
h=1
(
Ym (th) − Y¯
)2
∑N
h=1
(
Y¯ (th) − Ym (th)
)2
+
∑N
h=1
(
Ym (th) − Y¯
)2 (4.4)
where Ym (th) denotes the model value at time point h, Y¯ denotes the global av-
erage experimental value (average of experimental measurements over time)
and Y¯ (th) denotes the average experimental value at time point h (average of
experimental trials). Eqn. 5.4 measures the fraction of variation captured by the
model. In addition to correlation, the scaled standard error was used to measure
the agreement between the model:
sE =
1
maxh
(
Y¯ (th)
)

∑N
h=1
(
Y¯ (th) − Ym (th)
)2
N

1/2
(4.5)
Both Eqn. 5.4 and 5.5 were taken from [147].
4.5.3 The Measurement of Thrombin Generation
Platelet-poor plasma (PPP) samples with varied levels of factor VIII were ob-
tained from George King Biomedical (Overland Park, KS). Platelet-rich plasma
(PRP) samples were obtained from four patients scheduled to undergo coronary
vascular procedures. They gave an informed written consent for blood sam-
pling according to the IRB-approved protocol. Whole blood samples were col-
lected into 3.2% (0.105 M) buffered sodium citrate tubes containing 100 µg/ml
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corn trypsin inhibitor (CTI) to prevent platelet activation during the blood draw,
and isolation of platelet rich plasma. These patients were not being treated with
antithrombotic agents except for aspirin (81 mg per day). PRP and PPP were iso-
lated by centrifugation (10 min at 150 x g and 20 min at 2000 x g, respectively).
Platelet count (PLT) of PRP was adjusted to 200x103 per µl with autologous PPP
(AcT10 Coulter counter, Beckman Coulter, Miami FL).
Thrombin generation was measured by the calibrated automated thrombog-
raphy method using a fluorogenic thrombin substrate (Z-Gly-Gly-Arg-AMC,
Diagnostica Stago, Parsipanny, NJ) [207, 208]. Briefly, 80 µl of PRP or PPP
sample was added, and then 20 µl of tissue factor (TF)-based activator (Biodis,
Signes, France) was added to wells of the 96-well plate. The plate was incubated
for 2 to 3 min at 37oC and then 20 µl of the substrate buffer was added. A throm-
bin calibrator with known thrombin-like activity was monitored in parallel sam-
ple wells to allow for calculation of generated thrombin in nM. The progress of
the reaction was continuously monitored for 70 min at 37oC with a fluorescence
reader (Fluoroscan Ascent, Thermo Labsystems, Franklin, MA) equipped with a
390 nm excitation filter and a 460 nm emission filter. A dedicated software pro-
gram (Thrombinoscope, Synapse BV, Maastricht, The Netherlands) was used to
record the peak thrombin level.
4.5.4 Computation of overall state sensitivity coefficients.
The sensitive or fragile interactions of the coagulation architecture were deter-
mined by computing Overall State Sensitivity Coefficients (OSSC) [89]. Because
each parameter corresponds directly to a particular molecular interaction in the
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cascade, OSSC values were used to gauge which interactions were qualitatively
important. Large OSSC values for interactions relative to their peers indicated
fragility or sensitivity while small OSSC values indicated robustness. The OSSC
value for interaction j was defined as:
O j (t) =
k∗j
NS
( NT∑
h=1
NS∑
i=1
[
1
x∗i
∂xi
∂k j
∣∣∣∣∣∣
th
]2)1/2
(4.6)
where NT denotes the number of time points used in the simulation while NS
denotes the number of proteins/protein complexes in the model. The first-order
sensitivity coefficients:
si j (th) =
∂xi
∂k j
∣∣∣∣∣∣
th
(4.7)
were computed by solving the differential equation:
ds j
dt
= A (t) s j + b j (t) j = 1, 2, ,NP (4.8)
subject to the initial condition s j(t0) = 0. In Eqn. 5.8, the quantity j denotes the
parameter index, NP denotes the number of parameters, A denotes the Jacobian
matrix of the model equations and b j denotes the jth column of the matrix B,
which contains first-derivatives of the mass balances w.r.t. the parameter val-
ues. The quantity s j denotes the vector of first-order sensitivity coefficients w.r.t
parameter j. The Jacobian matrix (A) and the matrix of first-derivatives of the
mass balances w.r.t the parameter values (B) are given by:
A =
∂g
∂x
∣∣∣∣∣∣
(x∗,k∗)
B =
∂g
∂k
∣∣∣∣∣∣
(x∗,k∗)
(4.9)
where (x∗,k∗) denotes a point along the nominal or unperturbed system solu-
tion. The matrices A and B were numerically estimated at each time step us-
ing a generalized gradient algorithm [148] while the sensitivity balances were
solved using the LSODE routine of the OCTAVE programming environment
(v2.9.9; www.octave.org) on an Apple Computer MacOSX (Cupertino, CA;
v10.4.8) workstation.
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The connectivity matrix S (193 × 301) was used to rearrange the parameter
OSSC values to the species OSSCs through the equation:
Q = |S|O (4.10)
The rank orders of the species OSSCs were used to access the fragility of differ-
ent species in the model.
4.5.5 Statistical and clustering analysis of the shifts in overall
state sensitivity coefficients.
Three different tests were performed to identify large statistically significant
shifts in OSSC values between defective networks and the control. A Welch
t-test [149] was used to find all statistically significant shifts resulting from the
different structural perturbations and then a secondary test on the z−score of
each shift was preformed to find only the most prominent. The OSSC values
calculated over the family of parameter sets were assumed to follow normal
distributions for all cases. The statistical significance of shifts in OSSC values
relative to the control were determined by performing a Welch t-test with the
null hypothesis that the means of the sensitivity coefficients were equal at a
1% significance level. The Welch t-test is similar to the student t-test with the
exception that the two distributions being compared are not required to have
equal variances. The list of significant OSSC values was further restricted to
only those shifts with a magnitude larger than a specified z-score (0.1) away
from the squared mean displacement relative to the control:
d j,q =
(
O¯qj − O¯cj
)2
, j = 1, 2, ,NP (4.11)
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where O¯cj denotes the mean OSSC value over the family of parameter sets for
parameter j in the control while O¯qj denotes the same quantity for defective case
q. A significant shift in OSSC value was accepted if:
d j,q > zσdq + µdq (4.12)
where z denotes a desired z-score, σd j denotes the standard deviation of the total
displacement over all significant OSSC values for the qth defective case and µdq
denotes the mean of the significant displacements for the structurally defective
case q.
A large statistically significant shift in OSSC value, while indicative of the
shifting importance of an interaction, does not guarantee that an interaction
is ranked differently between cases. To this end, we used the Spearman rank
correlation denoted by ρ and defined as:
ρ = 1 − 6
∑NP
i=1 d
2
i
N
(
N2 − 1) (4.13)
to measure the difference in qualitative ranking between cases. The quantity
di denotes the difference in the ordinal rank of interaction i between a struc-
turally defective network and the control, N denotes the number of pairs of
values and NP denotes the number of parameters considered. The Spearman
rank is bounded by −1 ≤ ρ ≤ 1; a Spearman rank of one indicates that two
ranked lists are identical, a Spearman rank equal to negative one indicates that
two ranked lists are perfectly negatively correlated, while a Spearman rank of
zero indicates that two ranked lists are uncorrelated.
The distributions of OSSC values obtained from monte-carlo sampling were
clustered using a k-means algorithm [209]. The mean and standard deviation
obtained from the monte-carlo sensitivity analysis was used to estimate the un-
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derlying OSSC distribution (N = 100 points) where the OSSC values were as-
sumed to be normally distributed. Two hundred different clustering attempts
were run for each model to control for clustering artifacts. The most probable
configuration was reported.
4.5.6 Coupling analysis
Coupling coefficients of the form:
α
(
i, j, to, t f
)
=
(∫ t f
to
xi (t) dt
)−1 (∫ t f
to
x( j)i (t) dt
)
(4.14)
were calculated to understand the sensitivity of the parameters in the model.
The coupling coefficient α
(
i, j, to, t f
)
is the ratio of the integrated concentration
of a network output in the presence (numerator) and absence (denominator) of
structural or operational perturbation. If α
(
i, j, to, t f
)
> 1, then the perturbation
increases the output concentration. Conversely, if α
(
i, j, to, t f
)
 1 the perturba-
tion decreases the output concentration. Lastly, if α
(
i, j, to, t f
)
∼ 1 the perturbation
does not influence the output concentration.
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CHAPTER 5
FACTOR XI IS A POTENTIAL THERAPEUTIC TARGET FOR
THROMBOSIS THAT MAINTAINS HAEMOSTASIS
5.1 Abstract
The systems biology approach, together with computational, experimental and
observational inquiry, is highly relevant to drug discovery and the optimization
of medical treatments. In this study, we test our working hypothesis that fXI
related mechanisms are fragile in the process of blood coagulation and could be
a potential therapeutic target for thrombosis treatment. A mathematical model
of the blood coagulation cascade including fXI activities was built and validated
against published datasets generated from a cell-based model. The model ex-
plained the time-resolved thrombin generation profile with normalized error
≤30% and correlation coefficients ≥72%. The simulation results show that the
addition of intrinsic pathway protease fXI to the TF initiated coagulation re-
sulted in the formation of extra amount of thrombin and thrombin was recipro-
cally generated in a fXI-dependent way. To gauge the robustness and fragility of
each interaction in the cascade, overall state sensitivity coefficients (OSSC) were
calculated for each of the 301 model parameters over a parameter ensemble that
could predict reasonable thrombin generation profiles; the species sensitivity
was also calculated using the connectivity matrix and parameter OSSCs. Analy-
sis of the sensitivity results discloses that fX/FXa and thrombin were important
species in the extrinsic case; while besides thrombin, fXI/FXIa was also sensitive
in the combined and intrinsic cases. Theoretical considerations and experimen-
tal data suggest that fXI/FXIa could be excellent candidates as clinical targets
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in treatment of thrombotic diseases. Inhibition of fXI/FXIa could potentially re-
duce the risk of occlusive thrombi formation without sacrificing hemostasis as
deficiency of fXI results in bleeding manifestations only after trauma or surgery.
When taken together, these preliminary results support our hypothesis that fXI
related mechanisms are fragile in the process of blood coagulation and could be
a potential therapeutic target for thrombosis treatment with the advantage of
not affecting hemostasis.
5.2 Introduction
The systems biology approach, together with computational, experimental and
observational inquiry, is highly relevant to drug discovery and the optimization
of medical treatments. It has been frequently proposed that computer simula-
tions and analysis significantly increase the efficiency of drug discovery [73].
Assmus et al. and others maintain that analysis of the dynamics of human rel-
evant networks using predictive computer models and high-throughput data
generation will play an increasingly important role in medical research and the
elucidation of disease mechanisms [76, 77]. However, these techniques often
suffer from parametric and structural uncertainties in diagnosing complex bio-
logical networks [73, 84]. The conventional wisdom is that the data requirement
to fully identify and validate mechanistic models is too large. One tool that
could partially eleviate model uncertainty and potentially elucidate qualitative
properties of uncertain mechanistic models, such as robustness and fragility of
particular mechanisms, is sensitivity analysis.
Sensitivity analysis is an enabling tool for the investigation of robustness and
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fragility in networks relevant to human health and more generally for model-
based knowledge discovery. Robustness, a long-recognized property of living
systems and networks, allows function in the face of uncertainty while fragility,
i.e., extreme sensitivity, can potentially lead to catastrophic failure following
seemingly innocuous perturbations [85, 158, 159, 160, 84]. Cho et al. used sen-
sitivity analysis to study TNF-α-mediated NK-κB signalling where parametric
uncertainty was addressed using a monte-carlo parameter sampling protocol;
a parameter ensemble, generated from the best parameter guess, was used to
calculate the sensitivity profile in a region of parameter space [80]. Bullinger
and coworkers explored the robustness of models of programmed cell death
or apoptosis [88] while Stelling et al., computationally identified points of ro-
bustness and fragility, using monte-carlo sensitivity analysis and Overall State
Sensitivity Coefficients (OSSCs), in models of circadian rhythm [89]. Mahdavi
et al., employed sensitivity analysis to better understand stem cell differentia-
tion [161], while our group used an uncertain mechanistic model of the coag-
ulation cascade in combination with monte-carlo sensitivity analysis, to show
that computationally derived sensitive mechanisms were consistent with anti-
coagulation therapeutic strategies [162]. By screening a model of the extrinsic
pathway of blood coagulation using sensitivity analysis, we have previously
found that factor X/activated factor X (fX/FXa) and thrombin related mecha-
nisms were fragile and factor IX/activated factor IX (fIX/FIXa) related mecha-
nisms had moderately robust. Some anti-fX/FXa and direct thrombin inhibitors
have been evaluated in phase III clinical trials or have been licensed in North
America or Europe for the treatment of venous thromboembolism, deep ve-
nous thrombosis and pulmonary embolism [210]. And the treatment of throm-
botic disease with anti-fIX/FIXa antibodies often require high dosages to have
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an therapeutical effect [133]. However, the use of these anticoagulants is often
associated with therapy-related bleeding problems and has no significant im-
provement in safety/efficacy ratio [210, 211, 212]. Hence the development of
new therapies is necessary and requires the discovery of agents that are specific
for thrombus-forming mechanisms without affecting hemostasis.
Factor XI (fXI), closely related to mild bleeding disorder[27, 213, 205], often
receives less attention as a result of its in vivo insignificance. Deficiency in fXI
only affects people who has trauma or under surgery. However, recent studies
show that its feedback activation by thrombin consolidates blood coagulation
and fibrin clot formation [15, 16]. Elevated fXI activity levels are not only a
risk factor for deep venous thrombosis and possibly cardiovascular disease, but
also associated with stroke or cerebrovascular events [214, 215]. All these stud-
ies motivate us to study of the role of fXI in coagulation and its possibility as
potential therapeutic targets without a serious impact on hemostasis. In this
study, we use mathematical modeling and sensitivity analysis to test our work-
ing hypothesis that fXI related mechanisms are fragile in the process of blood
coagulation and could be a potential therapeutic target for thrombosis treat-
ment. A mathematical model of the blood coagulation cascade including fXI ac-
tivities (intrinsic pathway) was built and validated against published datasets
generated from a cell-based model [15]. The model explained the time-resolved
thrombin generation profile with normalized error ≤30% and correlation coeffi-
cients ≥72%. The simulation results show that the addition of intrinsic pathway
protease fXI to the Tissue Factor (TF) initiated coagulation resulted in the forma-
tion of extra amount of thrombin and thrombin was reciprocally generated in a
fXI-dependent way. We used monte-carlo sensitivity analysis to computation-
ally screen the model for sensitive mechanisms in the presence of either intrinsic
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pathway activators fXI and thrombin (intrinsic case), or extrinsic pathway acti-
vator TF (extrinsic case), or both pathways activators (combined case). Analysis
of the sensitivity results discloses that fX/FXa and thrombin were important
species in the extrinsic case; while besides thrombin, fXI/FIXa were also sensi-
tive in the combined and intrinsic cases. We then validated the fragility of fXI
related mechanisms in different cases and contrast with literature to determine
if they could be a potential therapeutic target for thrombosis treatment, thereby
proving or disproving our working hypothesis.
5.2.1 A review of the coagulation cascade.
Conventionally, the coagulation cascade has been known as two alternative or
convergent pathways known as the intrinsic pathway and the extrinsic path-
way [12, 52, 54, 60, 53, 8, 111, 109, 115, 110, 216, 217]. The extrinsic coagu-
lation cascade is initiated by the formation of the TF and Factor VIIa molec-
ular complex, following a series of enzymatic interactions leading to the for-
mation of thrombin. The detailed interactions and the roles of pro- and anti-
coagulants in the coagulation cascade could be found in a number of articles
[112, 10, 108, 20, 21, 22, 116, 117, 23]. The extrinsic pathway is believed to be
the major activation mechanism in vivo [12, 52, 54, 60, 53, 8, 111, 109]. However,
small quantities of active FXa generated by FVIIa-TF complex during the initia-
tion of the extrinsic pathway could result in the inactivation of TF pathway by
TFPI. When this inactivation occurs, an alternative system is needed to maintain
coagulation. The classic intrinsic pathway of coagulation is triggered by contact
activation of plasma protease factor XII, followed by sequential proteolytic ac-
tivation of fXI and fIX [14]. However, patients with deficiency in fXII do not
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experience abnormal hemostasis even after major trauma or surgery, whereas,
patients with fXI deficiency frequently present with excessive or even life-
threatening bleeding complication after trauma or surgical operations [14, 13].
Researches on this discrepancy indicate additional mechanisms for fXI activa-
tion in vivo, which is the activation of fXI by a catalytic amount of thrombin in
the presence of dextran sulfate [14, 13]. Further studies show that the surface
of activated platelets could substitute for dextran sulfate in vivo [18, 19]. More-
over, this feedback activation of fXI by thrombin is proven to be a preference
over contact activation of FXIIa [17]. Hence, the activation of fXI by thrombin
could serve as an alternative to maintain blood coagulation and has been well
studied by several groups [13, 14, 15, 16, 17, 18, 19]. Therefore, besides activation
by Factor XIIa, which is activated upon contact with negatively charged surface,
factor XI (fXI) in the intrinsic pathway could also be activated by thrombin and
its own active form, Factor XIa (FXIa) [13, 14, 18, 19, 17, 16, 15, 206, 205]. The
intrinsic pathway of coagulation joins with the extrinsic at the point where fIX
activated by FXIa to form FIXa (shown in Figure 5.1).
5.3 Results
Thrombin generation as a function of TF, FVIIa, fXI and thrombin were pre-
dicted, over an ensemble of parameter sets (N = 437, see Chapter 4), to be con-
sistent with published datasets from a cell-based model [15]. To gauge the ro-
bustness and fragility of each interaction in the cascade, a hundred parameter
sets were further selected from one parameter ensemble with a coefficient of
variance (CV) equals 2 for sensitivity analysis. The overall state sensitivity coef-
ficients (OSSCs) were calculated for each of the 301 model parameters over the
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Figure 5.1: Schematic illustration of the coagulation cascade.
selected parameter sets (see Methods). Simulation results and error quantifica-
tions for different cases (Table 5.1) are shown in Figure 5.2. The model explained
the time-resolved thrombin generation profile with normalized error ≤30% and
correlation coefficients ≥72%. The simulation results show that the addition of
intrinsic pathway protease fXI to the TF initiated coagulation resulted in the for-
mation of extra amount of thrombin and thrombin was reciprocally generated
in a fXI-dependent way. The OSSCs were clustered into groups with varied
levels of sensitivity (high, medium and low); the high and medium sensitive
groups for different cases are reported in Table 5.2. Pairwise comparison of the
OSSCs are shown in Figure 5.3 and the parameter indices of statistically signif-
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icant shifts for different pairs are reported in Table 5.3. The species sensitivity
was calculated using the connectivity matrix and parameter OSSCs; and the av-
erage ranks of the top 10 most sensitive species and their connectivities for all
cases are shown in Figure 5.4. Pairwise comparison of the rank-ordered species
sensitivity are shown in Figure 5.5 and the statistically significant shifts for dif-
ferent pairs are reported in Table 5.4. Analysis of the sensitivity results discloses
that fX/FXa and thrombin were important species in the extrinsic case; while
besides thrombin, fXI/FXIa were also sensitive in the combined and intrinsic
cases.
5.3.1 Thrombin generation in the presence and absence of fXI.
Figure 5.2 shows the time resolved generation of thrombin as a function of TF,
FVIIa, fXI and thrombin. Figure 5.2 A is thrombin generation profile of the
extrinsic case where only TF and FVIIa were present in the reaction system;
Figure 5.2 B is thrombin generation in the combined case where fXI was also
added in addition to TF and FVIIa; Figure 5.2 C and D show thrombin gener-
ation profiles in the intrinsic cases with different amounts of thrombin as the
initiator of the intrinsic pathway, since fXII was not available. The dotted lines
denoted the mean thrombin generation profile obtained from the parameter en-
semble (437 sets). A hundred parameter sets were further selected with a CV
of 2 for the sensitivity analysis. The model predictions of mean thrombin gen-
eration explained the generation of thrombin for all cases in Table 5.1 with the
normalized standard errors ≤ 30% and the correlation coefficients above 72%.
Thrombin generation were simulated using the ensemble of parameter sets and
the mean and standard deviation of thrombin concentrations at each time were
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Table 5.1: Treatement cases considered in the sensitivity analysis. Case A
denotes the ‘Combined’ case, where species for both extrinsic
and intrinsic pathways are present, Case B denotes the ‘Extrin-
sic’ case while cases C and D denote the ‘Intrinsic’ case with two
different initial thrombin concentrations.
Case Name TF (pM) VIIa (nM) XI (nM) IIa (nM)
A Extrinsic 1.0 20 – –
B Combined 1.0 20 60 –
C Intrinsic – – 60 0.5
D Intrinsic (5nM IIa) – – 60 5
calculated for all cases. The shadow areas denoted thrombin concentratrions
within ±1-standard deviation of the ensemble.
Thrombin generation profile typically consists of three stages: the initiation,
the propagation and the termination. The initiation stage is the part where no
or little thrombin is generated, the propagation is the part where large amount
thrombin formed in a short period of time due to increased thrombin gener-
ation rates, and the termination of thrombin is the result of fast consumption
of thrombin. Figure 5.2A shows that in the extrinsic case, the initiation stage
covered the first 15 min, followed by the propagation of thrombin. Thrombin
reached its maximal of 30 nM at about 40 minutes, then it gradually degraded
to 20 nM at one hour. The normalized standard error and the correlation coeffi-
cient in this case were 0.07 and 0.97, respectively, which was probably because of
the discrepancy between the mean simulation results and the experiment data
in the propagation stage. The thrombin generation profile in the extrinsic case
(case A) was quite similar to that in the intrinsic case (case C). As shown in Fig-
ure 5.2C, after 0.5 nM thrombin was added to initialize the reaction, thrombin
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propagation started at about 12 min, which was close to the lag time in extrinsic
case; furthermore, the rate and maximal amount of thrombin generated in this
case was about the same as those in the extrinsic case, especially when compar-
ing the experimental data. The model predicted a faster thrombin generation
in the propagation and a faster thrombin consumption in the termination stage.
This discrepancy caused a larger standard error of 0.24 and a smaller correlation
coefficient of 0.78. In the combined case (Figure 5.2B), both the rate and maximal
thrombin generation were increased as compared to that in either the extrinsic
or the intrinsic case . Thrombin concentration reached a maximum of 40 nM
at about 30 min. Our model prediction was consistent with the experimental
observation that feedback activation of fXI by thrombin resulted in additional
production of thrombin [16, 15]. Our model predictions of the combined case
(case B) correlated well with the experimental observation, which had a stan-
dard error of 0.10 and a correlation coefficient of 0.95.
The experimental observations of the thrombin generation in case C and case
D show that thrombin was reciprocally generated in a fXI-dependent manner,
i.e. increasing the initiating thrombin concentration resulted in increased FXIa
formation, which then increased the amount of thrombin formation. In Fig-
ure 5.2D, after 5 nM thrombin was added, the experiment results illustrated
gradually increased thrombin concentration to a maximum of 60 nM in a tem-
poral range of 0 to 20 min, which indicated a much faster thrombin generation
rate than that in case C. However, our simulation results in case D failed in pre-
dicting thrombin generation in the first 20 min; we predicted a lag time of 10 min
and a faster thrombin generation rate where thrombin concentration reached its
maximum within 15 min. As a result, a standard error of 0.30 and a correlation
coefficient of 0.72 were observed in this case.
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5.3.2 The fragility and robustness of the combined, intrinsic
and extrinsic coagulation pathways.
The OSSCs were calculated for cases A-D in Table 5.1. The scaled OSSC val-
ues were clustered into three groups (high, medium and low sensitivity) using
a k-mean algorithm. The mean and standard deviations of the OSSC values in
the high (Cluster I) and medium (Cluster II) sensitive groups are reported in
Table 5.2. 7 interactions in the extrinsic case (case A), 4 interactions in the com-
bined case (case B), and 5 interactions in the intrinsic cases (case C and D) are
shown in the most sensitive cluster (Cluser I). Among all these interactions, the
off rates of platelet activations by TXA2 and ADP were clustered in the high
sensitive group for all cases. In the extrinsic case, 3 out of 7 interactions were
associated with fX/FXa activities, all other interactions were related to platelet
activation by TXA2 or ADP. It is noted that, although all these 3 fX/FXa interac-
tions were not in the high sensitive group for the combined case (case B), they
were classified in the medium sensitive group (Cluster II). Furthermore, the se-
cretion of TXA2 by activated platelets was also not shown in the high sensitive
group for case B, in stead, it showed up in the medium sensitive group. In addi-
tion, the self-activation of intrinsic pathway protease fXI (on and catalytic rates)
were shown in the high sensitive group for the case B, C and D.
The medium sensitive group (Cluster II) consisted 24 interactions in case A,
20 interactions in case B, 25 interactions in case C and 18 interactions in case
D. For the extrinsic case (case A), one of the most important category of re-
actions in Cluster II was the surface binding interactions as 9 out of the total
24 interactions in Cluster II were binding interactions with active platelet sites;
while among other interactions, 6 interactions related to the formation and ac-
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Figure 5.2: Model predictions of thrombin generation versus time as a
function of TF, FVIIa, fXI and thrombin and experimental mea-
surments from a cell-based model. (A-D) Thrombin genera-
tion in the case A, B, C and D in Table 5.1, respectively. The
experimental thrombin generation assay was reproduced from
Wielder et al [15]. An ensemble of parameter sets (N = 437)
was generated using nine training data sets. The dotted lines
denote the mean thrombin concentrations calculated from the
parameter ensemble and the shadow areas denote one stan-
dard deviation of the ensemble. The normalized standard er-
rors (SE) and the correlations between the mean simulation val-
ues of the ensemble are reported in the corner of each panel. In
the experiments, recalcified PRP was incubated with different
concentrations of FVIIa, fXI and thrombin (see Table 5.1) in the
presence of collagen. Thrombin generation was initiated by TF
or small amount of thrombin.
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tivities of surface complex tenase or prothrombinase, 5 TF-VIIa activating inter-
actions, 3 platelets activations by thrombin and 1 ATIII inhibitory interaction.
Our findings in Cluster I and II for the extrinsic case were consistent to cer-
tain degree with our previous observations in the extrinsic pathway model [162]
that fX/FXa and thrombin related mechanisms were fragile, while fIX/FIXa and
fVIII/FVIIIa activation and activities were relatively robust.
Table 5.2: The distribution of the OSSCs for different cases 5.
p-index case A case B case C case D Description
Cluster I
172 0.83±0.23 0.76±0.20 0.84±0.19 0.76 ±0.18 TXA2 activates platelets (off)
175 0.74±0.27 0.48±0.17 0.57±0.24 0.63 ±0.25 ADP activates platelets (off)
126 0.62±0.18 – – – ATIII inhibits FXa (on)
50 0.60±0.21 – – – FXa binds platelet active sites (off)
13 0.54±0.19 – – – TF-FVIIa activates fX (catalytic)
164 0.37±0.17 – – – Activate platelets secret ADP
165 0.50±0.22 – 0.47±0.13 0.44±0.14 Activate platelets secret TXA2
197 – 0.68±0.40 0.80±0.23 0.62±0.33 FXIa self-activation (on)
199 – 0.50±0.27 0.65±0.13 0.49±0.16 FXIa self-activation (catalytic)
Cluster II
90 0.56±0.23 0.41±0.24 0.29±0.14 0.34±0.18 Prothrombinase activates fII (on)
59 0.41±0.20 0.29±0.16 0.22±0.13 0.29±0.18 fII binds platelets activate sites (on)
60 0.40±0.20 0.28±0.15 0.22±0.13 0.28±0.17 fII binds platelets activate sites (off)
58 0.35±0.26 0.27±0.20 0.30±0.10 0.36±0.15 FVIIIa binds platelet active sites (off)
57 0.35±0.26 0.27±0.20 0.30±0.10 0.36±0.15 FVIIIa binds platelet active sites (on)
123 0.27±0.18 0.33±0.30 0.33±0.27 0.53±0.32 ATIII inhibits FIXa (on)
47 0.50±0.17 0.34±0.18 – – fX binds platelet active sites (on)
48 0.50±0.17 0.34±0.18 – – fX binds platelet active sites (off)
49 0.50±0.18 0.33±0.18 – – FXa binds platelet active sites (on)
11 0.44±0.13 0.28±0.13 – – TF-FVIIa activates fX (on)
Continued on next page
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Table 5.2 (Continued)
p-index case A case B case C case D Description
12 0.34±0.09 0.22±0.10 – – TF-FVIIa activates fX (off)
147 0.47±0.37 0.26±0.29 0.31±0.30 – Thrombin activates platelets (catalytic)
97 0.45±0.18 0.29±0.16 0.20±0.08 – FXa binds FVa on platelet surface (on)
98 0.45±0.18 0.29±0.16 0.20±0.08 – FXa binds FVa on platelet surface (off)
95 0.32±0.28 – 0.17±0.11 0.25±0.18 FIXa (specific) binds FVIIIa (on)
96 0.32±0.28 – 0.17±0.11 0.25±0.18 FIXa (specific) binds FVIIIa (off)
81 0.32±0.28 – 0.17±0.11 0.24±0.18 Tenase activates fX on platelet surface (on)
45 0.32±0.25 – 0.15±0.09 0.22±0.14 FIXa binds specific platelet active sites (on)
46 0.31±0.25 – 0.14±0.09 0.21±0.13 FIXa binds specific platelet active sites (off)
156 0.27±0.21 – 0.19±0.19 – Thrombin activates platelets via PAR4 (off)
155 0.27±0.21 – 0.19±0.19 – Thrombin activates platelets via PAR4 (on)
14 0.31±0.11 – – – TF-FVIIa activates fIX (on)
15 0.28±0.10 – – – TF-FVIIa activates fIX (off)
16 0.23±0.15 – – – TF-FVIIa activates fIX (catalytic)
13 – 0.37±0.19 – – TF-FVIIa activates fX (catalytic)
165 – 0.42±0.11 – – Activate platelets secret TXA2
164 – 0.24±0.10 0.24±0.14 0.29±0.11 Activate platelets secret ADP
198 – 0.21±0.14 0.25±0.10 0.19±0.11 FXIa self-activation (off)
50 – 0.41±0.21 0.24±0.09 0.17±0.04 FXa binds platelet active sites (off)
126 – 0.36±0.19 – 0.18±0.08 ATIII inhibits FXa (on)
129 – – 0.19±0.12 0.19±0.06 ATIII inhibits thrombin (on)
93 – – 0.14±0.11 – FIXa binds FVIIIa on platelet surface (on)
94 – – 0.14±0.11 – FIXa binds FVIIIa on platelet surface (off)
78 – – 0.13±0.11 – Tenase activates fX on platelet surface (on)
144 – – 0.11±0.10 – Thrombin activates platelets via PAR1 (off)
143 – – 0.11±0.10 – FXa activates fV on platelet surface (on)
62 – – – 0.17±0.07 Thrombin binds platelet active sites (off)
210 – – – 0.16±0.08 FXIa activates fIX (on)
5The OSSC values were clustered using a k-means algorithm into three parts. The most
fragile parameters were shown in Cluster I; the most robust ones were shown in Cluster III.
The mean OSSC value (µ) ± one standard deviation (σ) in Cluster I and II are reported. p-index
denotes the parameter index in the reaction file.
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For the combined case (case B), 8 platelet binding interactions and 3 inter-
actions related to the formation and activities of prothrombinase, 3 interactions
of TF-VIIa activating fX, 2 ATIII inhibitions for FIXa and FXa and the others
were related to platelet activation. In total, there were 11 interactions related to
fX/FXa activities, 1 interaction related to fXI/FXIa, and 1 interaction related to
fIX/FIXa, etc. For case C and D, most of the medium sensitive parameters were
associated with the activities of platelets, thrombin, fIX/FIXa and fXI/FXIa.
When taken together, thrombin and platelets interactions were the most sensi-
tive interactions among all cases; fX/FXa activities were fragile in the extrinsic
and combined case, while less fragile in other cases; binding interactions were
moderately sensitive in the extrinsic and combined cases, but less important in
all other cases. Furthermore, TF-FVIIa mechanisms were sensitive in the extrin-
sic case, while robust in all other cases; similarly, fXI/FXIa mechanisms were
robust in the extrinsic case, while sensitive in the combined and intrinsic cases.
The statistically analysis of the pairwise comparisons of the OSSCs for dif-
ferent cases were used to gauge the importance of mechanisms in different cases
(Figure 5.3 and Table 5.3). Increases or decreases in the OSSC value of a reaction
in one case relative to the other indicated increased or decreased importance of
the reaction in different pathways. And all the shifts found in these pairwise
comparisons have shown to be in either high or medium sensitive group in one
case or the other. Comparing the intrinsic cases with different amount of initi-
ating thrombin (Figure 5.3D and Table 5.3), 6 statistically significant shifts were
observed. Among all these 6 shifts, 3 of them involved thrombin activity, 2 re-
lated to fXI/FXIa activity and 1 related to ATIII inhibition of FIXa. The results
indicated that the changes in the initiating thrombin concentration in the in-
trinsic cases not only affected the sensitivity of thrombin mechanisms, but also
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Figure 5.3: The pairwise parameter OSSC values calculated from sensitiv-
ity analyses for different cases in Table 5.1. Among the gener-
ated parameter ensemble, 100 parameter sets with a CV of 2
were selected for the sensitivity analyses. The mean and stan-
dard deviation of all parameter sets were shown in the figure.
had something to do with the fXI/FXIa mechanisms, and even fIX/FIX mech-
anism. After further investigating the OSSCs, although the relative importance
of most parameters was statistically shifted between these two cases, 3 out of
the 6 parameters were still clustered into the same sensitive group. For exam-
ple, although the on and catalytic rates of FXIa self-activation (parameter index
of 197 and 199) were statistically shifted when comparing case C with case D,
they were clustered into the high sensitive group (Cluster I) for both cases. On
the other hand, if a parameter was clustered into different groups, this param-
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Table 5.3: Statistical results of the indices of shifted parameters in pairwise
comparison of different cases (Table 5.1).
.
case C vs case A case C vs case B case A vs case B case C vs case D
11 11 – –
12 12 – –
13 13 – –
14 14 – –
47 47 – –
48 48 – –
49 49 – –
50 50 – –
126 126 126 –
197 – 197 197
199 – 199 199
– – 147 147
– – 175 –
– – – 123
– – – 155
– – – 156
eter was highly possible to be one of the statistically significant shifts, e.g. the
rates of thrombin activating platelets (parameter indices of 147, 155 and 156).
As compared to the combined case, 9 and 5 statistically significant shifts
were observed in the intrinsic and extrinsic cases, respectively; while 11 signifi-
cant shifts were observed when comparing the intrinsic case to the extrinsic case
(Table 5.3). Comparing the intrinsic to the combined case, except for 1 fIX/FIXa
mechanism (index 14), the remaining 8 mechanisms all related to fX/FXa activ-
ities; All these mechanisms were all shown to have reduced sensitivity in the
intrinsic case. When comparing the extrinsic to the combined case, the on and
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catalytic rates of fXI self-activation were shown to have increased sensitivity in
the combined case; while the other 3 mechanisms that related to the activation
of platelets and the inhibition of FXa became less significant in the combined
case. Comparing the intrinsic to the extrinsic case, 8 out of 11 significant shifts
related to fX/FXa activities and 1 related to FIXa were shown to have reduced
sensitivities in the intrinsic case; while the remaining 2 shifts were related to
fXI self-activation with apparently increased significance in the intrinsic case.
Overall, the sensitivity of fX/FXa mechanisms was generally shifted to be more
important in the extrinsic case; while the parameters related to fXI/FXIa inter-
actions was more sensitive in the intrinsic cases. In the combined case, both
fX/FXa and fXI/FXIa mechanisms were sensitive.
The sensitivity of species was accessed by multiplying the absolute connec-
tivity matrix with the parameter OSSC values, therefore it evaluates the com-
bination of the species connectivity and the parameter sensitivity. Figure 5.4
shows the average ranks of the top ten most sensitive species and their corre-
sponding connectivity in different cases (Table 5.1). In all cases, at least 8 out
of the top 10 most sensitive species show a connectivity greater than the mean
connectivity (4.9) + 1 standard deviation (6.1) of all species, which indicated that
the species sensitivity was highly influential by the species connectivity. Platelet
activators ADP and TXA2 ranked within the top 3 most sensitive species for all
cases; while thrombin ranked the 5th sensitive species except for the combined
case. In the extrinsic case, free and surface bound fX/FXa and TF-FVIIa were
ranked in the top 10 sensitive species (Figure 5.4A); while in the combined and
intrinsic cases, FXIa became more sensitive as shown in the top 10 sensitive
species (Figure 5.4B, C and D); FIXa was shown as the 8th sensitive species in
case D. The relative importances of fX/FXa, TF-FVIIa, fXI/FXIa were consistent
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Figure 5.4: The connectivities of species ranked as the top ten most sensi-
tive species for different cases in Table 5.1. The x-axis denotes
the average ranks of the top ten most sensitive species in differ-
ent cases, the y-axis denotes the corresponding connectivities
of the species.
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with our findings in the clustered parameter OSSCs (Table 5.2).
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Figure 5.5: The pairwise species OSSC ranks calculated from sensitivity
analyses for different cases in Table 5.1. The connectivity ma-
trix S (193 × 301) was used to rearrange the parameter OSSC
values to the species OSSCs. The rank orders of the species
OSSCs were used to access the fragility of different species in
the model. The mean and standard deviation of the ranks for
species OSSC values (100 sets) were shown in the figure.
The pairwise comparisons of the rank-ordered species sensitivity of different
cases are plotted in Figure 5.5 and the statistically significant shifts of the ranks
are reported in Table 5.4. As compared to the combined case, 15 and 7 species
were statistically significantly changed in the intrinsic and extrinsic cases, re-
6The mean ranks of the species OSSC values (µ) ± one standard deviation (σ) of the statisti-
cally shifted species are reported. s-index denotes species index in the pairwise comparison.
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spectively; in the intrinsic case, all these 15 species, including 8 TF-FVIIa/FVIIa
proteins or protein complexes and 4 PARs (protease-activated receptor) or PAR
complexes, became less important approved by the increased species sensitivity
ranks; in the extrinsic case, FXIIa and the other 6 fXI/FXIa or fXI/FXIa com-
plexes became less fragile as compared to that in the combined case. Compare
the intrinsic to the extrinsic cases, 6 fXI and fXII related species become more
important, while the other 8 species including TF-FVIIa, FXa and PAR related
species became less important in the intrinsic case. When considering the effect
of initiating thrombin in the intrinsic cases, the different amount of initiating
thrombin resulted in statistically significant changes in the sensitivity ranks of
7 PAR related species, 3 fVIII related species and 2 thrombin inhibitors. Those
PARs were associated with the activation of platelets by thrombin; and the in-
creased initial thrombin concentration (case D) resulted in decreased sensitivity
of all species shifted.
5.4 Discussion
We have previously reported that fX/FXa activity and thrombin-mediated
platelet activation were fragile mechanisms in the extrinsic pathway model, and
these mechanisms were targets of current anticoagulation preclinical develop-
ment, clinical therapies, and clinical trials in the treatment of thrombotic dis-
orders [162]. In this study, we used parameter OSSCs and species sensitivity
analysis to show that fX/FXa, thrombin and platelets were important species in
the extrinsic case; while besides thrombin and platelets, fXI/FXIa became more
important in the combined and intrinsic cases than that in the extrinsic case.
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Table 5.4: Statistical results of the shifts in the rank of species OSSCs for
pairwise comparison of different cases 6.
s-index species case C case A s-index species case C case B
(µ ± σ) (µ ± σ) (µ ± σ) (µ ± σ)
3 X-VIIa-TF 91.0±3.5 14.7±3.9 3 X-VIIa-TF 91.0±3.5 17.9±7.5
4 IX-VIIa-TF 95.0±5.5 29.3±7.0 4 IX-VIIa-TF 95.0±5.5 42.1±13.4
36 TF-FVIIa 87.9±2.2 6.0±1.9 6 VII-IIa 98.2±4.7 142.0±9.6
92 PAR3 170.4±13.9 83.4±2.9 35 VIIa 95.3±2.5 50.4±5.5
96 IIa-PAR3 186.5±11.2 120.6±12.8 36 TF-FVIIa 87.9±2.2 10.7±5.7
98 IIa-PAR4 166.8±15.1 78.8±4.4 39 X 53.8±7.2 14.5±6.6
102 PL-Psub-IIa-PAR4 183.9±12.1 116.0±13.1 78 VIIa-TF-ATIII 121.8±4.7 76.9±7.7
115 XIIa 98.6±6.3 172.2±3.3 81 TFPI-X-VIIa-TF 106.6±6.8 59.8±10.6
121 XI 11.4±6.9 106.5±4.7 82 TFPI-Xa-VIIa-TF 109.7±5.3 69.4±5.4
122 XIa 3.1±1.1 93.6±3.0 92 PAR3 170.4±13.9 94.0±3.8
127 XIIa-XI 99.6±6.3 179.1±3.8 96 IIa-PAR3 186.5±11.2 128.0±12.8
128 XIa-XI 6.5±3.6 169.6±6.1 98 IIa-PAR4 166.8±15.1 88.0±5.6
131 IIa-P2s-XI-P11s 51.0±11.8 115.3±7.0 102 PL-Psub-IIa-PAR4 183.9±12.1 123.2±12.8
185 IX-VIIa 130.4±5.8 62.4±2.5 184 X-VIIa 111.8±6.8 67.3±6.4
– – – – 185 IX-VIIa 130.4±5.8 91.6±1.5
s-index species case A case B s-index species case C case D
(µ ± σ) (µ ± σ) (µ ± σ) (µ ± σ)
115 XIIa 172.2±3.3 92.9±8.5 11 Xa-VIII 79.8±1.9 128.1±33.1
121 XI 106.5±4.7 24.3±18.4 19 VIII-P8s-Xa-P10s 83.0±2.1 128.2±33.0
122 XIa 93.6±3.0 10.9±11.7 20 VIII-P8s-IIa-P2s 88.8±5.2 122.2±28.4
127 XIIa-XI 179.1±3.8 93.9±8.5 91 PAR1 53.4±18.9 82.0±32.7
128 XIa-XI 169.6±6.1 17.4±15.9 93 PAR4 44.5±21.3 74.2±34.1
129 XI-P11s 102.1±3.6 50.3±12.0 94 IIa-PAR1 142.7±17.0 181.3±6.3
131 IIa-P2s-XI-P11s 115.3±7.0 58.1±16.7 95 PL-IIa-PAR1 165.9±20.6 188.0±3.4
– – – – 97 PL-IIa-PAR3 28.4±23.2 59.5±39.1
– – – – 100 PL-Psub-IIa-PAR1 138.6±19.7 179.8±6.4
– – – – 101 PL-Psub-IIa-PAR3 163.6±20.5 186.6±3.9
– – – – 169 HCII-DER 134.5±6.7 161.6±4.7
– – – – 170 HCII-DER-IIa 136.1±7.0 164.0±6.2
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It is known that thrombi formed at low thrombin concentrations are com-
posed of thick fibrin fibers and are highly susceptible to fibrinolysis; while
thrombi formed at high thrombin concentrations are composed of thin fibers
and are relatively resistant to fibrinolysis [218]. The addition of fXI in TF-
initiated coagulation results in extra thrombin generation, which could protect
fibrin clots from fibrinolysis [16] through the activation of thrombin activatable
fibrionolysis inhibitor (TAFI) [210]. Thus, fXI deficiency does not seem to pre-
vent the initiation of thrombi formation, but rather causes significant thrombi
instability that prevents occlusion of the vessel. Moreover, fXI deficiency relates
to only mild to moderate bleeding disorders and only has significant impact
after trauma or surgery. The relative important impact on thrombosis and the
relatively moderate impact on hemostasis make fXI an excellent target for the
treatment of thrombotic disorders.
Intravital microscopy clearly demonstrated that platelet-rich thrombi form
at sites of vessel injury in fXI-deficient mice [219, 220]. However, the platelet
aggregates were unstable and undergo fragmentation, resulting a substantial
reduction in thrombus growth and hence preventing injured vessels from oc-
clusion [220]. Baird et al. studied platelet accumulation and fibrin deposition
in fXI deficient mice after laser injury using digital fluorescence intravital mi-
croscopy [221]. As compared to wild-type mice, platelet accumulation was re-
duced by >90% and fibrin deposition at the site of injury by about 50% in fXI
deficient mice after laser injury [219]. Renne´ et al. investigated the intrinsic path-
way of coagulation on thrombus stability in mice and revealed that fXII- and
fXI-deficient mice did not experience excessive injury-related bleeding. How-
ever, intravital fluorescence microscopy and blood flow measurements in three
separate arterial beds revealed a severe defect in formation and stabilization
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of platelet-rich occlusive thrombi induced by different methods of injury [220].
Infusion of human fXI or fXII into fXI or fXII null mice restored arterial throm-
bus formation following FeCl3-induced injury of the carotid artery in the mouse
[222, 220].
Yamashita et al. studied the role of fXI on arterial thrombus growth in the
rabbit iliac artery in the presence of repeated balloon injury using a mouse mon-
oclonal antibody XI-5108 to inhibit the auto-activation of FXIa. Intravenous ad-
ministration of XI-5108 (3.0 mg kg−1) remarkably reduced thrombus growth,
and the activated partial thromboplastin time (APTT) was significantly pro-
longed; while prothrombin time (PT) and bleeding time (BT) remained un-
changed [223]. Gruber et al. also showed in a baboon model when thrombo-
sis was initiated by knitted dacron or TF-presenting teflon grafts deployed into
arteriovenous shunts , intraluminal thrombus growth was markedly reduced in
baboons treated with antihuman fXI antibody (aFXI) [224]. Compared with hep-
arin at doses significantly prolonged the APTT, PT and BT, aFXI also prolonged
the APTT, but the PT and BT were unaffected [224]. Recent studies showed
that fXI deficient C57BL/6 mice in a carotid artery injury were protected from
the formation of occlusive thrombi to a degree similar to fIX deficient mice af-
ter varied concentrations of ferric chloride were induced [225]. Carotid artery
blood flow was completely blocked within 10 min in C57BL/6 mice by applica-
tion of 3.5% FeCl3. In contrast, fXI- and fIX-deficient mice were fully protected
from occlusion induced by 5% FeCl3, and partially protected against the effect of
7.5% FeCl3. While fXI and fIX deficiencies were indistinguishable in the carotid
artery injury model, there was a marked difference in tail-bleeding-time assay.
The bleeding time in fXI-deficient mice, similar to that in and wild-type mice,
were significantly shortened than that in fIX-deficient mice [225]. Lin et al. de-
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signed and synthesized peptidomimetic inhimibitors of FXIa as novel anticoag-
ulants [226], They showed that compound 32 caused a doubling of the APTT in
human plasma and was efficacious in a rat model of venous thrombosis, which
suggested that fXI played a significant role in venous thrombosis and could be
a suitable target for the development of antithrombotic therapy.
Theoretical considerations and these experimental data [16, 210, 219, 220,
221, 222, 223, 224, 225, 226] suggested that fXI/FXIa could be excellent can-
didates as clinical targets in treatment of thrombotic disease. Inhibition of
fXI/FXIa could potentially reduce the risk of occlusive thrombi formation with-
out sacrificing hemostasis as deficiency of fXI results in bleeding manifesta-
tions only after trauma or surgery. Thus the use of sensitivity analysis could
capture important mechanisms in a human-related cascade, and these mecha-
nisms could be potentially excellent therapeutic targets in clinical treatments.
Although experiments in animal models and clinical trials are always the most
important steps in developing new drugs, mechanistic modeling and sensitivity
analysis could be used as the first step in selecting potential drug targets.
5.5 Methods
5.5.1 Formulation of the model equations.
The reactions considered in the coagulation model have been compiled from
literature [162, 204, 113, 69, 17, 205, 206, 16, 15, 60, 52, 146, 9, 8, 53]. Mass balance
equations are written around each protein or protein complex yielding the set
133
of differential equations (vector-form):
dx
dt
= Sr (x,k) = g (x,k) x (to) = xo (5.1)
The symbol S denotes the connectivity matrix (193 × 301), while x denotes
the 193-dimensional concentration vector of proteins or protein complexes and
r (x,k) denotes the 301-dimensional vector of reaction rates and k denotes the
parameter vector. Each row in S describes a particular protein or protein com-
plex while each column describes the stoichiometry associated with a specific
interaction in the network. Thus, the (i, j) element of S, denoted by σi j, de-
scribes how protein i is connected to rate process j. If σi j < 0, then protein i is
consumed in r j, conversely, if σi j > 0 protein i is produced by r j and if σi j = 0
there is no connection between protein i and rate process j. We have assumed
mass action kinetics for each interaction in the network; under the mass action
assumption the rate expression for protein-protein interaction q:
∑
j∈{Rq}
σ jqx j →
∑
p∈{Pq}
σpqxp (5.2)
is given by:
rq
(
x, kq
)
= kq
∏
j∈{Rq}
x−σ jqj (5.3)
where
{
Rq
}
denotes the set of reactants for reaction q,
{
Pq
}
denotes the prod-
uct set for reaction q, kq denotes the rate constant governing the qth interaction
and σ jq, σpq denote stoichiometric coefficients (elements of the matrix S). We
have treated every protein-protein interaction and catalytic mechanism as non-
negative. All reversible interactions were split into two irreversible steps, thus,
every element of the reaction rate vector r (x,k) took the form shown in Eqn.
5.3. The model equations were solved using the LSODE routine of the OCTAVE
programming environment (v2.9.9; www.octave.org) on an Apple Computer
134
MacOSX (Cupertino, CA; v10.4.8) workstation. Initial conditions were taken
from each experiment and roughly correspond to in-vivo physiological condi-
tions (Table fXItbl-cases). Among the parameter ensemble, 100 parameter sets
that resulted in CV of 2 were selected for the sensitivity analysis.
5.5.2 Error Analysis of the Coagulation Simulations.
The correlation between model simulations and experimental data was calcu-
lated using the relationship:
r2 =
∑N
h=1
(
Ym (th) − Y¯
)2
∑N
h=1
(
Y¯ (th) − Ym (th)
)2
+
∑N
h=1
(
Ym (th) − Y¯
)2 (5.4)
where Ym (th) denotes the model value at time point h, Y¯ denotes the global av-
erage experimental value (average of experimental measurements over time)
and Y¯ (th) denotes the average experimental value at time point h (average of
experimental trials). Eqn. 5.4 measures the fraction of variation captured by the
model. In addition to correlation, the scaled standard error was used to measure
the agreement between the model:
sE =
1
maxh
(
Y¯ (th)
)

∑N
h=1
(
Y¯ (th) − Ym (th)
)2
N

1/2
(5.5)
Both Eqn. 5.4 and 5.5 were taken from [147].
5.5.3 Computation of overall state sensitivity coefficients.
The sensitive or fragile interactions of the coagulation architecture were deter-
mined by computing Overall State Sensitivity Coefficients (OSSC) [89]. Because
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each parameter corresponds directly to a particular molecular interaction in the
cascade, OSSC values were used to gauge which interactions were qualitatively
important. Large OSSC values for interactions relative to their peers indicated
fragility or sensitivity while small OSSC values indicated robustness. The OSSC
value for interaction j was defined as:
O j (t) =
k∗j
NS
( NT∑
h=1
NS∑
i=1
[
1
x∗i
∂xi
∂k j
∣∣∣∣∣∣
th
]2)1/2
(5.6)
where NT denotes the number of time points used in the simulation while NS
denotes the number of proteins/protein complexes in the model. The first-order
sensitivity coefficients:
si j (th) =
∂xi
∂k j
∣∣∣∣∣∣
th
(5.7)
were computed by solving the differential equation:
ds j
dt
= A (t) s j + b j (t) j = 1, 2, ,NP (5.8)
subject to the initial condition s j(t0) = 0. In Eqn. 5.8, the quantity j denotes the
parameter index, NP denotes the number of parameters, A denotes the Jacobian
matrix of the model equations and b j denotes the jth column of the matrix B,
which contains first-derivatives of the mass balances w.r.t. the parameter val-
ues. The quantity s j denotes the vector of first-order sensitivity coefficients w.r.t
parameter j. The Jacobian matrix (A) and the matrix of first-derivatives of the
mass balances w.r.t the parameter values (B) are given by:
A =
∂g
∂x
∣∣∣∣∣∣
(x∗,k∗)
B =
∂g
∂k
∣∣∣∣∣∣
(x∗,k∗)
(5.9)
where (x∗,k∗) denotes a point along the nominal or unperturbed system solu-
tion. The matrices A and B were numerically estimated at each time step us-
ing a generalized gradient algorithm [148] while the sensitivity balances were
solved using the LSODE routine of the OCTAVE programming environment
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(v2.9.9; www.octave.org) on an Apple Computer MacOSX (Cupertino, CA;
v10.4.8) workstation.
The connectivity matrix S (193 × 301) was used to rearrange the parameter
OSSC values to the species OSSCs through the equation:
Q = |S|O (5.10)
The rank orders of the species OSSCs were used to access the fragility of differ-
ent species in the model.
5.5.4 Statistical and clustering analysis of the shifts in overall
state sensitivity coefficients.
Three different tests were performed to identify large statistically significant
shifts in OSSC values between defective networks and the control. A Welch
t-test [149] was used to find all statistically significant shifts resulting from the
different structural perturbations and then a secondary test on the z−score of
each shift was preformed to find only the most prominent. The OSSC values
calculated over the family of parameter sets were assumed to follow normal
distributions for all cases. The statistical significance of shifts in OSSC values
relative to the control were determined by performing a Welch t-test with the
null hypothesis that the means of the sensitivity coefficients were equal at a
1% significance level. The Welch t-test is similar to the student t-test with the
exception that the two distributions being compared are not required to have
equal variances. The list of significant OSSC values was further restricted to
only those shifts with a magnitude larger than a specified z-score (0.1) away
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from the squared mean displacement relative to the control:
d j,q =
(
O¯qj − O¯cj
)2
, j = 1, 2, ,NP (5.11)
where O¯cj denotes the mean OSSC value over the family of parameter sets for
parameter j in the control while O¯qj denotes the same quantity for defective case
q. A significant shift in OSSC value was accepted if:
d j,q > zσdq + µdq (5.12)
where z denotes a desired z-score, σd j denotes the standard deviation of the total
displacement over all significant OSSC values for the qth defective case and µdq
denotes the mean of the significant displacements for the structurally defective
case q.
A large statistically significant shift in OSSC value, while indicative of the
shifting importance of an interaction, does not guarantee that an interaction
is ranked differently between cases. To this end, we used the Spearman rank
correlation denoted by ρ and defined as:
ρ = 1 − 6
∑NP
i=1 d
2
i
N
(
N2 − 1) (5.13)
to measure the difference in qualitative ranking between cases. The quantity
di denotes the difference in the ordinal rank of interaction i between a struc-
turally defective network and the control, N denotes the number of pairs of
values and NP denotes the number of parameters considered. The Spearman
rank is bounded by −1 ≤ ρ ≤ 1; a Spearman rank of one indicates that two
ranked lists are identical, a Spearman rank equal to negative one indicates that
two ranked lists are perfectly negatively correlated, while a Spearman rank of
zero indicates that two ranked lists are uncorrelated.
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The distributions of OSSC values obtained from monte-carlo sampling were
clustered using a k-means algorithm [209]. The mean and standard deviation
obtained from the monte-carlo sensitivity analysis was used to estimate the un-
derlying OSSC distribution (N = 200 points) where the OSSC values were as-
sumed to be normally distributed. Two hundred different clustering attempts
were run for each model to control for clustering artifacts. The most probable
configuration was reported.
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CHAPTER 6
COMPUTATIONAL ANALYSIS OF THE EFFECT OF FLOW ON BLOOD
CLOT FORMATION
6.1 Abstract
A mathematical model, that was validated for thrombin and fibrin formation in
the absence of flow, was further refined to simulate blood clot formation under
simple pressure-driven parabolic flow after being exposed to different sizes of
tissue factors (TF) patches. The predicted clot times at various shear rates and
TF patch sizes were generally consistent with experimental observations using
microfluidic capillaries or parallel plate flow. Our numerical analysis elucidates
two counteracting effects of flow on the formation of arterial clot under condi-
tions of exposed TF: (1) inhibition of the initiation of blood clot formation by
the flow-mediated transport of enzymes; (2) promotion of rapid formation of
active factors and blood clots via shear induced platelet activation (SIPA) under
high shear. Thresholds in shear rates or TF patch sizes were observed for the
initiation of clot formation; the balance between the generation of active factors
and the removal of those factors by flow was possibly the reason for the thresh-
old phenomena. Extremely low shear, where the flow-mediated transport was
insignificant, and extremely high shear, where the generation of active factors
was significant, could both lead to the initiation of clotting; the shear rates, at
which the blood clotting did not initiate within 1000 seconds, were found to be
correlated with the normal physiological range of shear rates.
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6.2 Introduction
When the delicate balance between the pro- and anti-coagulants in the blood is
interrupted by plaque rupture, vessel damage, or dysfunctional endothelium,
blood clots could form at the site to interfere with normal blood flow, which is
central to cardiovascular diseases. The mechanisms underlying clot formation
or thrombosis were first identified over a hundred years ago when Virchow pro-
posed his triad of blood, surface, and flow. The local rheological flow conditions
are pivotal for the hemostatic system and largely affect the blood coagulation
and platelets activation and deposition [227]. The underlying chemical, phys-
ical, and biological processes culminated in clot formation in the presence of
flow have been proven difficult to model in a systematic, quantitative fashion.
In this paper, we built a mathematical model to study the effect of flow on the
formation of blood clots. It encompassed the extrinsic and intrinsic pathways
of thrombin generation, as well as the formation and lysis of fibrin clots; we
studied the effect of flow, the wound size (TF patch size) and the shear-induced
platelet activation (SIPA) on the time of clot formation under model simple flow.
6.2.1 The biology of clot formation and lysis:
Following injury, a family of proteins (coagulation factors) and a key group of
blood cells (platelets), both of which are normally inactive in the circulation, are
activated by several different interconnected mechanisms that eventually lead
to thrombin generation and fibrin clot formation at the wound site. Thrombin is
the terminal protease generated by the process of blood coagulation. There are
two pathways in the coagulation cascade which lead to thrombin generation:
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the intrinsic and extrinsic pathways [111, 108]. In the extrinsic pathway, the
exposed TF at the site of injury binds with circulating factor VII/VIIa to form TF-
FVIIa complex and initiates a series of enzymatic interactions that leads to the
formation of thrombin. The details of the coagulation process could be found in
many other articles [116, 117, 110, 111, 112, 108, 115, 162]. The protease thrombin
not only plays a key role in the feedback activation of upstream factors and
platelets, buts also activates the intrinsic protease factor XI (fXI) [13, 14, 16, 17,
206, 19, 15, 205]. The intrinsic pathway of coagulation joins up with the extrinsic
pathway at the point where fIX is activated by FXIa to form FIXa.
Thrombin irreversibly activates platelets through a family of transmem-
brane receptors on the platelet surface called Protease-Activated Receptors
(PARs) [113, 204]. Platelets, another key components for thrombus formation,
are produced in the bone marrow from megakaryocytes as cytoplasmic frag-
ments without genomic DNA [228]. The lack of genomic DNA makes platelets
incapable of transcription of nuclear material, rather structural and biosyn-
thetic proteins that are required for normal platelet function are translated from
megakaryocyte derived RNA. Platelets are present as inactive forms in the cir-
culation and remain inactive because of a series of signals emitted by normal
endothelial cells. However, platelets are highly reactive in the presence of vas-
cular injury; they respond to and interact with unique substances in the tissue
fragments released by ruptured plaques. These materials, primarily collagen,
fibronectin and von Willebrand factor (vWF), existing in the tissue fragments
promote platelet binding with the plaque ruptures (platelet adhesion) through
specific molecular recognition interactions. The adhered platelet is then acti-
vated by external signals such as Adenosine Diphosphate (ADP),Thromboxane
A2 (TXA2) and thrombin.
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Activated platelets have a different physical shape than their inactivate
counterparts and transmit chemical and peptide signals into the blood stream.
These signals attract additional platelets to the scene and promote further bind-
ing and activation. In particular, activated platelets secreted ADP and Throm-
boxane A2 (TXA2), both of which promote further activation. Jin et al. have
explored the molecular mechanisms of ADP induced activation of platelets and
have shown that the P2Yi receptor mediates ADP-induced shape change in ac-
tivated platelets [229]. The shift in shape will expose key phospholipid binding
sites that are required for the formation of the critical surface bound complexes
in the coagulation response. In addition, activated platelets secrete fibrinogen,
a linker-like substance which interacts with platelet glycoprotein surface recep-
tors (Glycoprotein IIb/IIIa) to cross-link other activated platelets thereby form-
ing a temporary platelet plug over the plaque ruptures. The platelet plug forms
in seconds after exposure to the tissue fragments and serves as a necessary scaf-
fold for the more permanent fibrin clot. Thrombin is a critical mediator be-
tween the formation of the platelet plug (platelet aggregation) and the fibrin clot
(thrombus). Thrombin cleaves fibrinogen into fibrin monomers that form fibrin
matrix on and between the aggregated platelet scaffold leading to the formation
of insoluble fibrin clot [230, 231, 11]. Once a fibrin clot is formed, it serves as a
cofactor for the activation of plasminogen to plasmin (PLA) by tissue-type plas-
minogen activator (tPA) or urokinase (uPA). Plasmin cleaves fibrin and leads to
the breakdown of a fibrin clot, which is normally called fibrinolysis. Throm-
bin also plays a role in fibrinolysis by cleaving thrombin activatable fibrinolysis
inhibitor (TAFI) to its active form activated TAFI (TAFIa), which will attenuate
fibrinolysis by blocking the binding sites of plasmin to fibrin.
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6.2.2 Review of flow effects on blood clot formation:
Arterial thrombosis usually occurs in flowing blood following the events such
as plaque rupture, vessel damage, or dysfunctioning endothelium [232, 233,
227]. The roles of blood flow in coagulation and thrombosis have been rightly
recognized more than a century ago by Virchow [42]. The flow behavior of
blood may partly explain the localization and morphology of arterial, intrac-
ardiac and venous thrombi within the human circulation, and even why the
increase in haematocrit, fibrinogen and other macromolecules, and rigid blood
cells may increase the risk of ischaemic events [234, 42].
Under pressure-driven flow, in a laminar regime, shear stress is maximum
at the vessel wall, and affects endothelial cell morphology and function. Fluid
shear stress is the force of shearing motion of blood per unit area. Extremely
low shear stress induces an intimal thickness of the arteries, which can develop
into an early atherosclerotic plaque under certain circumstances such as exces-
sive low density lipoprotein concentrations in blood [235]. The use of the non-
invasive detection method such as Doppler ultrasound, enables investigators
to localize atherosclerotic plaques in arteries as an indicator of atherosclerosis
[235]. The correlation between early plaque localization in human subjects and
areas of relative low and oscillatory wall shear stress implicates that this factor
as the key to the role of fluid dynamics in atherogenesis [235, 236, 237, 238]. This
intimal thickening can evolve into an early atherosclerotic plaque under certain
circumstances such as excessive low density lipoprotein concentrations in blood
[41]. Each early plaque exhibits an individual natural history of progression,
regression, or stabilization. In the presence of certain local, systemic, and ge-
netic factors, the local vascular wall might undergo excessive expansive remod-
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eling. A self-perpetuating vicious cycle is established among local endothelial
shear stress, excessive expansive remodeling, and plaque inflammation, trans-
forming the early plaque to a thin cap fibroatheroma [41]. The stenotic plaques
might either evolve with a phenotype promoting fibroproliferation consistently
throughout their natural history course or represent a final stage of scarring
in the setting of prior inflamed this cap fibroatheroma through repetitive mi-
croruptures and healing. Also, the stenotic plaques might infrequently undergo
local erosion or develop calcified nodules and eventually lead to local thrombus
formation and manifestation of an acute coronary syndrome [41].
Approximately 20 % of the early developed atherosclerotic plaques could
grow to stenotic plaques through constrictive remodeling and result in a high
local shear stress at the vessel wall [41]. High intra-stenotic shear stress may
activate platelets, promoting the formation of initial platelet-rich “white-head”
of arterial thrombi, while low post-stenotic shear stress may promote the for-
mation of subsequent, fibrin- and red cell-rich“red tail” [3]. Blood viscosity,
platelet microemboli, and activated leucocytes may each reduce post-stenotic
microcirculatory blood flow, promoting infarction. Such mechanisms may ex-
plain the associations of increased levels of blood and plasma viscosity, haema-
tocrit, white cell count, fibrinogen and vWF with risk and outcome of myocar-
dial, cerebral and limb infarction [232, 233, 239, 42, 227, 41].
When blood with a parabolic velocity profile passes through a narrow-
ing in the channel, it accelerates resulting in much higher wall shear stress
near the apex of stenosis. Platelets are also concentrated at the vessel wall
where they can be activated by high shear stress and well-placed to interact
with vWF and subendothelium, resulting in platelet adhesion and activation
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[240, 241, 39, 242, 243]. Shear-induced platelet activation (SIPA) and aggre-
gation are important mechanisms of arterial thrombosis formation. In 1975,
Brown used a cone and plate viscometer to demonstrate that exposing platelet-
rich plasma to fluid shear stresses > 50 dynes/cm2 resulted in changes in platelet
morphology, along with secretion (ADP,ATP, serotonin) and aggregation [244].
Higher shear stresses (300, 750 and 1000 dynes/cm2) were then proved to be
able to induce activation of platelets in the average residence times of 25 to
1650 ms [245]. Early studies of SIPA in rotational viscometers focused on rel-
ative long exposure times to elevated shear stresses (50 to 100 dynes/cm2) and a
threshold response of platelet to shear stress is often addressed in these stud-
ies [246, 245, 247, 248, 249]. However, the threshold stress depends heavily
on the time the platelets are subjected to the shear stress. Hellums et al. later
showed that shear-induced platelet activation was a function of both the shear
stress magnitude and the exposure time to shear by consolidating the finding
from several groups using different flow devices [250]. Boreda further derived
a platelet stimulation function defined by PSF = τ × t0.452, where the activation
state was linearly dependent on the magnitude of applied shear stress (τ) and
somewhat less dependent on exposure time (t) [251]. Platelet activation state
(PAS) measured in small diameter tubing directly increased with shear stress
and time of exposure to shear, and elicited procoagulant activity on the platelet
surface [252]. Thereby linking shear-mediated platelet responses to coagula-
tion reactions. Thus, exposure of platelets to shear conditions causes platelet
activation and that this activation is dependent on both shear stress and time
of exposure. Using these relationships, Raz et al. used numerical models to
study flow induced platelet activation resulting from stress histories along Lan-
grangian trajectories in the flow field and validated using Digital Particle Image
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Velocimetry (DPIV) in 84 % eccentric and axisymetric coronary stenosis model
[253]. CFD, DPIV and PAS assay results in their study agreed well in predicting
the level of platelet activation.
6.2.3 Review of the mathematical models:
Numerous models have been built to understand the underlying complex and
intertwined chemical and biological processes that lead to blood coagulation
[48, 20, 52, 12, 54, 60, 8, 9, 254]. In recent years, Mann and coworkers presented
an model for thrombin generation via the extrinsic pathway [52, 12], and ex-
tended it to include the role of inhibitors [53]. Kuharsky and Fogelson [60] as-
sumed the existence of a thin, well-mixed layer near the surface of the injured
vessel. Transport of species from the bulk flow into this layer was quantified by
an overall mass transfer coefficient. A more recent work by Anand et al. [8, 9]
suggested a reaction-diffusion model of clot formation and lysis under flow
conditions, using quasi-one-dimensional thrombus formation in a cylindrical
vessel. Sorensen et al. [69, 70] proposed a set of coupled convection-reaction-
diffusion equations to model platelet activation and deposition in flowing hu-
man blood. The equations were solved using finite element method in a two-
dimensional flow and the results were compared with experimental results of
platelet deposition onto collagen. In order to understand the complex biological
system governing blood clotting, a simple chemical system was developed by
Kastrup et. al [254, 255]. The group showed that the initiation of blood clotting
on a 2-D surface in response to TF patches in the absence of flow depended not
only on the size of individual patches [254], but also on the shape of the patch
[255].
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Most of the models focused on the reaction aspect of blood clotting. Only a
few of them studied the effect of flow on clot formation. This is possibly due
to the complexity arising from incorporating rheological aspects into the model,
which lies not only in the influence of flow on the biochemical reactions but
also the hemodynamic properties of blood flow itself. Even in the models that
considered flow effect, they mostly focused on the low to medium shear range
and ignored the effect of shear-induced platelet activation. In the present study,
we built a mathematical model to study the formation of blood clot under low,
medium, to high shear rates. We did a systematic research on the effect of flow-
mediate transport and the effect of SIPA on clot formation.
6.3 Results
The mathematical model consisted 193 species and 301 interactions in the blood
clotting system and it was developed to simulate blood clot formation in the
simple 1-D flow conditions. We considered simple unidirectional, pressure
driven flow, and shear rate in the boundary layer near the wall was used as
the shear rate. The model was first validated for the formation of fibrin under
quiescent conditions, shown in Figure 6.1, which worked as a supplement to the
previous validation results for thrombin generations in the absence of flow (see
Chapter 4 and 5); it was further developed to calculate clot time, which was a
function of either thrombin or fibrin concentration, and the validations against
experimental data were shown in Figure 6.2 and Figure 6.3 [256]. Since platelets
could be activated by shear after exposure for critical time [252], we introduced
platelet activation by different shear stresses at different exposure time; the
shear rates, viscosities of blood, shear stress, exposure time required for SIPA,
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and the rate of SIPA were shown in Table 6.1. The activation of platelets by shear
was compared against the experimental observation [241] and the formation of
fibrin and activated platelets (AP) were simulated under high shear conditions
(Figure 6.4). Threshold effects were observed for the initiation of clot forma-
tion under various shear conditions and the shear rates, under which the blood
clotting did not initiate in 1000 seconds, were found to be correlated with the
normal physiological range of shear rates.
6.3.1 Model validation against the formation of fibrin in the ab-
sence of flow.
Our previous model validation focused on the generation of thrombin under
quiescent conditions (see Chapter 4 and 5). However, generation of a stable
blood clot requires thrombin-mediated conversion of fibrinogen to fibrin. Con-
centration of fibrin is another important marker for blood clot formation. Here
in this part, we performed the simulation of fibrin formation after the addition
of physiological amount of fibrinogen, and we simulated the process of fibri-
nolysis by tPA, uPA and plasmin in the presence and absence of TAFI [257, 258].
We compared our results against experimental data [257, 258] and we found that
our model successfully predicted evolution of fibrin concentrations at different
experiment conditions (Figure 6.1). Fibrin formed when fibrinogen was cleaved
by thrombin; as shown in Figure 6.1A, after a lag phase of about 20 min, a burst
of fibrin formation was observed. Our simulation well captured the experimen-
tally observed time lag followed by surge in concentration in the formation of
fibrin. When fibrin formed, plasmin that was activated by tPA or uPA could
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cleave fibrin between its D and E domains and lead to the lysis of fibrin clots.
Furthermore, TAFIa activated by thrombin prevented fibrin from fibrinolysis
by competing with plasmin for fibrin binding sites. Figure 6.1B, 6.1C and 6.1D
show the effect of TAFI in fibrinolysis when either plasmin or plasmin activa-
tor (tPA or uPA) was present. In all, the fibrin concentrations (blue curves) in-
creased when TAFI was present, as the results of the inhibition of fibrinolysis by
TAFI. Our model simulations are in good agreement with the experiments in-
dicating that our model was not only capable in thrombin simulations but also
able to predict fibrin formation.
6.3.2 Threshold response to shear rate and the size of TF patch
for the generation of thrombin under the low to medium
shear.
Thrombin generation in an 1-D flow field was simulated under mild shear con-
ditions (5 to 50 s−1) (Figure 6.2A). In all simulations, the TF patch started at
position x = 600 µm. A TF patch of 200 µm, between position x of 600 and 800
µm, was used to initiate the coagulation cascade. The clot time was calculated
as the time when more than 0.1 nM of thrombin was formed. In both simulation
and experiment, in normal pooled plasma (NPP), the clot time remained con-
stant near 200 s for shear rate below 20 s−1, followed by a rapid increase in clot
time to 800 - 1000 s around shear rate of 30 s−1, yielding a threshold shear rate
between 20 to 30 s−1. For shear rates below the threshold, thrombin generation
initiated with 200 seconds. While increasing shear rates resulted in a decrease
in the initiation of thrombin formation; a clot time greater than 800 seconds was
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Figure 6.1: Model validation against experimental observations of the for-
mation of fibrin in the absence of flow. (A) Computational sim-
ulation (solid line) is consistent with experimental observation
of fibrin generation in time (shown as circles). The fibrin con-
centration was determined in diluted plasma samples by the
ELISA [257]. (B-D) The fibrinolysis in time by tPA, uPA and
plasmin (PLA) in the presence and absence of TAFI [258]. The
fibrin concentrations were scaled by the maximum in each cor-
responding experiment.
151
observed for any shear rate greater than the threshold. This threshold effect is
believed to be the result of competition between reaction and transport of acti-
vated coagulation factors [256]. The procoagulant factors got activated over the
TF patch and these active factors could either react with other factors at the site
or be transported from the site by the flow. Only when the concentration of acti-
vated factors exceeds a critical concentration at a position, thrombin generation
could initiate. Therefore, when the shear rate is low, the effect of transport is
not significant; the concentration of active factors could easily reach the critical
value near the site of TF patch. This was proved by the generation of throm-
bin at shear rate of 5 s−1 (Figure 6.2C and 6.2E). It clearly shows that thrombin
concentrations were much higher in positions near TF patch and it gradually
decreased along the flow direction. While after the shear rate increased to 40
s−1, thrombin generation initiated at the down-streams of the TF patch at time
greater than 1000 seconds or 16 minutes (Figure 6.2D). This was because when
the shear rate increased, the effect of flow-mediated removal of active factors
from the TF patches became more significant. The active coagulation factors cu-
mulated at at down-streams of the TF patch, which led to thrombin formation
far from the patch.
Figure 6.2B shows the effect of TF patch size on clot formation at a constant
shear rate. At a shear rate of 40 s−1, increasing the size of TF patch from 100
to 1600 µm resulted in a substantial decrease in clot time around 200 to 400 µm
of patch size. The threshold patch size between 200 and 400 µm observed in
the model prediction is again consistent with the experimental observations.
Similar mechanisms could apply in this case; the generation of active factors
was much faster when the TF patch increased and the concentration of active
factors could achieve the critical value at a much earlier stage, as depicted in
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Figure 6.2: Model simulations of thrombin formation in normal pooled
plasma (NPP). (A) and (B): Computational simulations are con-
sistent with experiment observations that clot time in NPP dis-
played a threshold response to shear rate at a constant patch
size of 200 µm (from 600 to 800 µm) (A) and to patch size at a
constant shear rate of 40 s−1 (B) [256]. Clot time was determined
as the time point at which ≥ 0.1 nM thrombin was generated in
the simulation. In the experiment, the generation of thrombin
was detected by fluorescence microscopy and the clot time was
the time point when a burst of thrombin was generated or the
initial formation of cross-linked fibrin appeared [256]. (C) and
(D): Thrombin concentrations versus time and position with
shear rates of 5 s−1 (C) and 40 s−1 (D) at a patch size of 200 µm.
(E) Thrombin concentrations versus position at 0 and 300 sec
at a shear rate of 5 s−1 and a patch size of 200 µm. Consistent
with experiments at 300 sec [256], thrombin generation did not
initiate at a shear rate of 40 s−1 (D), but did initiate at a shear
rate of 5 s−1 (C and E). (F) Thrombin concentrations versus time
and position at a shear rate of 40 s−1 and a patch size of 800 µm
(from 600 to 1400 µm).
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Figure 6.2B. We note that the initiation of thrombin generation occurred at posi-
tion away from the TF patch for t he shear rate of 40 s−1 regardless of patch size
(Figure 6.2D and F). This was possibly because the concentration of activated
factors reached its critical concentration at somewhere down-streams of the TF
patch as a result of increased flow-mediated removal effect.
6.3.3 Attenuation of fibrin clot formation by flow mediate
transport of enzymes
The above simulations were performed to predict thrombin generation in nor-
mal pooled plasma (NPP) where small amount of platelets was present. How-
ever, given the importance of platelets and fibrinogen in blood clot formation,
the experiments were also conducted in platelet rich plasma (PRP), where fib-
rinogen with fluorescence labels were also added in order to measure the for-
mation of fibrin mesh [256]. Our calculation of clot time using the time for
thrombin or fibrin ≥ 0.1 nM would return similar results; while here we used
the time calculated for fibrin formation. As shown in Figure 6.3A, the threshold
between shear rates of 70 to 100 s−1 was also observed in the PRP simulations.
At low shear rates, the formation of clots started within 200 seconds, while af-
ter the shear rate increased to a value greater than the threshold, the simulated
clot time increased to more than 400 seconds and continued to increase with
shear rates. However, in the experiments, the threshold effect was much more
distinct as the clot time sharply increased from 200 to about 1000 seconds right
after crossing the threshold (In Figure 6.3A Observation). Such a high threshold
value for clot time at shear rate between 70 and 100 s−1 in PRP correlated to the
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Figure 6.3: Model simulations of clot formation in platelet rich plasma
(PRP). (A) Computational simulations are generally consistent
with experiment observations that clot time in PRP displayed
a threshold response to shear rate at a constant patch size of
200 µm [256]. The bright-field microscopy was used to detect
the formation of fibrin mesh and aggregation of platelets [256].
In simulation, the clot time was calculated as the time point at
which ≥ 0.1 nM fibrin was generated. (B) and (C) Fibrin con-
centrations versus time and position with shear rates of 80 s−1
(B) and 20 s−1 (C). (D) Thrombin concentrations versus time
and position at a shear rate of 20 s−1. (E) and (F): Fibrin and
thrombin concentrations versus position at time of 0 and 300
sec at a shear rate of 20 s−1 and a patch size of 200 µm. Al-
though TF patches located between 600 and 800 µm, the maxi-
mum fibrin and thrombin concentrations at 300 sec were found
at downstream of the patches.
procoagulant phenotype at extremely low wall shear stress [256].
The 3-D plots of the fibrin concentrations versus time and position at two
different shear rates 20 s−1 and 80 s−1 are shown in Figure 6.3B and 6.3C . The
thrombin concentrations in time and position at shear rate of 20 s−1 is also de-
picted in Figure 6.3D. At high shear rate (80 s−1), fibrin formation did not initiate
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in about the first 600 s−1, while fibrin formation initiated in the first 100 seconds
at low shear rate (20 s−1). The initiation of thrombin and fibrin formation oc-
curred at about the same time as shown in Figure 6.3C and 6.3D. Figure 6.3E
and 6.3F show the spatial evolution of concentrations of fibrin and thrombin
at 0 and 300 seconds at shear rate 20 s−1. The maximum fibrin and thrombin
concentrations at 300 seconds were achieved at position about 2000 µm, which
was the down-stream of the TF patch.
6.3.4 Acceleration of clot time via SIPA under high shear
Since the activation of platelets by shear was not only the function of shear rate,
but also a weak function of time [252], we introduced platelet activation by dif-
ferent shear stresses at different time in PRP. The shear rates, viscosities of blood,
shear stress, exposure time required for SIPA, and the rate of SIPA were sum-
marized in Table 6.1. When the shear rate was below 100 s−1, SIPA was not
initiated druing the time span we considered. Hence the initiation time of fibrin
formation at the shear rates lower than 100 s−1 would be the same as those in Fig-
ure 6.3A, and thus in Figure 6.4A, we only showed the clot times for shear rates
≥ 100 s−1. With further increases in shear rates, the critical exposure time be-
came smaller and smaller, and the activation rate of platelets became larger and
larger. As a result, thus the activation of platelets increased drastically with in-
creasing shear rate. The concentration profiles of activated platelets (AP) clearly
show the impact of SIPA at different shear rates (Figure 6.4B), which were com-
pared against experiments [241]. To be consistent with the experiment setup,
the simulation was run over collagen patch as well; our model predicted appar-
ent threshold activation of platelets by shear, while the experiments showed a
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Table 6.1: Shear rate (γ˙), and its corresponding blood viscosity (η), shear
stress (τ = ηγ˙), critical exposure time (t), SIPA rate (r) 7.
shear rate viscosity (Newtonian/non-Newtonian) shear stress critical exposure time SIPA rate
(sec−1) (poise) (dynes/cm2) (sec) (sec−1)
10 0.04/0.09 0.4/0.9 ≥1200 –
20 0.04/0.08 0.8/1.6 ≥1200 –
40 0.04/0.07 1.6/2.8 ≥1200 –
60 0.04/0.06 2.4/3.6 ≥1200 –
70 0.04/0.06 2.8/4.2 ≥1200 –
80 0.04/0.06 3.2/4.8 ≥1200 –
100 0.04/0.06 4.0/6 ≥1200/780 0.1577
200 0.04 8 420 0.2133
500 0.04 20 60 0.5333
800 0.04 32 0 0.8533
1000 0.04 40 0 1.0667
1200 0.04 48 0 1.2800
1400 0.04 56 0 1.4933
1500 0.04 60 0 1.6000
3000 0.04 120 0 3.2000
more gradual increase of AP with increasing shear rates. When TF was present
in the patch, the AP concentrations became a little higher because additional
platelets were activated by thrombin that was initiated to form by TF.
Clots formation increased with the increase in shear rates when the effect
of SIPA was considered, which was proved by the initiation times of clot for-
7The viscosities of blood at different shear rates were estimated from the apparent absolute
steady shear blood viscosity of normal, healthy subjects [259]; the shear stresses were calculated
from shear rates and viscosity for both Newtonian and non-Newtonian blood, in this study, the
shear-thinning effect of non-Newtonian behavior of blood did not make much difference on
the simulation results; the critical exposure time were estimated from the exposure time/shear
stress plane and the derived platelet stimulation function (PAS = τt0.452)[250, 252, 251]; the SIPA
rates were estimated based on the experimental results [252] and by fitting with the experimen-
tal data [241].
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mation for shear range from 100 to as high as 3000 s−1 (shown in Figure 6.4A).
A threshold at shear rate between 800 to 1000 s−1 was observed as a competi-
tion result of SIPA and flow transport. When the shear rate increased to a value
above the threshold, platelet activation by shear was significant enough to cope
with the inhibitory effect of flow transport of active factors; in other words, the
formation of active factors by SIPA was faster than the removal of those factors
from the site by the flow. As a result, the concentration of active factors could
achieve the critical value and led to the formation of clots. Taken together, in all
cases with or without the effect of SIPA, the threshold effect on clot formation
was observed. This threshold effect had its physiological importance and had
been studied by several groups [60, 55, 260, 145, 261].
Furthermore, it is interesting to note that the threshold in the shear rates for
initiating fibrin formation (Figure 6.4A) correlated with the shear rate at which
the concentration of AP increased drastically (Figure 6.4B). Below the threshold,
the fibrin clot did not form within 1000 seconds (Figure 6.4A) and the activa-
tion of platelet was also not observed at 1 minute (Figure 6.4A); while after the
threshold, blood clotting initiated almost immediately and a large amount of
platelets became activated after being sheared for 1 minute. The formation of
fibrin and the activated platelet concentration were shown in Figure 6.4C and
6.4D, respectively. When the shear rate increased to 1500 s−1, the concentrations
of fibrin and AP versus time and position were shown in Figure 6.4E and 6.4F.
At a shear rate of 100 s−1, the induced activation of platelets took place after ex-
posing to the shear stress for about 780 seconds (Figure 6.4D); while it was clear
that the activation of platelets was much more quickly when the shear rate was
as high as 1500 s−1 (Figure 6.4F).
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Figure 6.4: Model simulation of clot formation in high shear conditions.
(A) Computational simulations of clot times under high shear
conditions at a constant TF patch size of 200 µm. (B) Com-
putational simulations and experimental observation of per-
centage platelet activation after exposed to shear rates of 100,
800, 1500 or 3000 s−1 for 1 minute. The simulations were con-
ducted over 200 µm collagen patches with or without TF. The
scaled platelet activation was calculated as all activated platelet
(AP) concentrations scaled by the maximum AP concentration
for simulation without TF. The experimental observations of
platelet deposition over collagen were also scaled by its maxi-
mum amount of deposited platelets [241]. (C) and (D): Fibrin
and AP concentrations versus time and position with a shear
rate of 100 s−1 . (E) and (F): Fibrin and AP concentrations ver-
sus time and position with a shear rate of 1500 s−1. The AP
concentrations shown here were for the movable AP only.
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The profiles of fibrin formation under different shear rates were quite differ-
ent as well (Figure 6.4C and Figure 6.4E). At low shear (100 s−1), fibrin concentra-
tion increased after a lag phase of about 1000 seconds; while at high shear (1500
s−1), the formation of fibrin started almost immediately after exposure to shear
and then degradation of fibrin, probably due to fibrinolysis, quickly showed up
after the maximum amount of fibrin was formed. Our model also showed that
SIPA could accelerate the burst of AP, which could contribute to the acute events
happening after the rupture of plaque at stenotic regions (high shear range).
This results indicated that at high shear conditions, e.g. stenosis, a platelet-rich
fibrin clot (white head) may form; while at low shear, e.g. post stenosis recircu-
lation region, a fibrin-rich clot was more preferred to form, which could possibly
capture red blood cell and form the red tail [3, 8, 239, 42, 227].
6.4 Discussion
Blood flow could affect the formation of clot in different ways. Two counter-
acting effects of flow on the formation of arterial clotting under conditions of
exposed tissue factors (TF) are: (1) flow-mediated transport of enzymes inhibit
the initiation of blood clot formation; (2) high shear inducing platelet activa-
tion promotes rapid clot formation. Extremely low and high shear stresses
could result in either the early formation of plaque or the activation and ag-
gregation of platelets. Early formed plaque, when combining with other risk
factors (e.g. excessive low density lipoprotein concentrations, etc), could grow
into high-risk plaque and may induce various ischemic events when ruptured.
On the other hand, the removal of active enzymes from the reactive vessel
surface by flow could inhibit the generation of thrombin to some extent. Re-
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searchers often concentrated one or the other effect of blood flow on clot for-
mation [235, 262, 263, 42, 264, 227, 41, 265]. However, the competition between
the ‘procoagulant’ effect of high shear stress and the ‘anti-coagulant’ effect of
flow-mediated removal has not been systematically studied. Here we use the
mathematical model to study the effect of flow with different shear rates on the
formation of blood clots. Our results showed that when SIPA was not occur-
ring in the model, the initiation of clot formation delayed with increasing shear
rates as a result of enhanced flow transport; however, when the shear rates were
high enough to induce platelet activation in a short time, the initiation of blood
clotting rapidly increased with shear rates.
Threshold effects were observed for the initiation of clot formation under
different shear conditions. A threshold regulation in the blood clotting systems
has been observed by many other researchers [60, 55, 260, 145, 261]. Jesty et. al.
proposed that the threshold regulation could play a major role among the vari-
ous mechanisms of regulation in blood clotting; they believed that the threshold
system was the result of the kinetic balance of formation and inhibition of the
feedback enzymes in clotting [260]. Both experimental evidence [254, 117] and
computational validation [60, 254] could be found in literature for the presence
of threshold under quiescent conditions. Okorie et. al. further provided both ex-
perimental and computation evidence for the TF thresholds that triggered clot-
ting under flow with different shear rates; different critical TF concentrations
were determined at wall shear rates of 100, 500 and 1000 s−1 [261]. For given
systems of particular kinetic properties, Beltrami et. al. found that lower flow
rates or larger active patches could result in exceeding the activation threshold
using a partial differential equation model of an archetypal feedback loop [55].
In our model, we found thresholds in both the shear rate and the TF patch size.
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The threshold here could be considered as the balance between the rates for the
generation of active factors and the rates for the removal of those active factors
by flow. Lower shear rates or larger active patches could result in exceeding the
activation threshold of clotting system; while extremely high shear rates could
also result in exceeding the activation threshold because of the effect of SIPA.
The shear rates we studied in this paper could be categorized, based on
the different thresholds, into three regions: low shear (shear rate < 100 s−1),
moderate shear (100 s−1 ≤ shear rate < 1000 s−1) and high shear (shear rate ≥
1000 s−1). It is interesting to note that the moderate shear region corresponded
to the physiological shear range (≈ 102 to 103 s−1) [256]; these physiologically
preferred shear rates not only related to the minimization work and the opti-
mization of efficient oxygen transport according to Murray’s law [266], but also
related to the prevention or inhibition of blood clotting. In the low shear re-
gion, the inhibitory effect of flow-mediated removal of active factors, which
was proposed and studied using a mathematical model of intravascular co-
agulation by Fogelson et al [264], was not significant enough; therefore the
concentrations of active factors could exceed the threshold. This finding was
also consistent with the experimental observation that the initiation of clotting
was increased with decreasing shear rates from 110 s−1 to 17 s−1 in the junc-
tion micro-fluidic flow vessel system [265]. The activation and aggregation of
platelets by high shear have been observed many years ago by a number of re-
searchers [244, 246, 245, 247, 248, 240, 241, 39, 242, 243], which were believed
to contribute to the onset of artery thrombosis [267] and correlated with throm-
bin generation [40]. Our model proved that extremely high shear rates would
also result in active factors concentration exceeding the activation threshold due
to SIPA. Other interesting findings included that the concentration of AP was
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much higher when the shear rates were high, which could lead to the formation
of platelet-rich thrombi under high shear.
Our mathematical model successful predicted blood clot formation in the
absence and presence of flow. While there are limitations in the model: the
model was only used to simulate blood clotting in a simple, model 1-D flow
system with constant shear rates, the physiological flow conditions in arteries
is more complex, e.g. the oscillation flow when the shear rate and stress at the
wall are continuously changing in time; and the concentrations of factors in the
model were assumed constants across the radius, while the diffusion in radius
direction could also be important. Given all these limitations, our model was
able to combine the complex interactions in the clotting system with the effect
of flow and to the best of our knowledge, our model is the first mathematical
model that did a systematic study of the effect of shear rates from really low
shear (10 s−1) to really high one (3000 s−1). Therefore, we believe this model
could provide insights into the blood clotting system under flow conditions.
6.5 Methods
The mathematical model of this study was designed to describe spatial dynam-
ics of clot formation initiated over a patch of tissue factor (TF). The species con-
servation equation was written around around each protein or protein complex:
Dc
Dt
= D∇2c + R (6.1)
where c (193 × 1) denotes the concentration vector of proteins or protein com-
plexes. The symbol D denotes the diffusion coefficients of all proteins or protein
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complexes. Except for platelets or platelet-bound species, the diffusion coeffi-
cients of other proteins were assumed to be 5×10−7cm2/s (approximate value for
a solution-phase protease in blood clotting, such as thrombin [254, 268, 227]);
the diffusion coefficients of platelets or platelet-bound species were given as
5×10−9cm2/s [60]. The reactions were assumed to occur within a boundary layer
of 2-3 µm (the distance over which platelets can attach to one another because of
their pseudopodia [269, 60]) in 1-dimensional (or pseudo-2D) flow field where x
is the direction of flow. The above convection-diffusion-reaction equation could
be simplified as:
∂c
∂t
= D
∂2c
∂x2
− vx ∂c
∂x
+ R (6.2)
where the velocity vx is calculated by multiplying the wall shear (sh) with one-
half of the boundary layer thickness (h) (vx = sh × h2 ).
The details for the reaction equation (R) and model parameters can be found
in the our previous work [162]. The initial concentrations were taken from
each experiment and roughly correspond to in-vivo physiological conditions. TF
patch in each simulation was located at the spatial grid started from x = 600 µm
and the initial conditions of platelets and fibrinogen concentrations were deter-
mined to be consistent to the NPP and PRP environments. All other parameters
and initial conditions held constant.
Given the large scale of the partial differential equation, it was solved using
a time-splitting method [270]. The key of the method is to separate chemical
species transport (i.e., convection and diffusion) from chemical reaction. At time
t = ti to t = ti+ 12 , we solve the convection-diffustion reactions only:
∂c
∂t
= D
∂2c
∂x2
− vx ∂c
∂x
c (ti) = c |t=ti (6.3)
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At time t = ti+ 12 to t = ti+1:
dc
dt
= Sr (c,k) = R (c, t) c
(
ti+ 12
)
= c |t=ti+ 12 (6.4)
Equation 6.3 was solved using the method of lines (MOL) [271] in the OCTAVE
programming environment (v2.9.9; www.octave.org), and the solutions at this
time step were used as the initial conditions of the next time step. Equation 6.4
was solved using the LSODE routine of the OCTAVE programming environ-
ment on an Apple Computer MacOSX (Cupertino, CA; v10.4.8) workstation.
6.6 Limitations and Future Directions
6.6.1 Limitations
Plasma flowing parallel to the wall convectively transports coagulation factors
from upstream to a region close to the reactive site (TF patch), and Brownian
motion mediates the radial movement toward the reactive wall. Local flow
conditions near the wall can significantly enhance or impede the transport of
molecule to (and away from) a reactive surface and are typically characterized
by the wall shear rate (γw), which is the rate at which the axial flow velocity in-
creases as one moves directly away from the vessel wall toward the center of the
vessel. Because the velocity profile across the vessel is roughly parabolic, the γw
approximates the flow velocities only near the wall. For fully developed, lami-
nar flow through a rigid tube the velocity at distance h (h  2r) from the wall
can be γw can be calculated as Vx(h) = γwh. Because the coagulation reactions
are initiated by the reactive TF surface and diffusion is only an effective means
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Figure 6.5: Illustration of the capillary with TF patch.
of transport over short distances, the reactions are assumed to occur within a
concentration boundary layer from the wall (Figure 6.5).
In this study, we assumed the species in a thin boundary near the vessel
wall were well-mixed and ignored the diffusion along y-direction. However, by
calculating the squared Thiele modulus for species l:
φ2l =
M∑
k=1
H2σlqrq(c∗, k)
D∗c∗l
(6.5)
where H is the characteristic length, i.e. the boundary layer thickness, D∗ is
the characteristic diffusion coefficient, c∗l is the characteristic concentration for
species l (we used the concentration vector at the centerline), M is the number
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Figure 6.6: Thiele modulus numbers for all species in the model.
of reactions, rq is the reaction rate and σlq denote stoichiometric coefficients (el-
ements of the connectivity matrix S). The distribution of Thiele modulus was
shown in Figure 6.6.
The squared Thiele modulus is the ratio of two characteristic times, diffu-
sion to reaction. If the reaction is very fast, its characteristic time is small and
the Thiele modulus is large (φ2  1), the concentration on the TF patch may be
small because the reaction is so fast that the material cannot diffuse to the sur-
face before it is reacted. Likewise, if the diffusion is very fast, its characteristic
time is small and the Thiele modulus is small (φ2  1), now the concentration
may not vary very much within the boundary layer because the diffusion is fast
enough to keep the boundary filled with reactants. If the reaction and diffusion
have similar characteristic time, the Thiele modulus approaches 1 (φ2 ≈ 1), the
diffusion and reaction phenomena have comparable importance.
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Most of the species have shown small Thiele modulus numbers, indicating
fast diffusion and slow reactions. However, for the species related to platelets
activation on the surface, large Thiele modulus was observed. These results
indicated that the well-mixed assumption in the boundary layer was not valid
for all species in the model. Furthermore, the Peclet number Pe = UH/D in the
model ranged from O(1) to O(103) for shear rates from 10 to 3000 s−1. Thus, some
characteristic behavior of flow on clot formation may be missed because of this
well-mixed assumption. Hence we proposed two solutions for the situation in
order to get more suitable model in Future Directions.
6.6.2 Future Directions
The main problem with the current model is related to the diffusion along y-
direction. Equation 6.2 can be re-written as:
∂c
∂t
= D(
∂2c
∂x2
+
∂2c
∂y2
) − vx ∂c
∂x
+ R (6.6)
with the boundary conditions:
c(∞, y) = cb (6.7)
∂c
∂t
(−∞, y) = 0 (6.8)
where x = ∞ denotes far away from the TF patch at downstream and x = ∞
denotes upstream far away from the patch. One solution for this is to average
the concentrations c(x, y) along y-direction to get average concentration in the
boundary layer at a given position x, which is defined as:
c¯(x) =
1
H
∫ H
0
c(x, y)dy (6.9)
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The velocity vx within the boundary layer can be estimated by multiplying the
wall shear (γw) with one-half of the boundary layer thickness (H) (v¯x =
γwH
2 ). The
boundary conditions in y-directions are:
∂c
∂y
(x,H) = 0 −∞ < x < ∞ (6.10)
∂c
∂y
(x, 0) = 0 x < 0 or x > L (6.11)
∂c
∂y
(x, 0) =
cb − c
H
0 ≤ x ≤ L (6.12)
where cb is the bulk concentration and L is the length of the TF patch. At the
top surface (y = H) of the boundary, no flux along y-direction. At the bottom
of the boundary (the vessel wall), for places without TF patch, no flux along
y-direction, while over the patch, the concentration change within the volume
(V) equals the diffusion along y-direction across the area (A), thus, (cb − c)V =
A∂c
∂y (x, 0) and H = V/A.
The boundary layer is defined using the same methodology from [60]. The
averaged boundary thickness can be estimated using:
H =
3
4
(
rLD
V
)1/3 (6.13)
where r is the radius of the capillary, L is the length of TF patch, D is the diffusion
coefficient of a protein, and V is the velocity at the centerline. If the boundary
layer is thinner than the typical distance at which platelets can attached to other
platelets (2 − 3µm), then we set H = 2.5µm.
The ordinary differential equation governing c¯(x) is obtained by averaging
each term in Equation 6.6 and can be solved using a time-splitting method as
stated in Methods [270].
∂c¯
∂t
= D
∂2c¯
∂x2
+
D
H
∂c
∂y
∣∣∣∣y=H
y=0
− v¯x ∂c¯
∂x
+ R (6.14)
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or, using the boundary conditions at the top and bottom of the boundary layer:
∂c¯
∂t
= D
∂2c¯
∂x2
− v¯x ∂c¯
∂x
+ R x < 0 or x > L (6.15)
∂c¯
∂t
= D
∂2c¯
∂x2
− D(cb − c¯)
H2
− v¯x ∂c¯
∂x
+ R 0 ≤ x ≤ L (6.16)
Another solution to capture diffusion of material in the y-direction is to
model the flow effect in two dimensional space using Finite Element Methods.
In this way, we can incorporate the diffusion along y-direction. However, be-
cause of the limited time, these two solutions were not included in this disser-
tation.
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APPENDIX A
CHAPTER 1 APPENDIX
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Table A.1: Nomenclature
fI fibrinogen
FIa fibrin
fII prothrombin
FIIa thrombin
fVII factor VII
FVIIa activated factor VII
fV factor V
FVa activated factor V
fVIII factor VIII
FVIIIa activated factor VIII
fIX factor IX
FIXa activated factor IX
fX factor X
FXa activated factor X
TF Tissue Factor
TFPI Tissue Factor Pathway Inhibitor
ATIII Antithrombin III
PC Protein C
APC activated Protein C
TM Thrombomodulin
PL resting platelets
AP activated platelets
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Table A.2: Initial Conditions for different cases in Figure 2.2
cases A B C and D E F
fII 1700/2000 nM 1700 nM 1400 nM 1400 nM 1400 nM
fVII – – – – 10 nM
FVIIa – – – – 0.5 nM
TF – – – – 1 pM
TF-FVIIa 1.25 pM 1.25 pM 1.25 pM 5/10/50/500/5000 pM –
fV 20 nM 20 nM 20 nM 20 nM 20 nM
fVIII 0.7 nM 0.7 nM 0.7 nM 0.7 nM 0.3 nM
fIX 90 nM 90 nM 90 nM 90 nM 70 nM
fX 170 nM 170 nM 170 nM 170 nM 135 nM
TFPI 0/1/2.5/5 nM 0/2.5 nM 2.5 nM – 3 nM
ATIII – 0/3400 nM – – 3000 nM
PC – – 65 nM – –
TM – – 0/1/10 nM – –
number of PL 150 150 150 150 150
number of PL binding sites on
subendothelium
100 100 100 100 100
number of fII/FIIa binding sites
on AP surfaces
50 50 50 20 0.5
number of fV/FVa binding sites
on AP surfaces
50 50 50 20 50
number of fVIII/FVIIIa binding
sites on AP surfaces
5 × 10−10 5 × 10−10 5 × 10−10 5 × 10−10 5 × 10−6
number of fIX/FIXa binding
sites on AP surfaces
50 50 50 20 5 × 10−8
number of specific fIX/FIXa
binding sites on AP surfaces
50 50 50 20 5 × 10−8
number of fX/FXa binding sites
on AP surfaces
50 50 50 20 150
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Table A.3: Reactions and parameter values used in the extrinsic coagulation
model 1.
p-index case A case B case C case D
Description
VII+TF
 VII-TF 5 × 10−2 5 × 10−3 – [60]
VIIa+TF
 VIIa-TF 5 × 10−2 5 × 10−3 – [60]
Xa+VII-TF
 Xa-VII-TF 5 × 10−3 1.0 – [60]
Xa-VII-TF→ VIIa-TF + Xa – – 5 × 10−3 [60]
IIa+VII-TF
 IIa-VII-TF 3.92 × 10−4 1.0 – [60]
IIa-VII-TF→ VIIa-TF +IIa – – 3.92 × 10−4 [60]
X+VII-TF
 X-VIIa-TF 0.1 5.5 – [54]
X-VII-TF→ VIIa-TF + Xa – – 1.4 [54]
IX+VIIa-TF
 IX-VIIa-TF 0.1 2.2 – [54]
IX-VII-TF→ VIIa-TF + IXa – – 0.47 [54]
VII+Xa
 VII-Xa 0.1 1.0 – [60, 53]
VII-Xa→ VIIa + Xa – – 0.5 [60, 53]
VII+IIa
 VII-IIa 0.1 10 – [60, 53]
VII-IIa→ VIIa + IIa – – 0.5 [60, 53]
V+IIa
 V-IIa 0.1 7.21 – [54]
V-IIa→ V + IIa – – 0.26 [54]
VIII+IIa
 VIII-IIa 0.1 152 – [54]
VIII-IIa→ VIIIa + IIa – – 0.9 [54]
Xa + IX
 Xa-IX 0.1 1.5 – [52]
Xa-IX→ Xa + IXa – – 2.3 × 10−2 [52]
Xa + V
 Xa-V 0.1 1.0 – [52, 54]
Xa-V→ Xa + Va – – 4.3 × 10−2 [52, 54]
Xa + VIII
 Xa-VIII 0.1 2.1 – [52, 54]
Xa-VIII→ Xa + VIIIa – – 2.3 × 10−2 [52, 54]
Xa + II
 Xa-II 7.5 × 10−6 1.0 × 10−9 – [53]
Xa-II
 IIa + Xa – – 7.5 × 10−6 [53]
IX + P9s
 IX-P9s 1.0 × 10−2 2.5 × 10−2 – [60]
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Reaction k+ (nM−1s−1) k− (s−1) kc (s−1) Source
IXa + P9s
 IXa-P9s 1.0 × 10−2 2.5 × 10−2 – [60]
IXa + P9s∗
 IXa-P9s∗ 1.0 × 10−2 2.5 × 10−2 – [60]
X + P10s
 X-P10s 0.1 2.5 × 10−2 – [60]
Xa + P10s
 Xa-P10s 0.1 2.5 × 10−2 – [60]
V + P5s
 V-P5s 5.7 0.17 – [60]
Va + P5s
 Va-P5s 5.7 0.17 – [60]
VIII + P8s
 VIII-P8s 5.0 × 10−2 0.17 – [60]
VIIIa + P8s
 VIIIa-P8s 5.0 × 10−2 0.17 – [60]
II + P2s
 II-P2s 1.0 × 10−2 5.9 – [60]
IIa + P2s
 IIa-P2s 1.0 × 10−2 2.042 – [60]
PL + Psub→ AP-Psub – – 0.9 [60]
PL + Psub→ PL-Psub – – 20 [60]
AP + Psub→ AP-Psub – – 0.2 [60]
PL + AP
 PL-AP 5 × 10−7 1.0 – [60]
PL-AP
 2AP – – 5 × 10−7 [60]
PL + AP-Psub
 PL-AP-Psub 5 × 10−7 1.0 – [60]
PL-AP-Psub→ AP+ AP-Psub – – 5 × 10−7 [60]
PL + IIa
 PL-IIa 3 × 10−7 1.0 – [60]
PL-IIa→ AP + IIa – – 3 × 10−7 [60]
PL-Psub + IIa
 PL-Psub-IIa 3 × 10−2 1.0 × 10−2 – [60]
PL-Psub-IIa→ AP-Psub + IIa – – 9 × 10−3 [60]
V-P5s + Xa-P10s
 V-P5s-Xa-P10s 0.1 1.0 – [60, 54]
V-P5s-Xa-P10s→ Va-P5s + Xa-P10s – – 4.6 [60, 54]
V-P5s + IIa-P2s
 V-P5s-IIa-P2s 1.73 × 10−2 1.0 – [60, 54]
V-P5s-IIa-P10s→ Va-P5s + IIa-P10s – – 4.6 [60, 54]
X-P10s+VIIIa-P8s-IXa-P9s
 X-P10s-VIIIa-P8s-IXa-P9s 0.1 1.0 × 10−2 – [60, 54]
X-P10s-VIIIa-P8s-IXa-P9s→ Xa-P10s + VIIIa-P8s-IXa-P9s – – 20.0 [60, 54]
X-P10s+VIIIa-P8s-IXa-P9s∗ 
 X-P10s-VIIIa-P8s-IXa-P9s∗ 0.1 0.01 – [60, 54]
X-P10s-VIIIa-P8s-IXa-P9s∗ → Xa-P10s + VIIIa-P8s-IXa-P9s∗ – – 20.0 [60, 54]
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Reaction k+ (nM−1s−1) k− (s−1) kc (s−1) Source
VIII-P8s + Xa-P10s
 VIII-P8s-Xa-P10s 0.1 2.1 - [60, 54]
VIII-P8s-Xa-P10s→ VIIIa-P8s + Xa-P10s – – 0.0232 [60, 54]
VIII-P8s + IIa-P2s
 VIII-P8s-IIa-P2s 0.1 152 – [60, 54]
VIII-P8s-IIa-P10s→ VIIIa-P8s + IIa-P10s – – 0.9 [60, 54]
II-P2s + Va-P5s-Xa-P10s
 II-P2s-Va-P5s-Xa-P10s 0.1 0.051 – [60, 54]
II-P2s-Va-P5s-Xa-P10s→ IIa-P2s + Va-P5s-Xa-P10s – – 301 [60, 54]
VIIIa-P8s + IXa-P9s
 VIIIa-P8s-IXa-P9s 0.1 0.4 – [60, 54]
VIIIa-P8s + IXa-P9s∗ 
 VIIIa-P8s-IXa-P9s∗ 0.1 0.4 – [60, 54]
Va-P5s + Xa-P10s
 Va-P5s-Xa-P10s 1.0 1.0 – [60, 54]
Xa-P10s + IX-P9s
 Xa-P10s-IX-P9s 1.0 × 10−3 1.5 – [52]
Xa-P10s-IX-P9s→ Xa-P10s + IX-P9s – – 2.3 × 10−2 [52]
APC + VIIIa-P8s
 APC-VIIIa-P8s 0.12 1.0 – [60]
APC-VIIIa-P8s→ APC+VIIIa-P8s-i – – 0.5 [60]
APC + Va-P8s
 APC-Va-P8s 0.12 1.0 – [60]
APC-Va-P8s→ APC+Va-P8s-i – – 0.5 [60]
APC + Va-P5s-Xa-P10s
 APC-Va-P5s-Xa-P10s 0.12 1.0 – [60, 8]
APC-Va-P5s-Xa-P10s→ APC + Va-P5s-Xa-P10s-i – – 0.5 [60, 8]
APC + VIIIa-P8s-IXa-P9s
 APC-VIIIa-P8s-IXa-P9s 0.12 1.0 – [60, 8]
APC-VIIIa-P8s-IXa-P9s→ APC + VIIIa-P8s-IXa-P9s-i – – 0.5 [60, 8]
APC + VIIIa-P8s-IXa-P9s∗ 
 APC-VIIIa-P8s-IXa-P9s∗ 0.12 1.0 – [60, 8]
APC-VIIIa-P8s-IXa-P9s∗ → APC + VIIIa-P8s-IXa-P9s∗-i – – 0.5 [60, 8]
TFPI + Xa
 TFPI-Xa 1.6 × 10−3 3.3 × 10−4 – [54, 60]
TFPI-Xa + VIIa-TF
 TFPI-Xa-VIIa-TF 1.0 × 10−3 1.1 × 10−3 – [60]
TFPI + Xa-VIIa-TF
 TFPI-Xa-VIIa-TF 0.32 1.1 × 10−4 – [53]
IIa→ IIa-i – – 1.35 × 10−4 [53]
ATIII + IXa
 ATIII-IXa 4.9 × 10−7 1.0 × 10−9 – [60, 53]
ATIII-IXa→ATIII+IXa-i – – 4.9 × 10−7 [60, 53]
ATIII + Xa
ATIII-Xa 2 × 10−4 1.0 × 10−9 – [60, 53]
ATIII-Xa→ ATIII+Xa-i – – 1.5 × 10−6 [60, 53]
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Reaction k+ (nM−1s−1) k− (s−1) kc (s−1) Source
ATIII + IIa
 ATIII-IIa 1.5 × 10−5 1.0 × 10−9 – [60, 53]
ATIII-IIa→ ATIII+IIa-i – – 4.75 × 10−6 [60, 53]
ATIII + VIIa-TF
 VIIIa-TF-ATIII 2.5 × 10−7 1.0 × 10−9 – [53]
PC + IIa
 PC-IIa 1.003 × 10−6 1.0 × 10−9 – [8, 116]
PC-IIa→ APC + IIa – – 1.67 × 10−4 [8, 116]
IIa + TM
 IIa-TM 3.0 × 10−2 4.5 × 10−2 – [116]
IIa-TM + PC
 IIa-TM-PC 1.4 × 10−4 0.5 – [116]
IIa-TM-PC→ IIa-TM + APC – – 40 [116]
1The mode consists of 92 protein or protein complexes and 148 interactions. The kinetics of
binding and reaction interactions are assumed to follow mass action rate laws where k+ denotes
the on-rate constant, k− denotes the off-rate constant and kc denotes the catalytic rate constants.
All binding interactions are assumed to be reversible. Values for the kinetic parameters and net-
work structure were taken from the literature, see [52, 54, 116, 60, 53, 8]. Of the 148 parameters
in the model, 138 were taken directly from literature or have a literature basis. Only 10 of 148
parameters have no direct literature source: of these, nine of ten parameters correspond to in-
teractions of APC with the FVIIIa-FIXa and FVa-FXa surface complexes. The parameter values
governing the interaction of APC with FVIIIa-FIXa/FVa-FXa were approximated by literature
values describing the interaction of APC with FVa and FVIIIa in plasma. The remaining un-
known parameter was the rate constant governing the nonspecific inactivation of FIIa (IIa→IIa-
i); we have assumed an arbitrary small value for this parameter. Last, there were differences
in in vitro assay temperatures from which parameters were taken; parameter values were ad-
justed to the assay temperature of Mann and coworker (T1 = 37oC). (1) Rate constant adjusted
to T1 = 37oC from T2 = 25oC using Arrhenius rate law, where Ea = 21kJ,R = 8.314gmol/K; (2)
Rate constant adjusted to T1 = 37oC from T2 = 22oCusing Arrhenius rate law.
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Table B.1: Extended reactions and parameter values used in this coagulation
model.
p-index case A case B case C case D
Description
IIa + PAR1-PL
 IIa-PAR1-PL 0.71 8.67 – [204, 113]
IIa + PAR1-PL-Psub
 IIa-PAR1-PL-Psub 0.13 6.46 – [204, 113]
IIa-PAR1-PL→ AP + IIa – – 0.03 [204, 113]
IIa-PAR1-PL-Psub→ AP-Psub + IIa – – 0.04 [204, 113]
IIa + PAR3-PL
 IIa-PAR3-PL 0.03 1.01 – [204, 113]
IIa + PAR3-PL-Psub
 IIa-PAR3-PL-Psub 0.10 8.74 – [204, 113]
IIa-PAR3-PL→ AP + IIa – – 0.82 [204, 113]
IIa-PAR3-PL-Psub→ AP-Psub + IIa – – 0.42 [204, 113]
IIa + PAR4-PL
 IIa-PAR4-PL 0.22 4.39 – [204, 113]
IIa + PAR4-PL-Psub
 IIa-PAR4-PL-Psub 0.88 1.59 – [204, 113]
IIa-PAR4-PL→ AP + IIa – – 0.24 [204, 113]
IIa-PAR4-PL-Psub→ AP-Psub + IIa – – 0.93 [204, 113]
AP→ APs + ADP – – 1 × 10−6 [69]
AP→ APs + TXA2 – – 1 × 10−6 [69]
AP→ APs + I – – 1 × 10−6 [69]
AP-Psub→ APs + ADP – – 1 × 10−3 [69]
AP-Psub→ APs + TXA2 – – 1 × 10−3 [69]
AP-Psub→ APs + I – – 1 × 10−3 [8]
ADP + PL
 ADP-PL 3 × 10−7 1.0 – [69]
ADP-PL→ AP + ADP – – 3 × 10−7 [69]
TXA2 + PL
 TXA2-PL 1.61 × 10−2 1.0 – [69]
TXA2-PL→ AP + TXA2 – – 1.61 × 10−2 [69]
ADP + PL-Psub
 ADP-PL-Psub 3 × 10−2 0.01 – [69]
ADP-PL-Psub→ AP-Psub + ADP – – 3 × 10−3 [69]
TXA2 + PL-Psub
 TXA2-PL-Psub 1.61 × 10−2 1.0 – [69]
TXA2-PL-Psub→ AP-Psub + TXA2 – – 1.61 × 10−2 [69]
IIa + I
 IIa-I 1.898 × 10−2 1.0 – [8]
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Reaction k+ (nM−1s−1) k− (s−1) kc (s−1) Source
IIa-I→ IIa + Ia – – 59 × 10−4 [8]
XII+Surface
 XII-Surface 0.1 0.1 – [17, 14]
XII-Surface→ XIIa+Surface – – 0.1 [17, 14]
XIIa+PK
 XIIa-PK 0.1 0.1 – [17, 14]
XIIa-PK→ XIIa+ K – – 0.1 [17, 14]
XII+K
 XII-K 0.1 0.1 – [17, 14]
XII-K→ XIIa+ K – – 0.1 [17, 14]
XIIa+ XII
 XIIa-XII 0.1 0.1 – [17, 14]
XIIa-XII→ 2XIIa – – 0.1 [17, 14]
XIIa+ XI
 XIIa-XI 0.3 × 10−3 0.1 – [17, 14]
XIIa-XI→ XIIa+XIa – – 0.35 [17, 14]
XIa + XI
 XIa-XI 1.3 × 10−3 0.1 – [17]
XIa-XI→ 2*XIa – – 0.13 [17]
XI + P11s
 XI-P11s 0.04 1.0 – [205, 206]
XIa + P11s∗ 
 XIa-P11s∗ 0.06 1.0 – [205, 206]
IIa-P2s + XI-P11s
 IIa-P2s-XI-P11s 0.0125 0.1 – [17, 16, 15]
IIa-P2s-XI-P11s→ IIa-P2s + XIa-P11s∗ – – 1.43 [17, 16, 15]
XIa + IX
 XIa-IX 0.016 0.1 – [206]
XIa-IX→ XIa + IXa – – 7.7 [206]
XIa-P11s∗ + IX
 XIa-P11s∗-IX 0.016 0.1 – [206]
XIa-P11s∗-IX→ XIa-P11s∗ + IXa – – 7.7 [206]
tPA+PAI1
 tPA-PAI1 0.02 2 × 10−3 – [272, 273, 274, 275]
uPA+PAI1
 uPA-PAI1 1.8 × 10−2 1.0 × 10−3 – [272, 273]
tPA+PAI2
 tPA-PAI2 1.2 × 10−4 1.0 × 10−6 – [274, 34]
uPA+PAI2
 uPA-PAI2 2.1 × 10−3 1.0 × 10−5 – [34]
PLG+tPA
 PLG-tPA 1.67 × 10−2 0.1 – [276, 277, 275]
PLG-tPA→ PLA+tPA – – 2.0 [276, 277, 275]
PLG+uPA
 PLG-uPA 3.3 × 10−3 0.1 – [278]
PLG-uPA→ PLA+uPA – – 73 [278]
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Reaction k+ (nM−1s−1) k− (s−1) kc (s−1) Source
PLA+A2AP
 PLA-A2AP 3.8 × 10−2 7.22 × 10−3 – [279, 280, 281, 282, 283, 284]
PLA-A2AP→ PLA+A2AP-inactive – – 4.2 × 10−3 [279, 280, 281, 282, 283, 284]
PLA+A2M
 PLA-A2M 5.0 × 10−4 1.0 × 10−5 – [283, 284, 285]
PLA-A2M→ PLA+A2M-inactive – – 1.0 × 10−5 [283, 284, 285]
FDPs+PLA
 FDPs-PLA 0.01 0.1 – [286, 287]
IIa+TAFI
 IIa-TAFI 1.29 × 10−3 0.1 – [258, 288]
IIa-TAFI→ IIa+TAFIa – – 61 [258, 288]
Ia+PLA
 Ia-PLA 7.45 × 10−5 0.1 – [257]
Ia-PLA→ Ddimer+FDPs+PLA – – 1.16 × 10−4 [257]
Ia+FDPs-PLA
 Ia-FDPs-PLA 7.45 × 10−5 0.1 – [257]
Ia-FDPs-PLA→ Ddimer+FDPs+FDPs-PLA – – 1.16 × 10−3 [257]
TAFIa+FDPs
 TAFIa-FDPs 100 1.0 × 10−4 – [286, 287]
H5+ATIII
 H5-ATIII 3.7 × 10−2 0.9 – [124, 289]
H5-ATIII+Xa
 H5-ATIII-Xa 2.0 × 10−2 1.0 × 10−9 – [124, 289]
H5-ATIII-Xa→ H5-ATIII+Xa-inactive – – 0.6 × 10−3 [124, 289]
H5-ATIII+IIa
 H5-ATIII-IIa 1.5 × 10−5 1.0 × 10−9 – [124, 289]
H5-ATIII-IIa→ H5-ATIII+IIa-inactive – – 0.5 × 10−5 [124, 289]
HCII+IIa
 HCII-IIa 4.5 × 10−7 1.0 × 10−9 – [290, 291, 292]
HCII+IIa-P2s
 HCII-IIa-P2s 4.5 × 10−7 1.0 × 10−9 – [290, 291, 292]
HCII+DER
 HCII-DER 0.9 1.0 × 10−9 – [290, 291, 292]
HCII-DER+IIa
 HCII-DER-IIa 0.02 1.0 × 10−9 – [290, 291, 292]
HCII-DER+IIa-P2s
 HCII-DER-IIa-P2s 0.02 1.0 × 10−9 – [290, 291, 292]
ARG +IIa
 ARG-IIa 0.033 0.33 – [290, 291]
ARG +IIa-P2s
 ARG-IIa-P2s 0.033 0.33 – [290, 291]
BIV+IIa
 BIV-IIa 0.43 0.82 – [290, 291]
BIV-IIa→ BIV-inactive+IIa – – 1.0 × 10−2 [290, 291]
BIV+IIa-P2s
 BIV-IIa-P2s 0.43 0.82 – [290, 291]
BIV-IIa-P2s→ BIV-inactive+IIa-P2s – – 1.0 × 10−2 [290, 291]
LEP+IIa
 LEP-IIa 0.29 1.7 × 10−5 – [290, 291]
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Reaction k+ (nM−1s−1) k− (s−1) kc (s−1) Source
LEP+IIa-P2s
 LEP-IIa-P2s 0.29 1.7 × 10−5 – [290, 291]
H5-ATIII+VIIa
 H5-ATIII-VIIa 1.7 × 10−7 1.0 × 10−9 – [293]
H5-ATIII+VIIa-TF
 H5-ATIII-VIIa-TF 4.5 × 10−7 1.0 × 10−9 – [293]
X+VIIa
 X-VIIa 4.0 × 10−5 0.1 – [28, 196]
X-VIIa→ Xa+VIIa – – 5.0 × 10−4 [28, 196]
IX+VIIa
 IX-VIIa 5.0 × 10−5 0.1 – [28, 196]
IX-VIIa→ IXa+VIIa – – 1.5 × 10−5 [28, 196]
APC+PCI
 APC-PCI 6.5 × 10−6 1.0 × 10−9 – [294]
IIa+PCI
 IIa-PCI 6.1 × 10−6 1.0 × 10−9 – [294]
Xa+PCI
 Xa-PCI 2.01 × 10−5 1.0 × 10−9 – [294]
XIa+PCI
 XIa-PCI 9.03 × 10−5 1.0 × 10−9 – [294]
uPA +PCI
 uPA-PCI 2.2 × 10−6 1.0 × 10−9 – [294]
tPA +PCI
 tPA-PCI 0.8 × 10−6 1.0 × 10−9 – [294]
K +PCI
 K-PCI 6.5 × 10−5 1.0 × 10−9 – [294]
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